Products and compositions

ABSTRACT

Products, compositions, and their uses are provided. In particular, nucleic acid products that modulate, in particular interfere with or inhibit, Factor XI (FXI) gene expression are provided. The products can be oligomeric compounds that comprise at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an FXI gene, wherein said first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 1 to 250.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on May 27, 2022, is named 4690_0046C_SL.txt and is 650.004 bytes in size.

FIELD

Nucleic acid products are provided that modulate, interfere with, or inhibit, Factor XI (FXI) gene expression. Methods, compounds, and compositions are provided for reducing expression of FXI mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate thromboembolic diseases, such as deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis, or other procoagulant condition.

BACKGROUND

The circulatory system requires mechanisms that prevent blood loss, as well as those that counteract inappropriate intravascular obstructions. Generally, coagulation comprises a cascade of reactions culminating in the conversion of soluble fibrinogen to an insoluble fibrin gel. The steps of the cascade involve the conversion of an inactive zymogen to an activated enzyme. The active enzyme then catalyzes the next step in the cascade.

Coagulation Cascade

The coagulation cascade may be initiated through two branches, the tissue factor pathway (also “extrinsic pathway”), which is the primary pathway, and the contact activation pathway (also “intrinsic pathway”).

The tissue factor pathway is initiated by the cell surface receptor tissue factor (TF, also referred to as Factor III), which is expressed constitutively by extravascular cells (pericytes, cardiomyocytes, smooth muscle cells, and keratinocytes) and expressed by vascular monocytes and endothelial cells upon induction by inflammatory cytokines or endotoxin. (Drake et al., Am J Pathol 1989, 134: 1087-1097). TF is the high affinity cellular receptor for coagulation Factor Vila, a serine protease. In the absence of TF, Vila has very low catalytic activity, and binding to TF is necessary to render Vila functional through an allosteric mechanism (Drake et al., Am J Pathol 1989, 134: 1087-1097). The TF-VIIa complex activates Factor X to Xa. Xa in turn associates with its co-factor Factor Va into a prothrombinase complex which in turn activates prothrombin, (also known as Factor II or Factor 2) to thrombin (also known as Factor IIa, or Factor 2a).

Thrombin activates platelets, converts fibrinogen to fibrin and promotes fibrin cross-linking by activating Factor XIII, thus forming a stable plug at sites where TF is exposed on extravascular cells. In addition, thrombin reinforces the coagulation cascade response by activating Factors V and VIII.

The contact activation pathway is triggered by activation of Factor XII to XIIa. Factor XIIa converts XI to XIa, and XIa converts IX to IXa. IXa associates with its cofactor Villa to convert X to Xa. The two pathways converge at this point as Factor Xa associates with Factor Va to activate prothrombin (Factor II) to thrombin (Factor IIa). Factor XI enhances both the formation and stability of clots in vitro, but is not thought to be involved in the initiation of clotting. Rather, Factor XI is important in the propagation phase of clot growth (von de Borne, et al., Blood Coagulation and Fibrinolysis, 2006, 17:251-257). Additionally, Factor XI-dependent amplification of thrombin formation leads to activation of TAFI (thrombin activatable fibrinolysis inhibitor), which renders clots less sensitive to fibrinolysis (Bouma et al, J Thromb Haemost 1999; 82: 1703-1708).

Inhibition of Coagulation

At least three mechanisms keep the coagulation cascade in check, namely the action of activated protein C, antithrombin, and tissue factor pathway inhibitor. Activated protein C is a serine protease that degrades cofactors Va and Villa. Protein C is activated by thrombin with thrombomodulin, and requires coenzyme Protein S to function. Antithrombin is a serine protease inhibitor (serpin) that inhibits serine proteases: thrombin, Xa, XIIa, XIa and IXa. Tissue factor pathway inhibitor inhibits the action of Xa and the TF-VIIa complex. (Schwartz A L et al., Trends Cardiovasc Med. 1997; 7:234-239.)

Disease

Thrombosis is the pathological development of blood clots, and an embolism occurs when a blood clot migrates to another part of the body and interferes with organ function. Thromboembolism may cause conditions such as deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. While most cases of thrombosis are due to acquired extrinsic problems, for example, surgery, cancer, immobility, some cases are due to a genetic predisposition, for example, antiphospholipid syndrome and the autosomal dominant condition, Factor V Leiden. (Bertina R M et al. Nature 1994; 369:64-67.)

Treatment

The most commonly used anticoagulants, warfarin, heparin, low molecular weight heparin (LMWH), and newer direct oral anticoagulants (DOAC), all possess significant drawbacks. Warfarin is typically used to treat patients suffering from atrial fibrillation. The drug interacts with vitamin K-dependent coagulation factors which include Factors II, VII, IX and X. Anticoagulant proteins C and S are also inhibited by warfarin. Drug therapy using warfarin is further complicated by the fact that warfarin interacts with other medications, including drugs used to treat atrial fibrillation, such as amiodarone.

Because therapy with warfarin is difficult to predict, patients must be carefully monitored in order to detect any signs of anomalous bleeding.

Heparin functions by activating antithrombin which inhibits both thrombin and Factor X (Bjork I, Lindahl U. Mol Cell Biochem. 1982 48: 161-182). Treatment with heparin may cause an immunological reaction that makes platelets aggregate within blood vessels that can lead to thrombosis. This side effect is known as heparin-induced thrombocytopenia (HIT) resulting in increased bleeding and requires patient monitoring. Prolonged treatment with heparin may also lead to osteoporosis. LMWH can also inhibit Factor II, but to a lesser degree than unfractioned heparin (UFH). LMWH has been implicated in the development of HIT.

Several direct oral anticoagulants have been FDA-approved for the treatment of thrombotic disease, including four Factor Xa inhibitors Betrixaban, Apixaban, Rivaroxaban and Edoxaban and one direct thrombin inhibitor Dabigatran. (Smith, M., Surg Clin N Am 2018 98:219-238). Rivaroxaban, Dabigatran and Edoxaban all exhibit increased bleeding, especially increased GI bleeding risk compared to warfarin.

There therefore remains a need for therapies to treat thromboembolic diseases without risk of increased bleeding. We, therefore, aim to provide compounds, methods, and pharmaceutical compositions for the treatment of such diseases.

Double-stranded RNA (dsRNA) able to complementarily bind expressed mRNA has been shown to be able to block gene expression (Fire et a.l, 1998, Nature. 1998 Feb. 19; 391 (6669):806-1 1 and Elbashir et at., 2001, Nature. 2001 May 24; 41 1 (6836):494-8) by a mechanism that has been termed RNA interference (RNAi). Short dsRNAs direct gene-specific, post-transcriptional silencing in many organisms, including vertebrates, and have become a useful tool for studying gene function. RNAi is mediated by the RNA-induced silencing complex (RISC), a sequence-specific, multi-component nuclease that destroys messenger RNAs homologous to the silencing trigger loaded into the RISC complex. Interfering RNA (iRNA) such as siRNAs, antisense RNA, and micro-RNA are oligonucleotides that prevent the formation of proteins by gene-silencing i.e. inhibiting gene translation of the protein through degradation of mRNA molecules. Gene-silencing agents are becoming increasingly important for therapeutic applications in medicine.

According to Watts and Corey in the Journal of Pathology (2012; Vol 226, p 365-379) there are algorithms that can be used to design nucleic acid silencing triggers, but all of these have severe limitations. It may take various experimental methods to identify potent siRNAs, as algorithms do not take into account factors such as tertiary structure of the target mRNA or the involvement of RNA binding proteins. Therefore the discovery of a potent nucleic acid silencing trigger with minimal off-target effects is a complex process. For the pharmaceutical development of these highly charged molecules it is necessary that they can be synthesised economically, distributed to target tissues, enter cells and function within acceptable limits of toxicity. An aim is to, therefore, provide compounds, methods, and pharmaceutical compositions for the treatment of thromboembolic diseases as described herein, which comprise oligomeric compounds that modulate and inhibit, gene expression by RNAi.

SUMMARY

Nucleic acid products are provided that modulate, interfere with, or inhibit, Factor XI (FXI) gene expression, and associated therapeutic uses. Specific oligomeric compounds and sequences are described herein. This summary is not intended to identify key features or essential features of the subject matter as described herein, nor is it intended to be used to determine the scope of that subject matter.

DETAILED DESCRIPTION AND EMBODIMENTS

The embodiments described below are exemplary but the skilled artisan will recognize that additional embodiments may be achieved.

It will be understood that the benefits and advantages described herein may relate to one embodiment or may relate to several embodiments. The embodiments are not limited to those that solve any or all of the stated problems or those that have any or all of the stated benefits and advantages.

Features of different aspects and embodiments may be combined as appropriate, as would be apparent to a skilled person, and may be combined with any of the aspects as described herein.

BRIEF DESCRIPTION OF THE DRAWINGS

The embodiments described below are by way of example only and with reference to the following non-limiting drawings, in which:

FIGS. 1a -1 zvi illustrate the stability of 250 duplexes: Table 1a displays the nucleobase sequences of 250 antisense sequences (SEQ ID NOs: 1 to 250) and of 250 corresponding sense sequences (SEQ ID NOs: 251 to 500). Table 1b displays the corresponding modified constructs (constructs 501 to 750 being the modified counterparts of SEQ ID NOs: 1 to 250; and constructs 751 to 1000 being the modified counterparts of SEQ ID NOs: 251 to 500). Owing to complementarity, construct 501 base pairs with construct 751, construct 502 base pairs with construct 752 and so forth, giving rise to duplexes (double-stranded molecules). These duplexes are numbered according to the SEQ ID NO of the antisense nucleobase sequence they comprise, e.g. the duplex formed from constructs 501 and 751 is referred to as duplex 1, the duplex formed from constructs 502 and 752 is referred to duplex 2, and so forth. Based on this numbering scheme, the parts of FIG. 1 illustrate the following:

FIG. 1a illustrates the stability of duplexes 1 to 8.

FIG. 1b illustrates the stability of duplexes 9 to 16.

FIG. 1c illustrates the stability of duplexes 17 to 24.

FIG. 1d illustrates the stability of duplexes 25 to 32.

FIG. 1e illustrates the stability of duplexes 33 to 40.

FIG. 1f illustrates the stability of duplexes 41 to 48.

FIG. 1g illustrates the stability of duplexes 49 to 56.

FIG. 1h illustrates the stability of duplexes 57 to 64.

FIG. 1i illustrates the stability of duplexes 65 70 72.

FIG. 1j illustrates the stability of duplexes 73 to 80.

FIG. 1k illustrates the stability of duplexes 81 to 88.

FIG. 1l illustrates the stability of duplexes 89 to 96.

FIG. 1m illustrates the stability of duplexes 97 to 104.

FIG. 1n illustrates the stability of duplexes 105 to 112.

FIG. 1o illustrates the stability of duplexes 113 to 120.

FIG. 1p illustrates the stability of duplexes 121 to 128.

FIG. 1q illustrates the stability of duplexes 129 to 136.

FIG. 1r illustrates the stability of duplexes 137 to 144.

FIG. 1s illustrates the stability of duplexes 145 to 152.

FIG. 1t illustrates the stability of duplexes 153 to 160.

FIG. 1u illustrates the stability of duplexes 161 to 168.

FIG. 1v illustrates the stability of duplexes 169 to 176.

FIG. 1w illustrates the stability of duplexes 177 to 184.

FIG. 1x illustrates the stability of duplexes 185 to 192.

FIG. 1y illustrates the stability of duplexes 193 to 200.

FIG. 1z illustrates the stability of duplexes 201 to 208.

FIG. 1 zi illustrates the stability of duplexes 209 to 216.

FIG. 1 zii illustrates the stability of duplexes 217 to 224.

FIG. 1 ziii illustrates the stability of duplexes 225 to 232.

FIG. 1 ziv illustrates the stability of duplexes 233 to 241.

FIG. 1 zv illustrates the stability of duplexes 242 to 248.

FIG. 1 zvi illustrates the stability of duplexes 249 and 250.

FIG. 2 illustrates the linear dose response of the two independent F11 qPCR assays as described in Example 2.

FIGS. 3 to 12 show the screening results for FXI gene expression as a percentage of gene expression in non-treated cells for oligomeric compounds including oligonucleotides of Table 1a/1b of Example 1.

FIG. 13 provides dose response curves for the 26 FXI lead compounds as identified in Example 2.

FIG. 14 provides dose response curves for the 5 FXI lead compounds as identified further to the results of FIG. 13.

FIGS. 15 to 17 show the overall sequences for oligomeric compounds F11-91, F11-46, F11-152.

FIGS. 18a-18p illustrate compounds selected for medicinal chemistry:

FIG. 18a illustrates a generic duplex.

FIG. 18b illustrates a duplex containing 5′ vinyl phosphonate.

FIG. 18c illustrates a duplex containing an iR loop stabilizer.

FIG. 18d illustrates a duplex containing an iR end stabilizer and seed de-stabilizer.

FIG. 18e illustrates a duplex containing an iR seed de-stabilizer.

FIG. 18f illustrates a duplex containing a minimum 2′-F.

FIG. 18g illustrates a duplex containing internal GalNAc.

FIG. 18h illustrates a duplex containing internal GalNAc and iR 3′-end stabilizer.

FIG. 18i illustrates a duplex containing 5′ bi-methyl vinyl-phosphonate.

FIG. 18j illustrates a duplex containing iR 5′-end stabilizer.

FIG. 18k illustrates a duplex containing 3×TEG-linker GalNAc.

FIG. 18l illustrates a generic duplex with matching 5′ nucleotide.

FIG. 18m illustrates a duplex containing iR 5′-end stabilizer.

FIG. 18n illustrates a duplex containing iR 3′-end stabilizer.

FIG. 18o illustrates a duplex containing iR 3′-end stabilizer.

FIG. 18p illustrates a duplex with canonical control.

FIGS. 19a-19c illustrate the performance of compounds shown in FIGS. 18a -18 p:

FIG. 19a is a table showing percent k/d at the highest concentration and IC₅₀ values for 91A to 910 and 91 Control constructs of FIGS. 18a -18 p.

FIG. 19b illustrates gene expression as a percent of NT for a variety of constructs (91A-91F, 91I).

FIG. 19c illustrates gene expression as a percent of NT for a variety of constructs (91J-91O).

FIGS. 20a-20h depict several constructs.

FIG. 20a illustrates a duplex containing an iR loop stabilizer.

FIG. 20b illustrates a duplex containing 5′ bi-methyl vinyl-phosphonate.

FIG. 20c illustrates a conventional duplex (34mer).

FIG. 20d illustrates a duplex containing an iR 3′-end stabilizer.

FIG. 20e illustrates a duplex containing vinyl-phosphonate.

FIG. 20f illustrates a conventional duplex (31 mer).

FIG. 20g illustrates a conventional duplex (33mer).

FIG. 20h provides the sequences of seven constructs.

FIG. 21 shows data for the compounds displayed in FIG. 20.

FIG. 22 shows the structure of compounds tested in humanized mice.

FIG. 23 shows the data obtained from testing in humanized mice.

FIG. 24 shows the design of an in vivo study with compound 91-Conv-31.

FIG. 25 shows performance of a compound in an in vivo study in terms of Factor XI activity knock-down.

FIG. 26 shows the molecular mechanism underlying the tests for targeting specificity as performed in the course of an in vivo study.

FIGS. 27a-27b provides the read-out of the results of the tests performed in FIG. 26:

FIG. 27a shows the time (sec) for activated partial thromboplastin (APTT) based on concentrations between 1 and 10 mg/kg.

FIG. 27b shows the time (sec) for prothrombin (PT) based on concentrations between 1 and 10 mg/kg.

FIG. 28 presents data demonstrating a lack of side effects.

DEFINITIONS

Unless specific definitions are provided, the nomenclature used in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical synthesis, and chemical analysis. Certain such techniques and procedures may be found for example in “Carbohydrate Modifications in Antisense Research” Edited by Sangvi and Cook, American Chemical Society, Washington D.C., 1994; “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., 21^(st) edition, 2005; and “Antisense Drug Technology, Principles, Strategies, and Applications” Edited by Stanley T. Crooke, CRC Press, Boca Raton, Fla.; and Sambrook et al., “Molecular Cloning, A laboratory Manual,” 2^(nd) Edition, Cold Spring Harbor Laboratory Press, 1989, which are hereby incorporated by reference for any purpose. Where permitted, all patents, applications, published applications and other publications and other data referred to throughout in the disclosure are incorporated by reference herein in their entirety.

Unless otherwise indicated, the following terms have the following meanings:

As used herein, “excipient” means any compound or mixture of compounds that is added to a composition as provided herein that is suitable for delivery of an oligomeric compound.

As used herein, “nucleoside” means a compound comprising a nucleobase moiety and a sugar moiety. Nucleosides include, but are not limited to, naturally occurring nucleosides (as found in DNA and RNA) and modified nucleosides. Nucleosides may be linked to a phosphate moiety, phosphate-linked nucleosides also being referred to as “nucleotides”.

As used herein, “chemical modification” or “chemically modified” means a chemical difference in a compound when compared to a naturally occurring counterpart. Chemical modifications of oligonucleotides include nucleoside modifications (including sugar moiety modifications and nucleobase modifications) and internucleoside linkage modifications. In reference to an oligonucleotide, chemical modification does not include differences only in nucleobase sequence.

As used herein, “furanosyl” means a structure comprising a 5-membered ring comprising four carbon atoms and one oxygen atom.

As used herein, “naturally occurring sugar moiety” means a ribofuranosyl as found in naturally occurring RNA or a deoxyribofuranosyl as found in naturally occurring DNA. A “naturally occurring sugar moiety” as referred to herein is also termed as an “unmodified sugar moiety”. In particular, such a “naturally occurring sugar moiety” or an “unmodified sugar moiety” as referred to herein has a —H (DNA sugar moiety) or —OH (RNA sugar moiety) at the 2′-position of the sugar moiety, especially a —H (DNA sugar moiety) at the 2′-position of the sugar moiety.

As used herein, “sugar moiety” means a naturally occurring sugar moiety or a modified sugar moiety of a nucleoside. As used herein, “modified sugar moiety” means a substituted sugar moiety or a sugar surrogate.

As used herein, “substituted sugar moiety” means a furanosyl that has been substituted. Substituted sugar moieties include, but are not limited to furanosyls comprising substituents at the 2′-position, the 3′-position, the 5′-position and/or the 4′-position. Certain substituted sugar moieties are bicyclic sugar moieties.

As used herein, “2′-substituted sugar moiety” means a furanosyl comprising a substituent at the 2′-position other than H or OH. Unless otherwise indicated, a 2′-substituted sugar moiety is not a bicyclic sugar moiety (i.e., the 2′-substituent of a 2′-substituted sugar moiety does not form a bridge to another atom of the furanosyl ring).

As used herein, “MOE” means —OCH₂CH₂OCH₃.

As used herein, “2′-F nucleoside” refers to a nucleoside comprising a sugar comprising fluorine at the 2′ position. Unless otherwise indicated, the fluorine in a 2′-F nucleoside is in the ribo position (replacing the OH of a natural ribose). Duplexes of uniformly modified 2′-fluorinated (ribo) oligonucleotides hybridized to RNA strands are not RNase H substrates while the ara analogs retain RNase H activity.

As used herein the term “sugar surrogate” means a structure that does not comprise a furanosyl and that is capable of replacing the naturally occurring sugar moiety of a nucleoside, such that the resulting nucleoside sub-units are capable of linking together and/or linking to other nucleosides to form an oligomeric compound which is capable of hybridizing to a complementary oligomeric compound. Such structures include rings comprising a different number of atoms than furanosyl (e.g., 4, 6, or 7-membered rings); replacement of the oxygen of a furanosyl with a non-oxygen atom (e.g., carbon, sulfur, or nitrogen); or both a change in the number of atoms and a replacement of the oxygen. Such structures may also comprise substitutions corresponding to those described for substituted sugar moieties (e.g., 6-membered carbocyclic bicyclic sugar surrogates optionally comprising additional substituents). Sugar surrogates also include more complex sugar replacements (e.g., the non-ring systems of peptide nucleic acid). Sugar surrogates include without limitation morpholinos, cyclohexenyls and cyclohexitols.

As used herein, “bicyclic sugar moiety” means a modified sugar moiety comprising a 4 to 7 membered ring (including but not limited to a furanosyl) comprising a bridge connecting two atoms of the 4 to 7 membered ring to form a second ring, resulting in a bicyclic structure. In certain embodiments, the 4 to 7 membered ring is a sugar ring. In certain embodiments the 4 to 7 membered ring is a furanosyl. In certain such embodiments, the bridge connects the 2 ‘-carbon and the 4’-carbon of the furanosyl.

As used herein, “nucleotide” means a nucleoside further comprising a phosphate linking group. As used herein, “linked nucleosides” may or may not be linked by phosphate linkages and thus includes, but is not limited to “linked nucleotides.” As used herein, “linked nucleosides” are nucleosides that are connected in a continuous sequence (i.e. no additional nucleosides are present between those that are linked).

As used herein, “nucleobase” means a group of atoms that can be linked to a sugar moiety to create a nucleoside that is capable of incorporation into an oligonucleotide, and wherein the group of atoms is capable of bonding with a complementary naturally occurring nucleobase of another oligonucleotide or nucleic acid. Nucleobases may be naturally occurring or may be modified.

As used herein the terms, “unmodified nucleobase” or “naturally occurring nucleobase” means the naturally occurring heterocyclic nucleobases of RNA or DNA: the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) (including 5-methyl C), and uracil (U).

As used herein, “modified nucleobase” means any nucleobase that is not a naturally occurring nucleobase.

As used herein, “modified nucleoside” means a nucleoside comprising at least one chemical modification compared to naturally occurring RNA or DNA nucleosides. Modified nucleosides can comprise a modified sugar moiety and/or a modified nucleobase.

As used herein, “bicyclic nucleoside” or “BNA” means a nucleoside comprising a bicyclic sugar moiety.

As used herein, “locked nucleic acid nucleoside” or “LNA” means a nucleoside comprising a bicyclic sugar moiety comprising a 4′-CH₂—O-2′ bridge.

As used herein, “2′-substituted nucleoside” means a nucleoside comprising a substituent at the 2′-position of the sugar moiety other than H or OH. Unless otherwise indicated, a 2′-substituted nucleoside is not a bicyclic nucleoside.

As used herein, “deoxynucleoside” means a nucleoside comprising 2′-H furanosyl sugar moiety, as found in naturally occurring deoxyribonucleosides (DNA). In certain embodiments, a 2′-deoxynucleoside may comprise a modified nucleobase or may comprise an RNA nucleobase (e.g., uracil).

As used herein, “oligonucleotide” means a compound comprising a plurality of linked nucleosides. In certain embodiments, an oligonucleotide comprises one or more unmodified ribonucleosides (RNA) and/or unmodified deoxyribonucleosides (DNA) and/or one or more modified nucleosides.

As used herein, “modified oligonucleotide” means an oligonucleotide comprising at least one modified nucleoside and/or at least one modified internucleoside linkage.

As used herein, “linkage” or “linking group” means a group of atoms that link together two or more other groups of atoms.

As used herein “internucleoside linkage” means a covalent linkage between adjacent nucleosides in an oligonucleotide.

As used herein “naturally occurring internucleoside linkage” means a 3′ to 5′ phosphodiester linkage.

As used herein, “modified internucleoside linkage” means any internucleoside linkage other than a naturally occurring internucleoside linkage. In particular, a “modified internucleoside linkage” as referred to herein can include a modified phosphorous linking group such as a phosphorothioate or phosphorodithioate internucleoside linkage.

As used herein, “terminal internucleoside linkage” means the linkage between the last two nucleosides of an oligonucleotide or defined region thereof.

As used herein, “phosphorus linking group” means a linking group comprising a phosphorus atom and can include naturally occurring phosphorous linking groups as present in naturally occurring RNA or DNA, such as phosphodiester linking groups, or modified phosphorous linking groups that are not generally present in naturally occurring RNA or DNA, such as phosphorothioate or phosphorodithioate linking groups. Phosphorus linking groups can therefore include without limitation, phosphodiester, phosphorothioate, phosphorodithioate, phosphonate, methylphosphonate, phosphoramidate, phosphorothioamidate, thionoalkylphosphonate, phosphotriesters, thionoalkylphosphotriester and boranophosphate.

As used herein, “internucleoside phosphorus linking group” means a phosphorus linking group that directly links two nucleosides.

As used herein, “oligomeric compound” means a polymeric structure comprising two or more substructures. In certain embodiments, an oligomeric compound comprises an oligonucleotide, such as a modified oligonucleotide. In certain embodiments, an oligomeric compound further comprises one or more conjugate groups and/or terminal groups and/or ligands. In certain embodiments, an oligomeric compound consists of an oligonucleotide. In certain embodiments, an oligomeric compound comprises a backbone of one or more linked monomeric sugar moieties, where each linked monomeric sugar moiety is directly or indirectly attached to a heterocyclic base moiety. In certain embodiments, oligomeric compounds may also include monomeric sugar moieties that are not linked to a heterocyclic base moiety, thereby providing abasic sites. Oligomeric compounds may be defined in terms of a nucleobase sequence only, i.e., by specifying the sequence of A, G, C, U (or T). In such a case, the structure of the sugar-phosphate backbone is not particularly limited and may or may not comprise modified sugars and/or modified phosphates. On the other hand, oligomeric compounds may be more comprehensively defined, i.e, by specifying not only the nucleobase sequence, but also the structure of the backbone, in particular the modification status of the sugars (unmodified, 2′-OMe modified, 2′-F modified etc.) and/or of the phosphates.

As used herein, “terminal group” means one or more atom attached to either, or both, the 3′ end or the 5′ end of an oligonucleotide. In certain embodiments, a terminal group comprises one or more terminal group nucleosides.

As used herein, “conjugate” or “conjugate group” means an atom or group of atoms bound to an oligonucleotide or oligomeric compound. In certain embodiments, a conjugate group links a ligand to a modified oligonucleotide or oligomeric compound. In general, conjugate groups can modify one or more properties of the compound to which they are attached, including, but not limited to pharmacodynamic, pharmacokinetic, binding, absorption, cellular distribution, cellular uptake, charge and/or clearance properties.

As used herein, “conjugate linker” or “linker” in the context of a conjugate group means a portion of a conjugate group comprising any atom or group of atoms and which covalently link an oligonucleotide to another portion of the conjugate group. In certain embodiments, the point of attachment on the oligomeric compound is the 3 ‘-oxygen atom of the 3’-hydroxyl group of the 3′ terminal nucleoside of the oligonucleotide. In certain embodiments the point of attachment on the oligomeric compound is the 5′-oxygen atom of the 5′-hydroxyl group of the 5′ terminal nucleoside of the oligonucleotide. In certain embodiments, the bond for forming attachment to the oligomeric compound is a cleavable bond. In certain such embodiments, such cleavable bond constitutes all or part of a cleavable moiety.

In certain embodiments, conjugate groups comprise a cleavable moiety (e.g., a cleavable bond or cleavable nucleoside) and ligand portion that can comprise one or more ligands, such as a carbohydrate cluster portion, such as an N-Acetyl-Galactosamine, also referred to as “GalNAc”, cluster portion. In certain embodiments, the carbohydrate cluster portion is identified by the number and identity of the ligand. For example, in certain embodiments, the carbohydrate cluster portion comprises 2 GalNAc groups. For example, in certain embodiments, the carbohydrate cluster portion comprises 3 GalNAc groups and this is particularly preferred. In certain embodiments, the carbohydrate cluster portion comprises 4 GalNAc groups. Such ligand portions are attached to an oligomeric compound via a cleavable moiety, such as a cleavable bond or cleavable nucleoside. The ligands can be arranged in a linear or branched configuration, such as a biantennary or triantennary configurations.

As used herein, “cleavable moiety” means a bond or group that is capable of being cleaved under physiological conditions. In certain embodiments, a cleavable moiety is cleaved inside a cell or sub-cellular compartments, such as an endosome or lysosome. In certain embodiments, a cleavable moiety is cleaved by endogenous enzymes, such as nucleases. In certain embodiments, a cleavable moiety comprises a group of atoms having one, two, three, four, or more than four cleavable bonds.

In certain embodiments, a cleavable moiety is a phosphodiester linkage.

As used herein, “cleavable bond” means any chemical bond capable of being broken.

As used herein, “carbohydrate cluster” means a compound having one or more carbohydrate residues attached to a linker group.

As used herein, “modified carbohydrate” means any carbohydrate having one or more chemical modifications relative to naturally occurring carbohydrates.

As used herein, “carbohydrate derivative” means any compound which may be synthesized using a carbohydrate as a starting material or intermediate.

As used herein, “carbohydrate” means a naturally occurring carbohydrate, a modified carbohydrate, or a carbohydrate derivative. A carbohydrate is a biomolecule including carbon (C), hydrogen (H) and oxygen (O) atoms. Carbohydrates can include monosaccharide, disaccharides, trisaccharides, tetrasaccharides, oligosaccharides or polysaccharides, such as one or more galactose moieties, one or more lactose moieties, one or more N-Acetyl-Galactosamine moieties, and/or one or more mannose moieties. A particularly preferred carbohydrate is N-Acetyl-Galactosamine moieties.

As used herein, “strand” means an oligomeric compound comprising linked nucleosides. The linker is not particularly limited, but includes phosphodiesters and variants thereof as disclosed herein. A strand may also be viewed as a plurality of linked nucleotides in which case the linker would be a covalent bond.

The term “construct” means a region of linked nucleosides which is defined in terms of nucleobase sequence and sugar modifications. A construct may coincide with a strand or compound, but may also be part thereof.

As used herein, “single strand” or “single-stranded” means an oligomeric compound comprising linked nucleosides that are connected in a continuous sequence without a break therebetween. Such single strands may include regions of sufficient self-complementarity so as to be capable of forming a stable self-duplex in a hairpin structure.

As used herein, “hairpin” means a single stranded oligomeric compound that includes a duplex formed by base pairing between sequences in the strand that are self-complementary and opposite in directionality.

As used herein, “hairpin loop” means an unpaired loop of linked nucleosides in a hairpin that is created as a result of hybridization of the self-complementary sequences. The resulting structure looks like a loop or a U-shape.

In particular, short hairpin RNA, also denoted as shRNA, comprises a duplex region and a loop connecting the regions forming the duplex. The end of the duplex region which does not carry the loop may be blunt-ended or carry (a) 3′ and/or (a) 5′ overhang(s). Advantageously, the construct is blunt-ended. Such molecules are also referred to as “mxRNAs”. As used herein, the term “mxRNA” is in particular understood as defined in WO 2020/044186 A2 which is incorporated by reference herein in its entirety. Particularly preferred hairpin RNAs in accordance with the invention are those shown in Tables 6 and 7 and FIGS. 15 to 18, 20 and 22.

As used herein, “directionality” means the end-to-end chemical orientation of an oligonucleotide based on the chemical convention of numbering of carbon atoms in the sugar moiety meaning that there will be a 5′-end defined by the 5′ carbon of the sugar moiety, and a 3′-end defined by the 3′ carbon of the sugar moiety. In a duplex or double stranded oligonucleotide, the respective strands run in opposite 5′ to 3′ directions to permit base pairing between them.

As used herein, “duplex”, also abbreviated as “dup”, means two or more complementary strand regions, or strands, of an oligonucleotide or oligonucleotides, hybridized together by way of non-covalent, sequence-specific interaction therebetween. Most commonly, the hybridization in the duplex will be between nucleobases adenine (A) and thymine (T), and/or (A) adenine and uracil (U), and/or guanine (G) and cytosine (C). The duplex may be part of a single stranded structure, wherein self-complementarity leads to hybridization, or as a result of hybridization between respective strands in a double stranded molecule.

As used herein, “double strand” or “double stranded” means a pair of oligomeric compounds that are hybridized to one another. In certain embodiments, a double-stranded oligomeric compound comprises a first and a second oligomeric compound.

As used herein, “expression” means the process by which a gene ultimately results in a protein.

Expression includes, but is not limited to, transcription, post-transcriptional modification (e.g., splicing, polyadenlyation, addition of 5′-cap), and translation.

As used herein, “transcription” or “transcribed” refers to the first of several steps of DNA based gene expression in which a target sequence of DNA is copied into RNA (especially mRNA) by the enzyme RNA polymerase. During transcription, a DNA sequence is read by an RNA polymerase, which produces a complementary, antiparallel RNA sequence called a primary transcript.

As used herein, “target sequence” means a sequence to which an oligomeric compound is intended to hybridize to result in a desired activity with respect to Factor XI expression. Oligonucleotides have sufficient complementarity to their target sequences to allow hybridization under physiological conditions.

As used herein, “nucleobase complementarity” or “complementarity” when in reference to nucleobases means a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to uracil (U). In both DNA and RNA, guanine (G) is complementary to cytosine (C). In certain embodiments, complementary nucleobase means a nucleobase of an oligomeric compound that is capable of base pairing with a nucleobase of its target sequence. For example, if a nucleobase at a certain position of an oligomeric compound is capable of hydrogen bonding with a nucleobase at a certain position of a target sequence, then the position of hydrogen bonding between the oligomeric compound and the target sequence is considered to be complementary at that nucleobase pair. Nucleobases comprising certain modifications may maintain the ability to pair with a counterpart nucleobase and thus, are still capable of nucleobase complementarity.

As used herein, “non-complementary” in reference to nucleobases means a pair of nucleobases that do not form hydrogen bonds with one another.

As used herein, “complementary” in reference to oligomeric compounds (e.g., linked nucleosides, oligonucleotides) means the capacity of such oligomeric compounds or regions thereof to hybridize to a target sequence, or to a region of the oligomeric compound itself, through nucleobase complementarity.

Complementary oligomeric compounds need not have nucleobase complementarity at each nucleoside. Rather, some mismatches are tolerated. In certain embodiments, complementary oligomeric compounds or regions are complementary at 70% of the nucleobases (70% complementary). In certain embodiments, complementary oligomeric compounds or regions are 80%> complementary. In certain embodiments, complementary oligomeric compounds or regions are 90%> complementary. In certain embodiments, complementary oligomeric compounds or regions are 95% complementary. In certain embodiments, complementary oligomeric compounds or regions are 100% complementary.

As used herein, “self-complementarity” in reference to oligomeric compounds means a compound that may fold back on itself, creating a duplex as a result of nucleobase hybridization of internal complementary strand regions. Depending on how close together and/or how long the strand regions are, then the compound may form hairpin loops, junctions, bulges or internal loops.

As used herein, “mismatch” means a nucleobase of an oligomeric compound that is not capable of pairing with a nucleobase at a corresponding position of a target sequence, or at a corresponding position of the oligomeric compound itself when the oligomeric compound hybridizes as a result of self-complementarity, when the oligomeric compound and the target sequence and/or self-complementary regions of the oligomeric compound, are aligned.

As used herein, “hybridization” means the pairing of complementary oligomeric compounds (e.g., an oligomeric compound and its target sequence). While not limited to a particular mechanism, the most common mechanism of pairing involves hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.

As used herein, “specifically hybridizes” means the ability of an oligomeric compound to hybridize to one nucleic acid site with greater affinity than it hybridizes to another nucleic acid site.

As used herein, “fully complementary” in reference to an oligomeric compound or region thereof means that each nucleobase of the oligomeric compound or region thereof is capable of pairing with a nucleobase of a complementary nucleic acid target sequence or a self-complementary region of the oligomeric compound. Thus, a fully complementary oligomeric compound or region thereof comprises no mismatches or unhybridized nucleobases with respect to its target sequence or a self-complementary region of the oligomeric compound.

As used herein, “percent complementarity” means the percentage of nucleobases of an oligomeric compound that are complementary to an equal-length portion of a target nucleic acid. Percent complementarity is calculated by dividing the number of nucleobases of the oligomeric compound that are complementary to nucleobases at corresponding positions in the target nucleic acid by the total length of the oligomeric compound.

As used herein, “percent identity” means the number of nucleobases in a first nucleic acid that are the same type (independent of chemical modification) as nucleobases at corresponding positions in a second nucleic acid, divided by the total number of nucleobases in the first nucleic acid.

As used herein, “modulation” means a change of amount or quality of a molecule, function, or activity when compared to the amount or quality of a molecule, function, or activity prior to modulation. For example, modulation includes the change, either an increase (stimulation or induction) or a decrease (inhibition or reduction) in gene expression.

As used herein, “type of modification” in reference to a nucleoside or a nucleoside of a “type” means the chemical modification of a nucleoside and includes modified and unmodified nucleosides.

Accordingly, unless otherwise indicated, a “nucleoside having a modification of a first type” may be an unmodified nucleoside.

As used herein, “differently modified” mean chemical modifications or chemical substituents that are different from one another, including absence of modifications. Thus, for example, a MOE nucleoside and an unmodified naturally occurring RNA nucleoside are “differently modified,” even though the naturally occurring nucleoside is unmodified. Likewise, DNA and RNA oligonucleotides are “differently modified,” even though both are naturally-occurring unmodified nucleosides. Nucleosides that are the same but for comprising different nucleobases are not differently modified. For example, a nucleoside comprising a 2′-OMe modified sugar moiety and an unmodified adenine nucleobase and a nucleoside comprising a 2′-OMe modified sugar moiety and an unmodified thymine nucleobase are not differently modified.

As used herein, “the same type of modifications” refers to modifications that are the same as one another, including absence of modifications. Thus, for example, two unmodified RNA nucleosides have “the same type of modification,” even though the RNA nucleosides are unmodified. Such nucleosides having the same type modification may comprise different nucleobases.

As used herein, “region” or “regions”, or “portion” or “portions”, mean a plurality of linked nucleosides that have a function or character as defined herein, in particular with reference to the subject-matter and definitions described herein. Typically such regions or portions comprise at least 10, at least 11, at least 12 or at least 13 linked nucleosides. For example, such regions can comprise 13 to 20 linked nucleosides, such as 13 to 16 or 18 to 20 linked nucleosides. Typically a first region as defined herein consists essentially of 18 to 20 nucleosides and a second region as defined herein consists essentially of 13 to 16 linked nucleosides.

As used herein, “pharmaceutically acceptable carrier or diluent” means any substance suitable for use in administering to an animal. In certain embodiments, a pharmaceutically acceptable carrier or diluent is sterile saline. In certain embodiments, such sterile saline is pharmaceutical grade saline.

As used herein, “substituent” and “substituent group,” means an atom or group that replaces the atom or group of a named parent compound. For example a substituent of a modified nucleoside is any atom or group that differs from the atom or group found in a naturally occurring nucleoside (e.g., a modified 2′-substituent is any atom or group at the 2′-position of a nucleoside other than H or OH). Substituent groups can be protected or unprotected. In certain embodiments, compounds of the present disclosure have substituents at one or at more than one position of the parent compound. Substituents may also be further substituted with other substituent groups and may be attached directly or via a linking group such as oxygen or an alkyl or hydrocarbyl group to a parent compound.

Such substituents can be present as the modification on the sugar moiety, in particular a substituent present at the 2′-position of the sugar moiety. Unless otherwise indicated, groups amenable for use as substituents include without limitation, one or more of halo, hydroxyl, alkyl, alkenyl, alkynyl, acyl, carboxyl, alkoxy, alkoxyalkylene and amino substituents. Certain substituents as described herein can represent modifications directly attached to a ring of a sugar moiety (such as a halo, such as fluoro, directly attached to a sugar ring), or a modification indirectly linked to a ring of a sugar moiety by way of an oxygen linking atom that itself is directly linked to the sugar moiety (such as an alkoxyalkylene, such as methoxyethylene, linked to an oxygen atom, overall providing an MOE substituent as described herein attached to the 2′-position of the sugar moiety).

As used herein, “alkyl,” as used herein, means a saturated straight or branched monovalent C₁₋₆ hydrocarbon radical, with methyl being a most preferred alkyl as a substituent at the 2′-position of the sugar moiety. The alkyl group typically attaches to an oxygen linking atom at the 2′ position of the sugar, therefore, overall providing an —O-alkyl substituent, such as an —OCH₃ substituent, on a sugar moiety of an oligomeric compound as described herein. This will be well understood be a person skilled in the art.

As used herein, “alkylene” means a saturated straight or branched divalent hydrocarbon radical of the general formula —C_(n)H_(2n)— where n is 1-6. Methylene or ethylene are preferred alkylenes.

As used herein, “alkenyl” means a straight or branched unsaturated monovalent C₂₋₆ hydrocarbon radical, with ethenyl or propenyl being most preferred alkenyls as a substituent at the 2′-position of the sugar moiety. As will be well understood in the art, the degree of unsaturation that is present in an alkenyl radical is the presence of at least one carbon to carbon double bond. The alkenyl group typically attaches to an oxygen linking atom at the 2′-position of the sugar, therefore, overall providing a —Oalkenyl substituent, such as an —OCH₂CH═CH₂ substituent, on a sugar moiety of an oligomeric compound as described herein. This will be well understood be a person skilled in the art.

As used herein, “alkynyl” means a straight or branched unsaturated C₂₋₆ hydrocarbon radical, with ethynyl being a most preferred alkynyl as a substituent at the 2′-position of the sugar moiety. As will be well understood in the art, the degree of unsaturation that is present in an alkynyl radical is the presence of at least one carbon to carbon triple bond. The alkynyl group typically attaches to an oxygen linking atom at the 2′-position of the sugar, therefore, overall providing a —Oalkynyl substituent on a sugar moiety of an oligomeric compound as described herein. This will be well understood be a person skilled in the art.

As used herein, “carboxyl” is a radical having a general formula —CO₂H.

As used herein, “acyl” means a radical formed by removal of a hydroxyl group from a carboxyl radical as defined herein and has the general Formula —C(O)—X where X is typically C₁₋₆ alkyl.

As used herein, “alkoxy” means a radical formed between an alkyl group, such as a C₁₋₆ alkyl group, and an oxygen atom wherein the oxygen atom is used to attach the alkoxy group either to a parent molecule (such as at the 2′-position of a sugar moiety), or to another group such as an alkylene group as defined herein. Examples of alkoxy groups include without limitation, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy and tert-butoxy. Alkoxy groups as used herein may optionally include further substituent groups.

As used herein, alkoxyalkylene means an alkoxy group as defined herein that is attached to an alkylene group also as defined herein, and wherein the oxygen atom of the alkoxy group attaches to the alkylene group and the alkylene attaches to a parent molecule. The alkylene group typically attaches to an oxygen linking atom at the 2′-position of the sugar, therefore, overall providing a —Oalkylenealkoxy substituent, such as an —OCH₂CH₂OCH₃ substituent, on a sugar moiety of an oligomeric compound as described herein. This will be well understood by a person skilled in the art and is generally referred to as an MOE substituent as defined herein and as known in the art.

As used herein, “amino” includes primary, secondary and tertiary amino groups.

As used herein, “halo” and “halogen,” mean an atom selected from fluorine, chlorine, bromine and iodine.

It will also be understood that oligomeric compounds as described herein may have one or more non-hybridizing nucleosides at one or both ends of one or both strands (overhangs) and/or one or more internal non-hybridizing nucleosides (mismatches) provided there is sufficient complementarity to maintain hybridization under physiologically relevant conditions. Alternatively, oligomeric compounds as described herein may be blunt ended at at least one end.

The term “comprising” is used herein to mean including the method steps or elements identified, but that such steps or elements do not comprise an exclusive list and as such there may be present additional steps or elements.

Further, to the extent that the term “includes” is used in either the detailed description or the claims, such term is intended to be inclusive in a manner similar to the term “comprising” as “comprising” is interpreted when employed as a transitional word in a claim.

Each of the constructs of the invention may or may not have a phosphate modification at the 5′ end group. Furthermore, and independently, each of the above constructs may or may not have a “3× GalNAc” coupled to the 3′ end group. Advantageously, a construct bears a 3× GalNAc ligand, such as a “toothbrush” moiety as disclosed herein. Particularly preferred are constructs which in addition have a 5′ phosphate, even though this is not a strict requirement, given that in the absence thereof, mammalian cells will add such phosphate in case it is absent from the molecule as administered.

The following are aspects of the present embodiments.

Aspect 1. An oligomeric compound capable of modulating, preferably inhibiting, expression of FXI, wherein the compound comprises at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an FXI gene, wherein the first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 1 to 250, or SEQ ID NOs 1251 to 1500.

Aspect 2. An oligomeric compound according to aspect 1, which further comprises at least a second region of linked nucleosides having at least a second nucleobase sequence that is at least partially complementary to the first nucleobase sequence and is selected from the following sequences, or a portion thereof: SEQ ID NOs 251 to 500, or SEQ ID NOs 1501 to 1750.

Aspect 3. An oligomeric compound according to aspect 1 or 2, wherein the first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 8, 13, 27, 39, 46, 91, 98, 103, 105, 109, 120, 140, 146, 151, 152, 163, 182, 183, 199, 207, 210, 218, 220, 223, 224, 238, or SEQ ID NOs 1258, 1263, 1277, 1289, 1296, 1341, 1348, 1353, 1355, 1359, 1370, 1390, 1396, 1401, 1402, 1413, 1432, 1433, 1449, 1457, 1460, 1468, 1470, 1473, 1474, 1488.

Aspect 4. An oligomeric compound according to aspect 3, wherein the second nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 258, 263, 277, 289, 296, 341, 348, 353, 355, 359, 370, 390, 396, 401, 402, 413, 432, 433, 449, 457, 460, 468, 470, 473, 474, 488, or SEQ ID NOs 1508, 1513, 1527, 1539, 1546, 1591, 1598, 1603, 1605, 1609, 1620, 1640, 1646, 1651, 1652, 1663, 1682, 1683, 1699, 1707, 1710, 1718, 1720, 1723, 1724, 1738.

Aspect 5. An oligomeric compound according to any of aspects 1 to 4, wherein the first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 8, 46, 91, 146, 152, 207, or SEQ ID NOs 1258, 1296, 1341, 1396, 1402, 1457.

Aspect 6. An oligomeric compound according to aspect 5, wherein the second nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 258, 296, 341, 396, 402, 457, or SEQ ID NOs 1508, 1546, 1591, 1646, 1652, 1707.

Aspect 7. An oligomeric compound according to any of aspects 1 to 6, wherein the first nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 46, 91, 152, or SEQ ID NOs 1296, 1341, 1402.

Aspect 8. An oligomeric compound according to aspect 7, wherein the second nucleobase sequence is selected from the following sequences, or a portion thereof: SEQ ID NOs 296, 341, 402, or SEQ ID NOs 1546, 1591, 1652.

Aspect 9. An oligomeric compound according to any of aspects 1 to 8, wherein the first nucleobase sequence is at least partially complementary to any of the following sequences, or a portion thereof: SEQ ID NOs 1001 to 1250.

Aspect 10. An oligomeric compound according to aspect 3 and/or 4, wherein the first nucleobase sequence is at least partially complementary to any of the following sequences, or a portion thereof: SEQ ID NOs 1008, 1013, 1027, 1039, 1046, 1091, 1098, 1103, 1105, 1109, 1120, 1140, 1146, 1151, 1152, 1163, 1182, 1183, 1199, 1207, 1210, 1218, 1220, 1223, 1224, 1238.

Aspect 11. An oligomeric compound according to aspect 5 and/or 6, wherein the first nucleobase sequence is at least partially complementary to any of the following sequences, or a portion thereof: SEQ ID NOs 1008, 1046, 1091, 1146, 1152, 1207.

Aspect 12. An oligomeric compound according to aspect 7 and/or 8, wherein the first nucleobase sequence is at least partially complementary to any of the following sequences, or a portion thereof: SEQ ID NOs 1046, 1091, 1152.

Aspect 13. An oligomeric compound capable of modulating, preferably inhibiting, expression of FXI, which compound comprises at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an FXI gene, wherein the RNA is selected from the following sequences, or a portion thereof: SEQ ID NOs 1001 to 1250.

Aspect 14. An oligomeric compound according to aspect 13, wherein the RNA is selected from the following sequences, or a portion thereof: SEQ ID NOs 1008, 1013, 1027, 1039, 1046, 1091, 1098, 1103, 1105, 1109, 1120, 1140, 1146, 1151, 1152, 1163, 1182, 1183, 1199, 1207, 1210, 1218, 1220, 1223, 1224, 1238.

Aspect 15. An oligomeric compound according to aspect 13 or 14, wherein the RNA is selected from the following sequences, or a portion thereof: SEQ ID NOs 1008, 1046, 1091, 1146, 1152, 1207.

Aspect 16. An oligomeric compound according to any of aspects 13 to 15, wherein the RNA is selected from the following sequences, or a portion thereof: SEQ ID NOs 1046, 1091, 1152.

Aspect 17. An oligomeric compound according to any of aspects 1 to 16, wherein the first region of linked nucleosides consists essentially of 18 to 20 linked nucleosides.

Aspect 18. An oligomeric compound according to any of aspects 2 to 17, wherein the second region of linked nucleosides consists essentially of 11 to 16, advantageously 12 to 15 or 13 to 16 linked nucleosides.

Aspect 19. An oligomeric compound according to any of aspects 2 to 18, which comprises at least one complementary duplex region that comprises at least a portion of the first nucleoside region directly or indirectly linked to at least a portion of the second nucleoside region.

Aspect 20. An oligomeric compound according to aspect 19, wherein each of the first and second nucleoside regions has a 5′ to 3′ directionality thereby defining 5′ and 3′ regions respectively thereof.

Aspect 21. An oligomeric compound according to aspect 20, wherein the 5′ region of the first nucleoside region is directly or indirectly linked to the 3′ region of the second nucleoside region, for example by complementary base pairing, and/or wherein the 3′ region of the first nucleoside region is directly or indirectly linked to the 5′ region of the second nucleoside region.

Aspect 22. An oligomeric compound according to any of aspects 1 to 21, which further comprises one or more ligands.

Aspect 23. An oligomeric compound according to aspect 21, wherein the one or more ligands are conjugated to the second nucleoside region.

Aspect 24. An oligomeric compound according to aspect 23, as dependent on aspect 20, wherein the one or more ligands are conjugated at the 3′ region of the second nucleoside region.

Aspect 25. An oligomeric compound according to any of aspects 22 to 24, wherein the one or more ligands are any cell directing moiety, such as lipids, carbohydrates, aptamers, vitamins and/or peptides that bind cellular membrane or a specific target on cellular surface.

Aspect 26. An oligomeric compound according to aspect 25, wherein the one or more ligands comprise one or more carbohydrates.

Aspect 27. An oligomeric compound according to aspect 26, wherein the one or more carbohydrates can be a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide or polysaccharide.

Aspect 28. An oligomeric compound according to aspect 27, wherein the one or more carbohydrates comprise one or more galactose moieties, one or more lactose moieties, one or more N-Acetyl-Galactosamine moieties, and/or one or more mannose moieties.

Aspect 29. An oligomeric compound according to aspect 28, wherein the one or more carbohydrates comprise one or more N-Acetyl-Galactosamine moieties.

Aspect 30. An oligomeric compound according to aspect 29, which comprises two or three N-Acetyl-Galactosamine moieties, preferably three.

Aspect 31. An oligomeric compound according to any of aspects 22 to 30, wherein the one or more ligands are attached to the oligomeric compound, preferably to the second nucleoside region thereof, in a linear configuration, or in a branched configuration.

Preferred is that the ligand has the following structure, also referred to as “toothbrush” herein:

A particularly preferred embodiment of “GalNAc” (as used herein) is the above structure.

Aspect 32. An oligomeric compound according to aspect 31, wherein the one or more ligands are attached to the oligomeric compound as a biantennary or triantennary configuration.

Aspect 33. An oligomeric compound according to aspect 19, wherein the oligomeric compound comprises a single strand comprising the first and second nucleoside regions, wherein the single strand dimerises whereby at least a portion of the first nucleoside region is directly or indirectly linked to at least a portion of the second nucleoside region so as to form the at least partially complementary duplex region.

Aspect 34. An oligomeric compound according to aspect 33, wherein the first nucleoside region has a greater number of linked nucleosides compared to the second nucleoside region, whereby the additional number of linked nucleosides of the first nucleoside region form a hairpin loop linking the first and second nucleoside regions.

Aspect 35. An oligomeric compound according to aspect 34, as dependent on aspect 20, whereby the hairpin loop is present at the 3′ region of the first nucleoside region.

Aspect 36. An oligomeric compound according to aspect 34 or 35, wherein the hairpin loop comprises 4 or 5 linked nucleosides.

Aspect 37. An oligomeric compound according to any of aspects 1 to 36, which comprises internucleoside linkages and wherein at least one internucleoside linkage is a modified internucleoside linkage.

Aspect 38. An oligomeric compound according to aspect 37, wherein the modified internucleoside linkage is a phosphorothioate or phosphorodithioate internucleoside linkage.

Aspect 39. An oligomeric compound according to aspect 38, which comprises 1 to 15 phosphorothioate or phosphorodithioate internucleoside linkages.

Aspect 40. An oligomeric compound according to aspect 39, which comprises 7, 8, 9 or 10 phosphorothioate or phosphorodithioate internucleoside linkages.

Aspect 41. An oligomeric compound according to any of aspects 38 to 40, as dependent on aspect 20, which comprises one or more phosphorothioate or phosphorodithioate internucleoside linkages at the 5′ region of the first nucleoside region.

Aspect 42. An oligomeric compound according to any of aspects 38 to 41, as dependent on aspect 20, which comprises one or more phosphorothioate or phosphorodithioate internucleoside linkages at the 5′ region of the second nucleoside region.

Aspect 43. An oligomeric compound according to any of aspects 38 to 42, as dependent on aspect 34, which comprises phosphorothioate or phosphorodithioate internucleoside linkages between at least two, preferably at least three, preferably at least four, preferably at least five, adjacent nucleosides of the hairpin loop, dependent on the number of nucleotides present in the hairpin loop.

Aspect 44. An oligomeric compound according to aspect 43, which comprises a phosphorothioate or phosphorodithioate internucleoside linkage between each adjacent nucleoside that is present in the hairpin loop.

Aspect 45. An oligomeric compound according to any of aspects 1 to 44, wherein at least one nucleoside comprises a modified sugar.

Aspect 46. An oligomeric compound according to aspect 45, wherein the modified sugar is selected from 2′ modified sugars; conformationally restricted nucleotides (CRN) sugar such as locked nucleic acid (LNA), (S)-constrained ethyl bicyclic nucleic acid, and constrained ethyl (cEt), tricyclo-DNA; morpholino, unlocked nucleic acid (UNA), glycol nucleic acid (GNA), D-hexitol nucleic acid (HNA), and cyclohexene nucleic acid (CeNA), and preferably is a 2′-O-methyl modified sugar.

Further 2′ modified sugars include 2′-O-alkyl modified sugar, 2′-O-methoxyethyl modified sugar, 2′-O-allyl modified sugar, 2′-C-allyl modified sugar, 2′-deoxy modified sugar such as 2′-deoxy ribose, 2′-F modified sugar, 2′-arabino-fluoro modified sugar, 2′-O-benzyl modified sugar, 2′-amino modified sugar, and 2′-O-methyl-4-pyridine modified sugar.

Aspect 47. An oligomeric compound according to aspect 45 or 46, wherein the modified sugar is a 2′-F modified sugar.

Aspect 48. An oligomeric compound according to any of aspects 45 to 47, as dependent on aspect 20, wherein sugars of the nucleosides at any of positions 2 and 14 downstream from the first nucleoside of the 5′ region of the first nucleoside region, do not contain 2′-O-methyl modifications.

Aspect 49. An oligomeric compound according to any of aspects 45 to 48, as dependent on aspect 20, wherein sugars of the nucleosides of the second nucleoside region, that correspond in position to any of the nucleosides of the first nucleoside region at any of positions 9 to 11 downstream from the first nucleotide of the 5′ region of the first nucleoside region, do not contain 2′-O-methyl modifications.

Aspect 50. An oligomeric compound according to aspect 48 or 49, wherein sugars of the nucleosides at any of positions 2 and 14 downstream from the first nucleoside of the 5′ region of the first nucleoside region, contain 2′-F modifications.

Aspect 51. An oligomeric compound according to any of aspects 48 to 50, wherein sugars of the nucleosides of the second nucleoside region, that correspond in position to any of the nucleosides of the first nucleoside region at any of positions 9 to 11 downstream from the first nucleoside of the 5′ region of the first nucleoside region, contain 2′-F modifications.

Aspect 52. An oligomeric compound according to any of aspects 45 to 51, as dependent on aspect 20, wherein one or more of the odd numbered nucleosides starting from the 5′ region of the first nucleoside region are modified, and/or wherein one or more of the even numbered nucleotides starting from the 5′ region of the first nucleoside region are modified, wherein typically the modification of the even numbered nucleotides is a second modification that is different from the modification of odd numbered nucleotides.

Aspect 53. An oligomeric compound according to aspect 52, wherein one or more of the odd numbered nucleosides starting from the 3′ region of the second nucleoside region are modified by a modification that is different from the modification of odd numbered nucleosides of the first nucleoside region.

Aspect 54. An oligomeric compound according to aspect 52 or 53, wherein one or more of the even numbered nucleosides starting from the 3′ region of the second nucleoside region are modified by a modification that is different from the modification of even numbered nucleosides of the first nucleoside region according to aspect 53.

Aspect 55. An oligomeric compound according to any of aspects 52 to 54, wherein at least one or more of the modified even numbered nucleosides of the first nucleoside region is adjacent to at least one or more of the differently modified odd numbered nucleosides of the first nucleoside region.

Aspect 56. An oligomeric compound according to any of aspects 52 to 55, wherein at least one or more of the modified even numbered nucleosides of the second nucleoside region is adjacent to at least one or more of the differently modified odd numbered nucleosides of the second nucleoside region.

Aspect 57. An oligomeric compound according to any of aspects 52 to 56, wherein sugars of one or more of the odd numbered nucleosides starting from the 5′ region of the first nucleoside region are 2′-O-methyl modified sugars.

Aspect 58. An oligomeric compound according to any of aspects 52 to 57, wherein one or more of the even numbered nucleosides starting from the 5′ region of the first nucleoside region are 2′-F modified sugars.

Aspect 59. An oligomeric compound according to any of aspects 52 to 58, wherein sugars of one or more of the odd numbered nucleosides starting from the 3′ region of the second nucleoside region are 2′-F modified sugars.

Aspect 60. An oligomeric compound according to any of aspects 52 to 59, wherein one or more of the even numbered nucleosides starting from the 3′ region of the second nucleoside region are 2′-O-methyl modified sugars.

Aspect 61. An oligomeric compound according to any of aspects 45 to 60, wherein sugars of a plurality of adjacent nucleosides of the first nucleoside region are modified by a common modification.

Aspect 62. An oligomeric compound according to any of aspects 45 to 61, wherein sugars of a plurality of adjacent nucleosides of the second nucleoside region are modified by a common modification.

Aspect 63. An oligomeric compound according to any of aspects 52 to 62, as dependent on aspect 34, wherein sugars of a plurality of adjacent nucleosides of the hairpin loop are modified by a common modification.

Aspect 64. An oligomeric compound according to any of aspects 61 to 63, wherein the common modification is a 2′-F modified sugar.

Aspect 65. An oligomeric compound according to any of aspects 61 to 63, wherein the common modification is a 2′-O-methyl modified sugar.

Aspect 66. An oligomeric compound according to aspect 65, wherein the plurality of adjacent 2′-O-methyl modified sugars are present in at least eight adjacent nucleosides of the first and/or second nucleoside regions.

Aspect 67. An oligomeric compound according to aspect 65, wherein the plurality of adjacent 2′-O-methyl modified sugars are present in three or four adjacent nucleosides of the hairpin loop.

Aspect 68. An oligomeric compound according to aspect 45, as dependent on aspect 34, wherein the hairpin loop comprises at least one nucleoside having a modified sugar.

Aspect 69. An oligomeric compound according to aspect 68, wherein the at least one nucleoside is adjacent a nucleoside with a differently modified sugar.

Aspect 70. An oligomeric compound according to aspect 69, wherein the modified sugar is a 2′-O-methyl modified sugar, and the differently modifies sugar is a 2′-F modified sugar.

Aspect 71. An oligomeric compound according to any of aspects 1 to 70, which comprises one or more nucleosides having an un-modified sugar moiety.

Aspect 72. An oligomeric compound according to aspect 71, wherein the unmodified sugar is present in the 5′ region of the second nucleoside region.

Aspect 73. An oligomeric compound according to aspect 71 or 72, as dependent on aspect 34, wherein the unmodified sugar is present in the hairpin loop.

Aspect 74. An oligomeric compound according to any of aspects 1 to 73, wherein one or more nucleosides of the first nucleoside region and/or the second nucleoside region is an inverted nucleoside and is attached to an adjacent nucleoside via the 3′ carbon of its sugar and the 3′ carbon of the sugar of the adjacent nucleoside, and/or one or more nucleosides of the first nucleoside region and/or the second nucleoside region is an inverted nucleoside and is attached to an adjacent nucleoside via the 5′ carbon of its sugar and the 5′ carbon of the sugar of the adjacent nucleoside.

Aspect 75. An oligomeric compound according to any of aspects 1 to 74, which is blunt ended.

Aspect 76. An oligomeric compound according to any of aspects 1 to 74, wherein either the first or second nucleoside region has an overhang.

Aspect 77. An oligomeric compound capable of modulating, preferably inhibiting, expression of FXI, wherein the compound comprises at least a first region of linked nucleosides having at least a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an FXI gene, wherein the first nucleobase sequence is a modified sequence and is selected from the following sequences, or a portion thereof: construct NOs 501 to 750, or construct NOs 1751 to 2000.

Aspect 78. An oligomeric compound according to aspect 77, which further comprises at least a second region of linked nucleosides having at least a second nucleobase sequence that is at least partially complementary to the first nucleobase sequence, wherein the second nucleobase sequence is a modified sequence and is selected from the following sequences, or a portion thereof: construct NOs 751 to 1000, or construct NOs 2001 to 2250.

Aspect 79. An oligomeric compound according to aspect 77 or 78, wherein the first nucleobase sequence is selected from the following sequences, or a portion thereof: construct NOs 508, 513, 527, 539, 546, 591, 598, 603, 605, 609, 620, 640, 646, 651, 652, 663, 682, 683, 699, 707, 710, 718, 720, 723, 724, 738, or construct NOs 1758, 1763, 1777, 1789, 1796, 1841, 1848, 1853, 1855, 1859, 1870, 1890, 1896, 1901, 1902, 1913, 1932, 1933, 1949, 1957, 1960, 1968, 1970, 1973, 1974, 1988.

Aspect 80. An oligomeric compound according to aspect 79, wherein the second nucleobase sequence is selected from the following sequences, or a portion thereof: construct NOs 758, 763, 777, 789, 796, 841, 848, 853, 855, 859, 870, 890, 896, 901, 902, 913, 932, 933, 949, 957, 960, 968, 970, 973, 974, 988, or construct NOs 2008, 2013, 2027, 2039, 2046, 2091, 2098, 2103, 2105, 2109, 2120, 2140, 2146, 2151, 2152, 2163, 2182, 2183, 2199, 2207, 2210, 2218, 2220, 2223, 2224, 2238.

Aspect 81. An oligomeric compound according to any of aspects 77 to 80, wherein the first nucleobase sequence is selected from the following sequences, or a portion thereof: construct NOs 508, 546, 591, 646, 652, 707, or construct NOs 1758, 1796, 1841, 1896, 1902, 1957.

Aspect 82. An oligomeric compound according to aspect 81, wherein the second nucleobase sequence is selected from the following sequences, or a portion thereof: construct NOs 758, 796, 841, 896, 902, 957, or construct NOs 2008, 2046, 2091, 2146, 2152, 2207.

Aspect 83. An oligomeric compound according to any of aspects 77 to 82, wherein the first nucleobase sequence is selected from the following sequences, or a portion thereof: construct NOs 546, 591, 652, or construct NOs 1796, 1841, 1902.

Aspect 84. An oligomeric compound according to aspect 83, wherein the second nucleobase sequence is selected from the following sequences, or a portion thereof: construct NOs 796, 841, 902, or construct NOs 2046, 2091, 2152.

Aspect 85. An oligomeric compound according to any of aspects 77 to 84, which is further characterised according to any of aspects 17 to 44, or 74 to 76.

Aspect 86. An oligomeric compound capable of modulating, preferably inhibiting, expression of FXI, which is selected from the following sequences: SEQ ID NOs 2251 to 2253, or SEQ ID NOs 2284 to 2288, preferably SEQ ID NO: 2287.

Aspect 87. An oligomeric compound capable of modulating, preferably inhibiting, expression of FXI, which is selected from the following sequences: construct NOs 2254 to 2283.

Aspect 88. An oligomeric compound according to aspect 86 or 87, which further comprises one or more ligands.

Aspect 89. An oligomeric compound according to aspect 88, wherein the one or more ligands are conjugated at the 3 ‘ region of the sequences, preferably at the 3’ terminal nucleoside.

Aspect 90. An oligomeric compound according to aspect 88, wherein the one or more ligands are conjugated at non-terminal positions.

Aspect 91. An oligomeric compound according to any of aspects 88 to 90, wherein the one or more ligands are any cell directing moiety, such as lipids, carbohydrates, aptamers, vitamins and/or peptides that bind cellular membrane or a specific target on cellular surface.

Aspect 92. An oligomeric compound according to aspect 91, wherein the one or more ligands comprise one or more carbohydrates.

Aspect 93. An oligomeric compound according to aspect 92, wherein the one or more carbohydrates can be a monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide or polysaccharide.

A preferred monosaccharide is hexose.

Aspect 94. An oligomeric compound according to aspect 93, wherein the one or more carbohydrates comprise one or more galactose moieties, one or more lactose moieties, one or more N-Acetyl-Galactosamine moieties, and/or one or more mannose moieties.

Aspect 95. An oligomeric compound according to aspect 94, wherein the one or more carbohydrates comprise one or more N-Acetyl-Galactosamine moieties.

Aspect 96. An oligomeric compound according to aspect 95, which comprises two or three N-Acetyl-Galactosamine moieties, preferably three.

Aspect 97. An oligomeric compound according to any of aspects 88 to 96, wherein the one or more ligands are attached to the oligomeric compound in a linear configuration, or in a branched configuration.

Aspect 98. An oligomeric compound according to aspect 97, wherein the one or more ligands are attached to the oligomeric compound as a biantennary or triantennary configuration.

Aspect 99. An oligomeric compound according to any of aspects 86 to aspect 98, wherein the sequences self dimerise so as to form an at least partially complementary duplex region.

Aspect 100. An oligomeric compound according to aspect 99, having a nucleobase sequence and structure as shown in any of FIGS. 15 to 17 or 18 to 20, construct NOs: 2290 to 2292 being preferred, construct NO: 2290 being particularly preferred.

Aspect 101. A composition comprising an oligomeric compound according to any of aspects 1 to 100, and a physiologically acceptable excipient.

Aspect 102. An oligomeric compound according to any of aspects 1 to 100, for use in therapy.

Aspect 103. An oligomeric compound according to any of aspects 1 to 100, for use in the treatment of a disease or disorder.

Aspect 104. A method of treating a disease or disorder comprising administration of an oligomeric compound according to any of aspects 1 to 100, to an individual in need of treatment.

Aspect 105. A method according to aspect 104, wherein the oligomeric compound is administered subcutaneously or intravenously to the individual.

Aspect 106. Use of an oligomeric compound according to any of aspects 1 to 100, for use in research as a gene function analysis tool.

Aspect 107. Use according to aspect 103, or a method according to aspect 104, wherein the disease or disorder is a thromboembolic disease.

Aspect 108. Use or method according to aspect 107, wherein the thromboembolic disease is selected from the group consisting of deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, stroke, thrombosis associated with chronic kidney disease or end-stage renal disease (ESRD), including thrombosis associated with dialysis, or other procoagulant condition.

Aspect 109. Use or method according to aspect 108, wherein the thromboembolic disease is deep vein thrombosis, pulmonary embolism, or a combination thereof.

Aspect 110. Use of an oligomeric compound according to any of items 1 to 100 in the manufacture of a medicament for a treatment of a disease or disorder. The diseases and disorders are advantageously the same as set forth herein above.

The molecules disclosed herein, including, but not limited to, the hairpin RNAs as shown in Tables 6 and 7 and FIGS. 15 to 18, 20 and 22 are characterized by surprisingly outstanding performance, including in an in vivo setting; see, for example, the evidence shown in FIGS. 24 and 25. These data show a long-lasting down-regulation of Factor XI in response to administration of constructs as described herein. Further evidence of surprising performance of a plurality of constructs can be seen in the in vitro data provided in the Examples, including the data shown in FIG. 19.

The Figures as provided herein illustrate exemplary methods and data. While the methods are shown and described as being a series of acts that are performed in a particular sequence, it is to be understood and appreciated that the methods are not limited by the order of the sequence. For example, some acts can occur in a different order than what is described herein. In addition, an act can occur concurrently with another act. Further, in some instances, not all acts may be required to implement a method described herein.

The order of the steps of the methods described herein is exemplary, but the steps may be carried out in any suitable order, or simultaneously where appropriate. Additionally, steps may be added or substituted in, or individual steps may be deleted from any of the methods without departing from the scope of the subject matter described herein. Aspects of any of the Examples described above may be combined with aspects of any of the other Examples described to form further Examples.

It will be understood that the above description of a preferred embodiment is given by way of example only and that various modifications may be made by those skilled in the art. What has been described above includes Examples of one or more embodiments. It is, of course, not possible to describe every conceivable modification and alteration of the above compounds, compositions or methods for purposes of describing the aforementioned aspects, but one of ordinary skill in the art can recognize that many further modifications and permutations of various aspects are possible. Accordingly, the described aspects are intended to embrace all such alterations, modifications, and variations that fall within the scope of the appended claims.

EXAMPLES

The following Examples illustrate certain embodiments of the present disclosure and are not limiting. Moreover, where specific embodiments are provided, the inventors have contemplated generic application of those specific embodiments. For example, disclosure of an oligonucleotide having a particular motif or modification patterns provides reasonable support for additional oligonucleotides having the same or similar motif or modification patterns.

The syntheses of the RNAi constructs disclosed herein may be carried out using synthesis methods known to the person skilled in the art, such as synthesis methods disclosed in https://en.wikipedia.org/wiki/Oligonucleotide_synthesis {retrieved on 16 Feb. 2022}, wherein the methods disclosed on this website are incorporated by reference herein in their entirety. The only difference to the synthesis method disclosed in this reference is that GalNAc phosphoramidite immobilized on a support is used in the synthesis method during the first synthesis step.

The terms “construct number” and “SEQ ID NO” are used equivalently herein, especially with respect to 67 nucleobase sequences. Nucleobase sequences generally do not carry information about modifications of the sugar-phosphate backbone.

Example 1

Oligomeric compounds were synthesized using the oligonucleotides as set out in Tables 1a and 1 b below.

TABLE 1a Summary sequence table for active nucleobase sequences: Seq Seq Oligo ID Antisense (Guide) Strand ID Sense (Passenger) Strand Name No Sequence (5′ to 3′) No Sequence (5′ to 3′) F11-   1 UCAAAAUCUUAGGUGACUC 251 CACCUAAGAUUUUGA 01 F11-   2 UAUUGAUUUAAAAUGCCAC 252 CAUUUUAAAUCAAUA 02 F11-   3 UAGAAAUCGCUGCUGUCCU 253 CAGCAGCGAUUUCUA 03 F11-   4 UAUAAGAAAAUCAUCCUGA 254 GAUGAUUUUCUUAUA 04 F11-   5 UAAACACCGUAUUAGGGAA 255 CUAAUACGGUGUUUA 05 F11-   6 UAAAUCAGUGUCAUGGUAA 256 CAUGACACUGAUUUA 06 F11-   7 UAUACCCGCUUUCUGCCAU 257 CAGAAAGCGGGUAUA 07 F11-   8 UAGAUGUUUUAAGGAGACA 258 UCCUUAAAACAUCUA 08 F11-   9 UGGUAUCUUGGCUUUCUGG 259 AAAGCCAAGAUACCA 09 F11-  10 UCUCUGUAUCUCUUCUGGC 260 GAAGAGAUACAGAGA 10 F11-  11 UAUGGAUUAUUAUUUCUUG 261 AAAUAAUAAUCCAUA 11 F11-  12 UAGCCAGAUUAGAAAGUGC 262 UUUCUAAUCUGGCUA 12 F11-  13 UAGCGGACGGCAUUGGUGC 263 CAAUGCCGUCCGCUA 13 F11-  14 UAUUUCAGAUUGAUUUAAA 264 AAUCAAUCUGAAAUA 14 F11-  15 UUUGUCUCUUAGUUUUCUG 265 AAACUAAGAGACAAA 15 F11-  16 UAGAACACUGGGAUGCUGU 266 CAUCCCAGUGUUCUA 16 F11-  17 UCCACUUGAUAUAAGAAAA 267 CUUAUAUCAAGUGGA 17 F11-  18 UCAUUUUCUUACAAACACC 268 UUUGUAAGAAAAUGA 18 F11-  19 UUAAUGCGUGUACUGGGCA 269 CAGUACACGCAUUAA 19 F11-  20 UAGGACAGAGGGCCUCCCG 270 AGGCCCUCUGUCCUA 20 F11-  21 UCAACCGGGAUGAUGAGUG 271 CAUCAUCCCGGUUGA 21 F11-  22 UGACAAAGAUUUCUUUGAG 272 AAGAAAUCUUUGUCA 22 F11-  23 UGAGGAAGCAUGCUGGCAC 273 CAGCAUGCUUCCUCA 23 F11-  24 UGGAAAAUGUCCCUAAUAC 274 UAGGGACAUUUUCCA 24 F11-  25 UUUAAGUAACACUUGCCCU 275 CAAGUGUUACUUAAA 25 F11-  26 UCAAUAUCAUACCCGCUUU 276 CGGGUAUGAUAUUGA 26 F11-  27 UAAAUGUACCACUUGAUAU 277 CAAGUGGUACAUUUA 27 F11-  28 UAGAAAAUCAUCCUGAAAA 278 CAGGAUGAUUUUCUA 28 F11-  29 UUAACACUUGCCCUUCCCU 279 AAGGGCAAGUGUUAA 29 F11-  30 UAGCAUUUUCUUACAAACA 280 UGUAAGAAAAUGCUA 30 F11-  31 UCAAACACCGUAUUAGGGA 281 UAAUACGGUGUUUGA 31 F11-  32 UAGCGGCUGUUAAUAUCCA 282 UAUUAACAGCCGCUA 32 F11-  33 UGAGCGGCUGUUAAUAUCC 283 AUUAACAGCCGCUCA 33 F11-  34 UGAGACAAAGAUUUCUUUG 284 GAAAUCUUUGUCUCA 34 F11-  35 UUGGGUUAUUUUAUGUCCU 285 CAUAAAAUAACCCAA 35 F11-  36 UGAGCCAUGACACUGUCGA 286 CAGUGUCAUGGCUCA 36 F11-  37 UCAGAUUAGAAAGUGCACA 287 CACUUUCUAAUCUGA 37 F11-  38 UAGAAUACCCAGAAAUCGC 288 UUUCUGGGUAUUCUA 38 F11-  39 UCAGAUGUUUUAAGGAGAC 289 CCUUAAAACAUCUGA 39 F11-  40 UUGUAUCCAGAGAUGCCUC 290 CAUCUCUGGAUACAA 40 F11-  41 UGAGUCACACAUUCACCAG 291 UGAAUGUGUGACUCA 41 F11-  42 UCAAAGAAAGAUGUGUCCU 292 CACAUCUUUCUUUGA 42 F11-  43 UACCACUUGAUAUAAGAAA 293 UUAUAUCAAGUGGUA 43 F11-  44 UAAGAAAGCUUUAAGUAAC 294 CUUAAAGCUUUCUUA 44 F11-  45 UUUAUUUCAGAUUGAUUUA 295 UCAAUCUGAAAUAAA 45 F11-  46 UUGGUGUGAGCAUUGCUUG 296 CAAUGCUCACACCAA 46 F11-  47 UAUCAUCCUGAAAAGACCU 297 CUUUUCAGGAUGAUA 47 F11-  48 UGUGAGCAUUGCUUGAAAG 298 CAAGCAAUGCUCACA 48 F11-  49 UCUGUAUCUCUUCUGGCAC 299 CAGAAGAGAUACAGA 49 F11-  50 UACCUUAAUGUGUAUCCAG 300 AUACACAUUAAGGUA 50 F11-  51 UAUCAUGGAUUAUUAUUUC 301 UAAUAAUCCAUGAUA 51 F11-  52 UCAAAGAUUUCUUUGAGAU 302 CAAAGAAAUCUUUGA 52 F11-  53 UGAAGUAUUUUAGUUGGAG 303 AACUAAAAUACUUCA 53 F11-  54 UAGAUUGAUUUAAAAUGCC 304 UUUUAAAUCAAUCUA 54 F11-  55 UGGGUAUCUUGGCUUUCUG 305 AAGCCAAGAUACCCA 55 F11-  56 UAGGAGACAAAGAUUUCUU 306 AAUCUUUGUCUCCUA 56 F11-  57 UGUCAUGGUAAAAUGAAGA 307 CAUUUUACCAUGACA 57 F11-  58 UAUAUCCAGUUCUUCUCCC 308 GAAGAACUGGAUAUA 58 F11-  59 UAAUAUCCAGUUCUUCUCC 309 AAGAACUGGAUAUUA 59 F11-  60 UCUGUGGUUUCCAGUUUCA 310 ACUGGAAACCACAGA 60 F11-  61 UAGAUUAGAAAGUGCACAG 311 GCACUUUCUAAUCUA 61 F11-  62 UAGAAAUCAGUGUCAUGGU 312 UGACACUGAUUUCUA 62 F11-  63 UUGGAUUAUUAUUUCUUGA 313 GAAAUAAUAAUCCAA 63 F11-  64 UCCAGAUUAGAAAGUGCAC 314 ACUUUCUAAUCUGGA 64 F11-  65 UCUCAUUAUCCAUUUUACA 315 AAAUGGAUAAUGAGA 65 F11-  66 UUUGGGCCAUUCCUGGGAA 316 CAGGAAUGGCCCAAA 66 F11-  67 UUGGGCUUGAUUUUGGUGG 317 CAAAAUCAAGCCCAA 67 F11-  68 UCAGAUUGAUUUAAAAUGC 318 UUUAAAUCAAUCUGA 68 F11-  69 UAAGCAACCGGGAUGAUGA 319 CAUCCCGGUUGCUUA 69 F11-  70 UCUUAAUGUGUAUCCAGAG 320 GGAUACACAUUAAGA 70 F11-  71 UGUAAUUCACUGUGGUUUC 321 CCACAGUGAAUUACA 71 F11-  72 UACAUUUCUAUCUCCUUUG 322 GGAGAUAGAAAUGUA 72 F11-  73 UCACUGGUUUCCAAUGAUG 323 AUUGGAAACCAGUGA 73 F11-  74 UGAAUCUGUGUAAUUCACU 324 AAUUACACAGAUUCA 74 F11-  75 UGUCCUAUUCACUCUUGGC 325 AGAGUGAAUAGGACA 75 F11-  76 UAGCAUUGCUUGAAAGAAU 326 UUUCAAGCAAUGCUA 76 F11-  77 UAAUACCCAGAAAUCGCUG 327 GAUUUCUGGGUAUUA 77 F11-  78 UAUUAUUAUUUCUUGAACC 328 CAAGAAAUAAUAAUA 78 F11-  79 UAAGUAUUUUAGUUGGAGA 329 CAACUAAAAUACUUA 79 F11-  80 UGAAUCCAGUCCACGUACU 330 CGUGGACUGGAUUCA 80 F11-  81 UAGACAAAGAUUUCUUUGA 331 AGAAAUCUUUGUCUA 81 F11-  82 UACAGGAUUUCAGUGAAAA 332 CACUGAAAUCCUGUA 82 F11-  83 UAACAAGGCAAUAUCAUAC 333 GAUAUUGCCUUGUUA 83 F11-  84 UAAGGCAAUAUCAUACCCG 334 UAUGAUAUUGCCUUA 84 F11-  85 UAUACCCAGAAAUCGCUGC 335 CGAUUUCUGGGUAUA 85 F11-  86 UGAUUGAUUUAAAAUGCCA 336 AUUUUAAAUCAAUCA 86 F11-  87 UCCUAUUCACUCUUGGCAG 337 CAAGAGUGAAUAGGA 87 F11-  88 UGUAGACACGCAAAAUCUU 338 UUUUGCGUGUCUACA 88 F11-  89 UUGAGUUUUCUCCAGAAUC 339 CUGGAGAAAACUCAA 89 F11-  90 UAUUUCUUUGAGAUUCUUU 340 AAUCUCAAAGAAAUA 90 F11-  91 UUAUAAGAAAAUCAUCCUG 341 AUGAUUUUCUUAUAA 91 F11-  92 UAAAAUCUUAGGUGACUCU 342 UCACCUAAGAUUUUA 92 F11-  93 UACACUGGGAUGCUGUGCC 343 CAGCAUCCCAGUGUA 93 F11-  94 UUGCACAGGAUUUCAGUGA 344 UGAAAUCCUGUGCAA 94 F11-  95 UAUACAAGCCAGAUUAGAA 345 AAUCUGGCUUGUAUA 95 F11-  96 UUGUGGUUUCCAGUUUCAA 346 AACUGGAAACCACAA 96 F11-  97 UUGCCCUUCCCUUCGUUGC 347 CGAAGGGAAGGGCAA 97 F11-  98 UAAAAUCAUCCUGAAAAGA 348 UUCAGGAUGAUUUUA 98 F11-  99 UCCAAGAAAUCAGUGUCAU 349 CACUGAUUUCUUGGA 99 F11- 100 UGGCAUAUGGGUCGUUGAG 350 ACGACCCAUAUGCCA 100 F11- 101 UAGAAUCUGUGUAAUUCAC 351 AUUACACAGAUUCUA 101 F11- 102 UAUCCAGUCCACGUACUCG 352 UACGUGGACUGGAUA 102 F11- 103 UCCUCUGUAUCUCUUCUGG 353 AAGAGAUACAGAGGA 103 F11- 104 UGCACAGGAUUUCAGUGAA 354 CUGAAAUCCUGUGCA 104 F11- 105 UGUAAAAUGAAGAAUGGCA 355 AUUCUUCAUUUUACA 105 F11- 106 UGUCGUUGAGAAUCUGUGU 356 AGAUUCUCAACGACA 106 F11- 107 UGCAACAAUAUCCAGUUCU 357 CUGGAUAUUGUUGCA 107 F11- 108 UCAGCGGACGGCAUUGGUG 358 AAUGCCGUCCGCUGA 108 F11- 109 UGAAAGCUUUAAGUAACAC 359 UACUUAAAGCUUUCA 109 F11- 110 UGCAGUGUUUCUGUAACAC 360 UACAGAAACACUGCA 110 F11- 111 UGAGAAUCUGUGUAAUUCA 361 UUACACAGAUUCUCA 111 F11- 112 UUCCAGUCCACGUACUCGA 362 GUACGUGGACUGGAA 112 F11- 113 UUGUGAGCAUUGCUUGAAA 363 AAGCAAUGCUCACAA 113 F11- 114 UCCGGGAUGAUGAGUGCAG 364 ACUCAUCAUCCCGGA 114 F11- 115 UCCACUUUAUCGAGCUUCG 365 GCUCGAUAAAGUGGA 115 F11- 116 UCAUUAUCCAUUUUACACA 366 UAAAAUGGAUAAUGA 116 F11- 117 UAACCGGGAUGAUGAGUGC 367 UCAUCAUCCCGGUUA 117 F11- 118 UUUCUUUGGGCCAUUCCUG 368 AAUGGCCCAAAGAAA 118 F11- 119 UCUAAGGGUAUCUUGGCUU 369 CAAGAUACCCUUAGA 119 F11- 120 UUUGGUGUGAGCAUUGCUU 370 AAUGCUCACACCAAA 120 F11- 121 UCAUAUGGGUCGUUGAGAA 371 CAACGACCCAUAUGA 121 F11- 122 UUUAAUGUGUAUCCAGAGA 372 UGGAUACACAUUAAA 122 F11- 123 UUCAGAUGUUUUAAGGAGA 373 CUUAAAACAUCUGAA 123 F11- 124 UUUCCAAUGAUGGAGCCUC 374 CUCCAUCAUUGGAAA 124 F11- 125 UAGAAUCCAGUCCACGUAC 375 GUGGACUGGAUUCUA 125 F11- 126 UUUUGAGAUUCUUUGGGCC 376 CAAAGAAUCUCAAAA 126 F11- 127 UAAUCAUCCUGAAAAGACC 377 UUUUCAGGAUGAUUA 127 F11- 128 UAGACACGCAAAAUCUUAG 378 GAUUUUGCGUGUCUA 128 F11- 129 UCGUACUCGACCACGUUGG 379 CGUGGUCGAGUACGA 129 F11- 130 UCAUCCAGUCACCCAGCAA 380 UGGGUGACUGGAUGA 130 F11- 131 UAACACUGGGAUGCUGUGC 381 AGCAUCCCAGUGUUA 131 F11- 132 UCAGAAAGAGCUUUGCUCU 382 CAAAGCUCUUUCUGA 132 F11- 133 UUUCUUUGAGAUUCUUUGG 383 AGAAUCUCAAAGAAA 133 F11- 134 UAGCAACAAUAUCCAGUUC 384 UGGAUAUUGUUGCUA 134 F11- 135 UACCACUUUAUCGAGCUUC 385 CUCGAUAAAGUGGUA 135 F11- 136 UCCCUUCCCUUCGUUGCAG 386 AACGAAGGGAAGGGA 136 F11- 137 UCGCAAAAUCUUAGGUGAC 387 CCUAAGAUUUUGCGA 137 F11- 138 UAGCGUGUUACUGUGGAGG 388 CACAGUAACACGCUA 138 F11- 139 UCUCCUUCCCUGUAGCCGG 389 CUACAGGGAAGGAGA 139 F11- 140 UGUCCUCUGUAUCUCUUCU 390 GAGAUACAGAGGACA 140 F11- 141 UGUAUCUUGGCUUUCUGGA 391 GAAAGCCAAGAUACA 141 F11- 142 UCUCUUGGCAGUGUUUCUG 392 AACACUGCCAAGAGA 142 F11- 143 UGAAAUCAGUGUCAUGGUA 393 AUGACACUGAUUUCA 143 F11- 144 UCUUCCCUGUAGCCGGCAC 394 CGGCUACAGGGAAGA 144 F11- 145 UCUGGCCGCUCCCUUUGAG 395 AAGGGAGCGGCCAGA 145 F11- 146 UCACGCAAAAUCUUAGGUG 396 UAAGAUUUUGCGUGA 146 F11- 147 UGAAACCAGAAAGAGCUUU 397 CUCUUUCUGGUUUCA 147 F11- 148 UAAAGCUUUAAGUAACACU 398 UUACUUAAAGCUUUA 148 F11- 149 UACAAGCCAGAUUAGAAAG 399 CUAAUCUGGCUUGUA 149 F11- 150 UACUCAUUAUCCAUUUUAC 400 AAUGGAUAAUGAGUA 150 F11- 151 UCCUGAAAAGACCUUGUUG 401 AAGGUCUUUUCAGGA 151 F11- 152 UGGUUUCCAAUGAUGGAGC 402 CAUCAUUGGAAACCA 152 F11- 153 UCAGUUUCUGGCAGGCCUC 403 CCUGCCAGAAACUGA 153 F11- 154 UAUGGCAGAACACUGGGAU 404 CAGUGUUCUGCCAUA 154 F11- 155 UAGAUUUCUUUGAGAUUCU 405 UCUCAAAGAAAUCUA 155 F11- 156 UGUUUCCAGUUUCAACAAG 406 UUGAAACUGGAAACA 156 F11- 157 UUCCUCUGUAUCUCUUCUG 407 AGAGAUACAGAGGAA 157 F11- 158 UCAUCCUGAAAAGACCUUG 408 GUCUUUUCAGGAUGA 158 F11- 159 UUUGAGUUUUCUCCAGAAU 409 UGGAGAAAACUCAAA 159 F11- 160 UAAUUCACUGUGGUUUCCA 410 AACCACAGUGAAUUA 160 F11- 161 UAAGAUUUCUUUGAGAUUC 411 CUCAAAGAAAUCUUA 161 F11- 162 UGGAGACAAAGAUUUCUUU 412 AAAUCUUUGUCUCCA 162 F11- 163 UGAAAAUCAUCCUGAAAAG 413 UCAGGAUGAUUUUCA 163 F11- 164 UCUUUCUGCCAUUUUAUAC 414 AAAAUGGCAGAAAGA 164 F11- 165 UAGUCCACGUACUCGACCA 415 CGAGUACGUGGACUA 165 F11- 166 UUUAAUGCGUGUACUGGGC 416 AGUACACGCAUUAAA 166 F11- 167 UUAAUGUGUAUCCAGAGAU 417 CUGGAUACACAUUAA 167 F11- 168 UGAUUCUUUGGGCCAUUCC 418 UGGCCCAAAGAAUCA 168 F11- 169 UUGAAACCAGAAAGAGCUU 419 UCUUUCUGGUUUCAA 169 F11- 170 UCACACAUUCACCAGAAAC 420 CUGGUGAAUGUGUGA 170 F11- 171 UACAAAGAUUUCUUUGAGA 421 AAAGAAAUCUUUGUA 171 F11- 172 UCAUUUCUAUCUCCUUUGG 422 AGGAGAUAGAAAUGA 172 F11- 173 UUUUCUGUAACACUGUCUU 423 CAGUGUUACAGAAAA 173 F11- 174 UGGAUUUCAGUGAAAAUCC 424 UUUCACUGAAAUCCA 174 F11- 175 UCGCUCCCUUUGAGCACAG 425 GCUCAAAGGGAGCGA 175 F11- 176 UCAGUCCACGUACUCGACC 426 GAGUACGUGGACUGA 176 F11- 177 UAGGCAUAUGGGUCGUUGA 427 CGACCCAUAUGCCUA 177 F11- 178 UAUGUCCUCUGUAUCUCUU 428 GAUACAGAGGACAUA 178 F11- 179 UGCUUGAUUUUGGUGGUAC 429 CACCAAAAUCAAGCA 179 F11- 180 UAUGAUGGAGCCUCCACAC 430 GGAGGCUCCAUCAUA 180 F11- 181 UUCGUUGAGAAUCUGUGUA 431 CAGAUUCUCAACGAA 181 F11- 182 UUUAUCCAUUUUACACAAC 432 UGUAAAAUGGAUAAA 182 F11- 183 UUGUCCUAUUCACUCUUGG 433 GAGUGAAUAGGACAA 183 F11- 184 UCAAUAUCCAGUUCUUCUC 434 AGAACUGGAUAUUGA 184 F11- 185 UCUUUGAGAUUCUUUGGGC 435 AAAGAAUCUCAAAGA 185 F11- 186 UCACUCUUGGCAGUGUUUC 436 CACUGCCAAGAGUGA 186 F11- 187 UCUUGAAAGAAUACCCAGA 437 GGUAUUCUUUCAAGA 187 F11- 188 UAGGCAAUAUCAUACCCGC 438 GUAUGAUAUUGCCUA 188 F11- 189 UCUGUGUAAUUCACUGUGG 439 AGUGAAUUACACAGA 189 F11- 190 UAAUAUCCACUGGUUUCCA 440 AACCAGUGGAUAUUA 190 F11- 191 UUGAAAGAAUACCCAGAAA 441 UGGGUAUUCUUUCAA 191 F11- 192 UGUUAAUAUCCACUGGUUU 442 CAGUGGAUAUUAACA 192 F11- 193 UUGUCAUGGUAAAAUGAAG 443 AUUUUACCAUGACAA 193 F11- 194 UAUUCUUUGGGCCAUUCCU 444 AUGGCCCAAAGAAUA 194 F11- 195 UCAGUUCCUCCAACGAUCC 445 CGUUGGAGGAACUGA 195 F11- 196 UGGGUGUGCUUCAGUAGAC 446 ACUGAAGCACACCCA 196 F11- 197 UGAAGAAAGCUUUAAGUAA 447 UUAAAGCUUUCUUCA 197 F11- 198 UAUCCUGAAAAGACCUUGU 448 GGUCUUUUCAGGAUA 198 F11- 199 UAGAAAGCUUUAAGUAACA 449 ACUUAAAGCUUUCUA 199 F11- 200 UCAGUGUUUCUGUAACACU 450 UUACAGAAACACUGA 200 F11- 201 UGACACGCAAAAUCUUAGG 451 AGAUUUUGCGUGUCA 201 F11- 202 UGUGUGAGCAUUGCUUGAA 452 AGCAAUGCUCACACA 202 F11- 203 UACCAGAAAGAGCUUUGCU 453 AAGCUCUUUCUGGUA 203 F11- 204 UAGAAAGUGCACAGGAUUU 454 CCUGUGCACUUUCUA 204 F11- 205 UUUUAUUUCAGAUUGAUUU 455 CAAUCUGAAAUAAAA 205 F11- 206 UUAUCCAGUUCUUCUCCCA 456 AGAAGAACUGGAUAA 206 F11- 207 UCCGUGAAAGUGAAGAGUA 457 CUUCACUUUCACGGA 207 F11- 208 UGGUGUGCUUCAGUAGACA 458 UACUGAAGCACACCA 208 F11- 209 UGGACAGAGGGCCUCCCGA 459 GAGGCCCUCUGUCCA 209 F11- 210 UAAGAAAAUCAUCCUGAAA 460 AGGAUGAUUUUCUUA 210 F11- 211 UUGAGAUUCUUUGGGCCAU 461 CCCAAAGAAUCUCAA 211 F11- 212 UAUGUUUUAAGGAGACAAA 462 UCUCCUUAAAACAUA 212 F11- 213 UCACAGUUUCUGGCAGGCC 463 UGCCAGAAACUGUGA 213 F11- 214 UACAAUAUCCAGUUCUUCU 464 GAACUGGAUAUUGUA 214 F11- 215 UACAUUCACCAGAAACUGA 465 UUUCUGGUGAAUGUA 215 F11- 216 UCAAGGCAAUAUCAUACCC 466 AUGAUAUUGCCUUGA 216 F11- 217 UCUCCAACGAUCCUGGGCU 467 CAGGAUCGUUGGAGA 217 F11- 218 UCUGAAACCAGAAAGAGCU 468 CUUUCUGGUUUCAGA 218 F11- 219 UAAUCUCCCUUGCAAGCGU 469 UUGCAAGGGAGAUUA 219 F11- 220 UUGUGUAAUUCACUGUGGU 470 CAGUGAAUUACACAA 220 F11- 221 UUUUCAGUGAAAAUCCAGA 471 GAUUUUCACUGAAAA 221 F11- 222 UAAAUCAUCCUGAAAAGAC 472 UUUCAGGAUGAUUUA 222 F11- 223 UUACACUCAUUAUCCAUUU 473 GGAUAAUGAGUGUAA 223 F11- 224 UUUGGCAGUGUUUCUGUAA 474 AGAAACACUGCCAAA 224 F11- 225 UGGUACACUCAUUAUCCAU 475 AUAAUGAGUGUACCA 225 F11- 226 UAGGCAGGCAUAUGGGUCG 476 CCAUAUGCCUGCCUA 226 F11- 227 UCCAGUUUCAACAAGGCAA 477 CUUGUUGAAACUGGA 227 F11- 228 UUGGCCGCUCCCUUUGAGC 478 AAAGGGAGCGGCCAA 228 F11- 229 UACUGUGGUUUCCAGUUUC 479 CUGGAAACCACAGUA 229 F11- 230 UCUUUGGGCCAUUCCUGGG 480 GGAAUGGCCCAAAGA 230 F11- 231 UUAAGAAAAUCAUCCUGAA 481 GGAUGAUUUUCUUAA 231 F11- 232 UCUCUUUUAUUUCAGAUUG 482 CUGAAAUAAAAGAGA 232 F11- 233 UUCUUUGAGAUUCUUUGGG 483 AAGAAUCUCAAAGAA 233 F11- 234 UAAUGAUGGAGCCUCCACA 484 GAGGCUCCAUCAUUA 234 F11- 235 UGAAGAAUGGCAGAACACU 485 UUCUGCCAUUCUUCA 235 F11- 236 UCAAUGAUGGAGCCUCCAC 486 AGGCUCCAUCAUUGA 236 F11- 237 UAUGGAGCCUCCACACAGG 487 UGUGGAGGCUCCAUA 237 F11- 238 UCCCAAGAAAUCAGUGUCA 488 ACUGAUUUCUUGGGA 238 F11- 239 UGAGCCUCCACACAGGUGU 489 CUGUGUGGAGGCUCA 239 F11- 240 UCUCCCAAGAAAUCAGUGU 490 UGAUUUCUUGGGAGA 240 F11- 241 UCCUCCACACAGGUGUCUC 491 CACCUGUGUGGAGGA 241 F11- 242 UCCAAUGAUGGAGCCUCCA 492 GGCUCCAUCAUUGGA 242 F11- 243 UUUUCCAAUGAUGGAGCCU 493 UCCAUCAUUGGAAAA 243 F11- 244 UUCCCAAGAAAUCAGUGUC 494 CUGAUUUCUUGGGAA 244 F11- 245 UAGCCUCCACACAGGUGUC 495 CCUGUGUGGAGGCUA 245 F11- 246 UUCUUCUCCCAAGAAAUCA 496 UUCUUGGGAGAAGAA 246 F11- 247 UGUUUCCAAUGAUGGAGCC 497 CCAUCAUUGGAAACA 247 F11- 248 UUCCAAUGAUGGAGCCUCC 498 GCUCCAUCAUUGGAA 248 F11- 249 UUGGAGCCUCCACACAGGU 499 GUGUGGAGGCUCCAA 249 F11- 250 UGCCUCCACACAGGUGUCU 500 ACCUGUGUGGAGGCA 250

In above Table 1a:

A represents adenine;

U represents uracil;

C represents cytosine;

G represents guanine.

TABLE 1b Summary sequence table for active nucleobase sequences with chemical modifications: Oligo construct Antisense (Guide) Strand construct Sense (Passenger) Strand Name No Sequence (5′ to 3′) No Sequence (5′ to 3′) F11- 501 PmU.fC.mA.fA.mA.fA.mU.fC.mU.fU.m 751 fC.mA.fC.mC.fU.mA.fA.mG.fA.mU 01M A.fG.mG.fU.mG.fA.mC.fU.mC .fU.mU.fU.mG.fA F11- 502 PmU.fA.mU.fU.mG.fA.mU.fU.mU.fA.m 752 fC.mA.fU.mU.fU.mU.fA.mA.fA.mU 02M A.fA.mA.fU.mG.fC.mC.fA.mC .fC.mA.fA.mU.fA F11- 503 PmU.fA.mG.fA.mA.fA.mU.fC.mG.fC.m 753 fC.mA.fG.mC.fA.mG.fC.mG.fA.m 03M U.fG.mC.fU.mG.fU.mC.fC.mU U.fU.mU.fC.mU.fA F11- 504 PmU.fA.mU.fA.mA.fG.mA.fA.mA.fA.m 754 fG.mA.fU.mG.fA.mU.fU.mU.fU.m 04M U.fC.mA.fU.mC.fC.mU.fG.mA C.fU.mU.fA.mU.fA F11- 505 PmU.fA.mA.fA.mC.fA.mC.fC.mG.fU.m 755 fC.mU.fA.mA.fU.mA.fC.mG.fG.m 05M A.fU.mU.fA.mG.fG.mG.fA.mA U.fG.mU.fU.mU.fA F11- 506 PmU.fA.mA.fA.mU.fC.mA.fG.mU.fG.m 756 fC.mA.fU.mG.fA.mC.fA.mC.fU.m 06M U.fC.mA.fU.mG.fG.mU.fA.mA G.fA.mU.fU.mU.fA F11- 507 PmU.fA.mU.fA.mC.fC.mC.fG.mC.fU.m 757 fC.mA.fG.mA.fA.mA.fG.mC.fG.m 07M U.fU.mC.fU.mG.fC.mC.fA.mU G.fG.mU.fA.mU.fA F11- 508 PmU.fA.mG.fA.mU.fG.mU.fU.mU.fU.m 758 fU.mC.fC.mU.fU.mA.fA.mA.fA.mC 08M A.fA.mG.fG.mA.fG.mA.fC.mA .fA.mU.fC.mU.fA F11- 509 PmU.fG.mG.fU.mA.fU.mC.fU.mU.fG.m 759 fA.mA.fA.mG.fC.mC.fA.mA.fG.mA 09M G.fC.mU.fU.mU.fC.mU.fG.mG .fll.mA.fC.mC.fA F11- 510 PmU.fC.mU.fC.mU.fG.mU.fA.mU.fC.m 760 fG.mA.fA.mG.fA.mG.fA.mU.fA.m 10M U.fC.mU.fU.mC.fU.mG.fG.mC C.fA.mG.fA.mG.fA F11- 511 PmU.fA.mU.fG.mG.fA.mU.fU.mA.fU.m 761 fA.mA.fA.mU.fA.rnA.fU.mA.fA.mU 11M U.fA.mU.fU.mU.fC.mU.fU.mG .fC.mC.fA.mU.fA F11- 512 PmU.fA.mG.fC.mC.fA.mG.fA.mU.fU.m 762 fU.mU.fU.mC.fU.mA.fA.mU.fC.m 12M A.fG.mA.fA.mA.fG.mU.fG.mC U.fG.mG.fC.mU.fA F11- 513 PmU.fA.mG.fC.mG.fG.mA.fC.mG.fG. 763 fC.mA.fA.mU.fG.mC.fC.mG.fU.m 13M mC.fA.mU.fU.mG.fG.mU.fG.mC C.fC.mG.fC.mU.fA F11- 514 PmU.fA.mU.fU.mU.fC.mA.fG.mA.fU.m 764 fA.mA.fU.mC.fA.mA.fU.mC.fU.mG 14M U.fG.mA.fU.mU.fU.mA.fA.mA .fA.mA.fA.mU.fA F11- 515 PmU.fU.mU.fG.mU.fC.mU.fC.mU.fU.m 765 fA.mA.fA.mC.fU.mA.fA.mG.fA.mG 15M A.fG.mU.fU.mU.fU.mC.fU.mG .fA.mC.fA.mA.fA F11- 516 PmU.fA.mG.fA.mA.fC.mA.fC.mU.fG.m 766 fC.mA.fU.mC.fC.mC.fA.mG.fU.m 16M G.fG.mA.fU.mG.fC.mU.fG.mU G.fU.mU.fC.mU.fA F11- 517 PmU.fC.mC.fA.mC.fU.mU.fG.mA.fU.m 767 fC.mU.fU.mA.fU.mA.fU.mC.fA.mA 17M A.fU.mA.fA.mG.fA.mA.fA.mA .fG.mU.fG.mG.fA F11- 518 PmU.fC.mA.fU.mU.fU.mU.fC.mU.fU.m 768 fU.mU.fU.mG.fU.mA.fA.mG.fA.m 18M A.fC.mA.fA.mA.fC.mA.fC.mC A.fA.mA.fU.mG.fA F11- 519 PmU.fU.mA.fA.mU.fG.mC.fG.mU.fG.m 769 fC.mA.fG.mU.fA.mC.fA.mC.fG.m 19M U.fA.mC.fU.mG.fG.mG.fC.mA C.fA.mU.fU.mA.fA F11- 520 PmU.fA.mG.fG.mA.fC.mA.fG.mA.fG.m 770 fA.mG.fG.mC.fC.mC.fU.mC.fU.m 20M G.fG.mC.fC.mU.fC.mC.fC.mG G.fU.mC.fC.mU.fA F11- 521 PmU.fC.mA.fA.mC.fC.mG.fG.mG.fA.m 771 fC.mA.fU.mC.fA.mU.fC.mC.fC.m 21M U.fG.mA.fU.mG.fA.mG.fU.mG G.fG.mU.fU.mG.fA F11- 522 PmU.fG.mA.fC.mA.fA.mA.fG.mA.fU.m 772 fA.mA.fG.mA.fA.mA.fU.mC.fU.mU 22M U.fU.mC.fU.mU.fU.mG.fA.mG .fU.mG.fU.mC.fA F11- 523 PmU.fG.mA.fG.mG.fA.mA.fG.mC.fA.m 773 fC.mA.fG.mC.fA.mU.fG.mC.fU.m 23M U.fG.mC.fU.mG.fG.mC.fA.mC U.fC.mC.fU.mC.fA F11- 524 PmU.fG.mG.fA.mA.fA.mA.fU.mG.fU.m 774 fU.mA.fG.mG.fG.mA.fC.mA.fU.m 24M C.fC.mC.fU.mA.fA.mU.fA.mC U.fU.mU.fC.mC.fA F11- 525 PmU.fU.mU.fA.mA.fG.mU.fA.mA.fC.m 775 fC.mA.fA.mG.fU.mG.fU.mU.fA.m 25M A.fC.mU.fU.mG.fC.mC.fC.mU C.fU.mU.fA.mA.fA F11- 526 PmU.fC.mA.fA.mU.fA.mU.fC.mA.fU.m 776 fC.mG.fG.mG.fU.mA.fU.mG.fA.m 26M A.fC.mC.fC.mG.fC.mU.fU.mU U.fA.mU.fU.mG.fA F11- 527 PmU.fA.mA.fA.mU.fG.mU.fA.mC.fC.m 777 fC.mA.fA.mG.fU.mG.fG.mU.fA.m 27M A.fC.mU.fU.mG.fA.mU.fA.mU C.fA.mU.fU.mU.fA F11- 528 PmU.fA.mG.fA.mA.fA.mA.fU.mC.fA.m 778 fC.mA.fG.mG.fA.mU.fG.mA.fU.m 28M U.fC.mC.fU.mG.fA.mA.fA.mA U.fU.mU.fC.mU.fA F11- 529 PmU.fU.mA.fA.mC.fA.mC.fU.mU.fG.m 779 fA.mA.fG.mG.fG.mC.fA.mA.fG.m 29M C.fC.mC.fU.mU.fC.mC.fC.mU U.fG.mU.fU.mA.fA F11- 530 PmU.fA.mG.fC.mA.fU.mU.fU.mU.fC.m 780 fU.mG.fU.mA.fA.mG.fA.mA.fA.mA 30M U.fU.mA.fC.mA.fA.mA.fC.mA .fU.mG.fC.mU.fA F11- 531 PmU.fC.mA.fA.mA.fC.mA.fC.mC.fG.m 781 fU.mA.fA.mU.fA.mC.fG.mG.fU.m 31M U.fA.mU.fU.mA.fG.mG.fG.mA G.fU.mU.fU.mG.fA F11- 532 PmU.fA.mG.fC.mG.fG.mC.fU.mG.fU. 782 fU.mA.fU.mU.fA.mA.fC.mA.fG.mC 32M mU.fA.mA.fU.mA.fU.mC.fC.mA .fC.mG.fC.mU.fA F11- 533 PmU.fG.mA.fG.mC.fG.mG.fC.mU.fG. 783 fA.mU.fU.mA.fA.mC.fA.mG.fC.mC 33M mU.fU.mA.fA.mU.fA.mU.fC.mC .fG.mC.fU.mC.fA F11- 534 PmU.fG.mA.fG.mA.fC.mA.fA.mA.fG.m 784 fG.mA.fA.mA.fU. mC.fU. mU.fU.m 34M A.fU .mU .fU .mC.fU .mU .fU .mG G.fU.mC.fU.mC.fA F11- 535 PmU.fU.mG.fG.mG.fU.mU.fA.mU.fU.m 785 fC.mA.fU.mA.fA.mA.fA.mU.fA.mA 35M U.fU.mA.fU.mG.fU.mC.fC.mU .fC.mC.fC.mA.fA F11- 536 PmU.fG.mA.fG.mC.fC.mA.fU.mG.fA.m 786 fC.mA.fG.mU.fG.mU.fC.mA.fU.m 36M C.fA.mC.fU.mG.fU.mC.fG.mA G.fG.mC.fU.mC.fA F11- 537 PmU.fC.mA.fG.mA.fU.mU.fA.mG.fA.m 787 fC.mA.fC.mU.fU.mU.fC.mU.fA.mA 37M A.fA.mG.fU.mG.fC.mA.fC.mA .fU.mC.fU.mG.fA F11- 538 PmU.fA.mG.fA.mA.fU.mA.fC.mC.fC.m 788 fU.mU.fU.mC.fU.mG.fG.mG.fU.m 38M A.fG.mA.fA.mA.fU.mC.fG.mC A.fU.mU.fC.mU.fA F11- 539 PmU.fC.mA.fG.mA.fU.mG.fU.mU.fU.m 789 fC.mC.fU.mU.fA.mA.fA.mA.fC.mA 39M U.fA.mA.fG.mG.fA.mG.fA.mC .fU.mC.fU.mG.fA F11- 540 PmU.fU.mG.fU.mA.fU.mC.f.mA.fG.m 790 fC.mA.fU.mC.fU.mC.fU.mG.fG.m 40M A.fG.mA.fU.mG.fC.mC.fU.mC A.fU.mA.fC.mA.fA F11- 541 PmU.fG.mA.fG.mU.fC.mA.fC.mA.fC.m 791 fU.mG.fA.mA.fU.mG.fU.mG.fU.m 41M A.fU.mU.fC.mA.fC.mC.fA.mG G.fA.mC.fU.mC.fA F11- 542 PmU.fC.mA.fA.mA.fG.mA.fA.mA.fG.m 792 fC.mA.fC.mA.fU. mC.fU. mU.fU.m 42M A.fU.mG.fU.mG.fU.mC.fC.mU C.fU.mU.fU.mG.fA F11- 543 PmU.fA.mC.fC.mA.fC.mU.fU.mG.fA.m 793 fU.mU.fA.mU.fA.mU.fC.mA.fA.mG 43M U.fA.mU.fA.mA.fG.mA.fA.mA .fU.mG.fG.mU.fA F11- 544 PmU.fA.mA.fG.mA.fA.mA.fG.mC.fU.m 794 fC.mU.fU.mA.fA.mA.fG. mC.fU. m 44M U.fU.mA.fA.mG.fU.mA.fA.mC U.fU.mC.fU.mU.fA F11- 545 PmU.fU.mU.fA.mU.fU.mU.fC.mA.fG.m 795 fU.mC.fA.mA.fU.mC.fU.mG.fA.mA 45M A.fU.mU.fG.mA.fU.mU.fU.mA .fA.mU.fA.mA.fA F11- 546 PmU.fU.mG.fG.mU.fG.mU.fG.mA.fG. 796 fC.mA.fA.mU.fG.mC.fU.mC.fA.m 46M mC.fA.mU.fU.mG.fC.mU.fU.mG C.fA.mC.fC.mA.fA F11- 547 PmU.fA.mU.fC.mA.fU.mC.fC.mU.fG.m 797 fC.mU.fU.mU.fU.mC.fA.mG.fG.m 47M A.fA.mA.fA.mG.fA.mC.fC.mU A.fU.mG.fA.mU.fA F11- 548 PmU.fG.mU.fG.mA.fG.mC.fA.mU.fU.m 798 fC.mA.fA.mG.fC.mA.fA.mU.fG.m 48M G.fC.mU.fU.mG.fA.mA.fA.mG C.fU.mC.fA.mC.fA F11- 549 PmU.fC.mU.fG.mU.fA.mU.fC.mU.fC.m 799 fC.mA.fG.mA.fA.mG.fA.mG.fA.m 49M U.fU.mC.fU.mG.fG.mC.fA.mC U.fA.mC.fA.mG.fA F11- 550 PmU.fA.mC.fC.mU.fU.mA.fA.mU.fG.m 800 fA.mU.fA.mC.fA.mC.fA.mU.fU.mA 50M U.fG.mU.fA.mU.fC.mC.fA.mG .fA.mG.fG.mU.fA F11- 551 PmU.fA.mU.fC.mA.fU.mG.fG.mA.fU.m 801 fU.mA.fA.mU.fA.mA.fU.mC.fC.mA 51M U.fA.mU.fU.mA.fU.mU.fU.mC .fU.mG.fA.mU.fA F11- 552 PmU.fC.mA.fA.mA.fG.mA.fU.mU.fU.m 802 fC.mA.fA.mA.fG.mA.fA.mA.fU.mC 52M C.fU.mU.fU.mG.fA.mG.fA.mU .fU.mU.fU.mG.fA F11- 553 PmU.fG.mA.fA.mG.fU.mA.fU.mU.fU.m 803 fA.mA.fC.mU.fA.mA.fA.mA.fU.mA 53M U.fA.mG.fU.mU.fG.mG.fA.mG .fC.mU.fU.mC.fA F11- 554 PmU.fA.mG.fA.mU.fU.mG.fA.mU.fU.m 804 fU.mU.fU.mU.fA.mA.fA.mU.fC.mA 54M U.fA.mA.fA.mA.fU.mG.fC.mC .fA.mU.fC.mU.fA F11- 555 PmU.fG.mG.fG.mU.fA.mU.fC.mU.fU.m 805 fA.mA.fG.mC.fC.mA.fA.mG.fA.mU 55M G.fG.mC.fU.mU.fU.mC.fU.mG .fA.mC.fC.mC.fA F11- 556 PmU.fA.mG.fG.mA.fG.mA.fC.mA.fA.m 806 fA.mA.fU.mC.fU.mU.fU.mG.fU.m 56M A.fG.mA.fU.mU.fU.mC.fU.mU C.fU.mC.fC.mU.fA F11- 557 PmU.fG.mU.fC.mA.fU.mG.fG.mU.fA.m 807 fC.mA.fU.mU.fU.mU.fA.mC.fC.mA 57M A.fA.mA.fU.mG.fA.mA.fG.mA .fU.mG.fA.mC.fA F11- 558 PmU.fA.mU.fA.mU.fC.mC.fA.mG.fU.m 808 fG.mA.fA.mG.fA.mA.fC.mU.fG.m 58M U .fC. mU .fU .mC .fU. mC .fC .mC G.fA.mU.fA.mU.fA F11- 559 PmU.fA.mA.fU.mA.fU.mC.fC.mA.fG.m 809 fA.mA.fG.mA.fA.mC.fU.mG.fG.m 59M U.fU.mC.fU.mU.fC.mU.fC.mC A.fU.mA.fU.mU.fA F11- 560 PmU.fC.mU.fG.mU.fG.mG.fU.mU.fU. 810 fA.mC.fU.mG.fG.mA.fA.mA.fC.m 60M mC.fC.mA.fG.mU.fU.mU.fC.mA C.fA.mC.fA.mG.fA F11- 561 PmU.fA.mG.fA.mU.fU.mA.fG.mA.fA.m 811 fG.mC.fA.mC.fU.mU.fU.mC.fU.m 61M A.fG.mU.fG.mC.fA.mC.fA.mG A.fA.mU.fC.mU.fA F11- 562 PmU.fA.mG.fA.mA.fA.mU.fC.mA.fG.m 812 fU.mG.fA.mC.fA.mC.fU.mG.fA.m 62M U.fG.mU.fC.mA.fU.mG.fG.mU U.fU.mU.fC.mU.fA F11- 563 PmU.fU.mG.fG.mA.fU.mU.fA.mU.fU.m 813 fG.mA.fA.mA.fU.mA.fA.mU.fA.mA 63M A.fU.mU.fU.mC.fU.mU.fG.mA .fU.mC.fC.mA.fA F11- 564 PmU.fC.mC.fA.mG.fA.mU.fU.mA.fG.m 814 fA.mC.fU.mU.fU.mC.fU.mA.fA.mU 64M A.fA.mA.fG.mU.fG.mC.fA.mC .fC.mU.fG.mG.fA F11- 565 PmU.fC.mU.fC.mA.fU.mU.fA.mU.fC.m 815 fA.mA.fA.mU.fG.mG.fA.mU.fA.mA 65M C.fA.mU.fU.mU.fU.mA.fC.mA .fU.mG.fA.mG.fA F11- 566 PmU.fU.mU.fG.mG.fG.mC.fC.mA.fU.m 816 fC.mA.fG.mG.fA.mA.fU.mG.fG.m 66M U.fC.mC.fU.mG.fG.mG.fA.mA C.fC.mC.fA.mA.fA F11- 567 PmU.fU.mG.fG.mG.fC.mU.fU.mG.fA. 817 fC.mA.fA.mA.fA.mU.fC.mA.fA.mG 67M mU.fU.mU.fU.mG.fG.mU.fG.mG .fC.mC.fC.mA.fA F11- 568 PmU.fC.mA.fG.mA.fU.mU.fG.mA.fU.m 818 fU.mU.fU.mA.fA.mA.fU.mC.fA.mA 68M U.fU.mA.fA.mA.fA.mU.fG.mC .fU.mC.fU.mG.fA F11- 569 PmU.fA.mA.fG.mC.fA.mA.fC.mC.fG.m 819 fC.mA.fU.mC.fC.mC.fG.mG.fU.m 69M G.fG.mA.fU.mG.fA.mU.fG.mA U.fG.mC.fU.mU.fA F11- 570 PmU.fC.mU.fU.mA.fA.mU.fG.mU.fG.m 820 fG.mG.fA.mU.fA.mC.fA.mC.fA.m 70M U.fA.mU.fC.mC.fA.mG.fA.mG U.fU.mA.fA.mG.fA F11- 571 PmU.fG.mU.fA.mA.fU.mU.fC.mA.fC.m 821 fC.mC.fA.mC.fA.mG.fU.mG.fA.m 71M U.fG.mU.fG.mG.fU.mU.fU.mC A.fU.mU.fA.mC.fA F11- 572 PmU.fA.mC.fA.mU.fU.mU.fC.mU.fA.m 822 fG.mG.fA.mG.fA.mU.fA.mG.fA.m 72M U.fC.mU.fC.mC.fU.mU.fU.mG A.fA.mU.fG.mU.fA F11- 573 PmU.fC.mA.fC.mU.fG.mG.fU.mU.fU.m 823 fA.mU.fU.mG.fG.mA.fA.mA.fC.m 73M C.fC.mA.fA.mU.fG.mA.fU.mG C.fA.mG.fU.mG.fA F11- 574 PmU.fG.mA.fA.mU.fC.mU.fG.mU.fG.m 824 fA.mA.fU.mU.fA.mC.fA.mC.fA.mG 74M U.fA.mA.fU.mU.fC.mA.fC.mU .fA.mU.fU.mC.fA F11- 575 PmU.fG.mU.fC.mC.fU.mA.fU.mU.fC.m 825 fA.mG.fA.mG.fU.mG.fA.mA.fU.m 75M A.fC.mU.fC.mU.fU.mG.fG.mC A.fG.mG.fA.mC.fA F11- 576 PmU.fA.mG.fC.mA.fU.mU.fG.mC.fU.m 826 fU.mU.fU.mC.fA.mA.fG.mC.fA.mA 76M U.fG.mA.fA.mA.fG.mA.fA.mil .fU.mG.fC.mU.fA F11- 577 PmU.fA.mA.fU.mA.fC.mC.fC.mA.fG.m 827 fG.mA.fU.mU.fU.mC.fU.mG.fG.m 77M A.fA.mA.fU.mC.fG.mC.fU.mG G.fU.mA.fU.mU.fA F11- 578 PmU.fA.mU.fU.mA.fU.mU.fA.mU.fU.m 828 fC.mA.fA.mG.fA.mA.fA.mil .fA.mA 78M U.fC.mll.fll.mG.fA.mA.fC.mC .fU.mA.fA.mU.fA F11- 579 PmU.fA.mA.fG.mU.fA.mU.fU.mU.fU.m 829 fC.mA.fA.mC.fU.mA.fA.mA.fA.mU 79M A.fG.mU.fU.mG.fG.mA.fG.mA .fA.mC.fU.mU.fA F11- 580 PmU.fG.mA.fA.mU.fC.mC.fA.mG.fU.m 830 fC. mG .fU. mG .fG. mA.fC. mU .fG. m 80M C.fC.mA.fC.mG.fU.mA.fC.mU G.fA.mU.fU.mC.fA F11- 581 PmU.fA.mG.fA.mC.fA.mA.fA.mG.fA.m 831 fA.mG.fA.mA.fA.mU.fC.mU.fU.mU 81M U .fU .mil .fC .mil .fU .mil .fG .mA .fG.mU.fC.mU.fA F11- 582 PmU.fA.mC.fA.mG.fG.mA.fU.mU.fU.m 832 fC. mA.fC. mU.fG.mA.fA.mA.fU.mC 82M C.fA.mG.fU.mG.fA.mA.fA.mA .fC.mU.fG.mU.fA F11- 583 PmU.fA.mA.fC.mA.fA.mG.fG.mC.fA.m 833 fG.mA.fU.mA.fU.mU.fG.mC.fC.m 83M A.fU.mA.fU.mC.fA.mU.fA.mC U.fU.mG.fU.mU.fA F11- 584 PmU.fA.mA.fG.mG.fC.mA.fA.mU.fA.m 834 fU.mA.fU.mG.fA.mU.fA.mU.fU.m 84M U.fC.mA.fU.mA.fC.mC.f.mG G.fC.mC.fU.mU.fA F11- 585 PmU.fA.mU.fA.mC.fC.mC.fA.mG.fA.m 835 fC.mG.fA.mU.fU.mU.fC.mU.fG.m 85M A.fA.mU.fC.mG.fC.mU.fG.mC G.fG.mU.fA.mU.fA F11- 586 PmU.fG.mA.fU.mU.fG.mA.fU.mU.fU.m 836 fA.mU.fU.mU.fU.mA.fA.mA.fU.mC 86M A.fA.mA.fA.mU.fG.mC.fC.mA .fA.mA.fU.mC.fA F11- 587 PmU.fC.mC.fU.mA.fU.mU.fC.mA.fC.m 837 fC.mA.fA.mG.fA.mG.fU.mG.fA.m 87M U.fC.mU.fU.mG.fG.mC.fA.mG A.fU.mA.fG.mG.fA F11- 588 PmU.fG.mU.fA.mG.fA.mC.fA.mC.fG.m 838 fU.mU.fU.mU.fG.mC.fG.mU.fG.m 88M C.fA.mA.fA.mA.fU.mC.fU.mU U.fC.mU.fA.mC.fA F11- 589 PmU.fU.mG.fA.mG.fU.mU.fU.mU.fC.m 839 fC.mU.fG.mG.fA.mG.fA.mA.fA.m 89M U.fC.mC.fA.mG.fA.mA.fU.mC A.fC.mU.fC.mA.fA F11- 590 PmU.fA.mU.fU.mU.fC.mU.fU.mU.fG.m 840 fA.mA.fU.mC.fU.mC.fA.mA.fA.mG 90M A.fG.mA.fU.mU.fC.mU.fU.mU .fA.mA.fA.mU.fA F11- 591 PmU.fU.mA.fU.mA.fA.mG.fA.mA.fA.m 841 fA.mU.fG.mA.fU.mU.fU.mU.fC.m 91M A.fU.mC.fA.mU.fC.mC.fU.mG U.fU.mA.fU.mA.fA F11- 592 PmU.fA.mA.fA.mA.fU.mC.fU.mU.fA.m 842 fU.mC.fA.mC.fC.mU.fA.mA.fG.mA 92M G.fG.mU.fG.mA.fC.mU.fC.mU .fU.mU.fU.mU.fA F11- 593 PmU.fA.mC.fA.mC.fU.mG.fG.mG.fA.m 843 fC.mA.fG.mC.fA.mU.fC.mC.fC.m 93M U.fG.mC.fU.mG.fU.mG.fC.mC A.fG.mU.fG.mU.fA F11- 594 PmU.fU.mG.fC.mA.fC.mA.fG.mG.fA.m 844 fU.mG.fA.mA.fA.mU.fC.mC.fU.m 94M U.fU.mU.fC.mA.fG.mU.fG.mA G.fU.mG.fC.mA.fA F11- 595 PmU.fA.mU.fA.mC.fA.mA.fG.mC.fC.m 845 fA.mA.fU.mC.fU.mG.fG.mC.fU.m 95M A.fG.mA.fU.mU.fA.mG.fA.mA U.fG.mU.fA.mU.fA F11- 596 PmU.fU.mG.fU.mG.fG.mU.fU.mU.fC. 846 fA.mA.fC.mU.fG.mG.fA.mA.fA.mC 96M mC.fA.mG.fU.mU.fU.mC.fA.mA .fC.mA.fC.mA.fA F11- 597 PmU.fU.mG.fC.mC.fC.mU.fU.mC.fC.m 847 fC.mG.fA.mA.fG.mG.fG.mA.fA.m 97M C.fU.mU.fC.mG.fU.mU.fG.mC G.fG.mG.fC.mA.fA F11- 598 PmU.fA.mA.fA.mA.fU.mC.fA.mU.fC.m 848 fU.mU.fC.mA.fG.mG.fA.mU.fG.m 98M C.fU.mG.fA.mA.fA.mA.fG.mA A.fU.mU.fU.mU.fA F11- 599 PmU.fC.mC.fA.mA.fG.mA.fA.mA.fU.m 849 fC.mA.fC.mU.fG.mA.fU.mU.fU.m 99M C.fA.mG.fU.mG.fU.mC.fA.mU C.fU.mU.fG.mG.fA F11- 600 PmU.fG.mG.fC.mA.fU.mA.fU.mG.fG.m 850 fA.mC.fG.mA.fC.mC.fC.mA.fU.mA 100M G.fU.mC.fG.mU.fU.mG.fA.mG .fU.mG.fC.mC.fA F11- 601 PmU.fA.mG.fA.mA.fU.mC.fU.mG.fU.m 851 fA.mU.fU.mA.fC.mA.fC.mA.fG.mA 101M G.fU.mA.fA.mU.fU.mC.fA.mC .fU.mU.fC.mU.fA F11- 602 PmU.fA.mU.fC.mC.fA.mG.fU.mC.fC.m 852 fU.mA.fC.mG.fU.mG.fG.mA.fC.m 102M A.fC.mG.fU.mA.fC.mU.fC.mG U.fG.mG.fA.mU.fA F11- 603 PmU.fC.mC.fU.mC.fU.mG.fU.mA.fU.m 853 fA.mA.fG.mA.fG.mA.fU.mA.fC.mA 103M C.fU.mC.fU.mU.fC.mU.fG.mG .fG.mA.fG.mG.fA F11- 604 PmU.fG.mC.fA.mC.fA.mG.fG.mA.fU.m 854 fC.mU.fG.mA.fA.mA.fU.mC.fC.m 104M U.fU.mC.fA.mG.fU.mG.fA.mA U.fG.mU.fG.mC.fA F11- 605 PmU.fG.mU.fA.mA.fA.mA.fU.mG.fA.m 855 fA.mU.fU.mC.fU.mU.fC.mA.fU.m 105M A.fG.mA.fA.mU.fG.mG.fC.mA U.fU.mU.fA.mC.fA F11- 606 PmU.fG.mU.fC.mG.fU.mU.fG.mA.fG. 856 fA.mG.fA.mU.fU.mC.fU.mC.fA.mA 106M mA.fA.mU.fC.mU.fG.mU.fG.mU .fC.mG.fA.mC.fA F11- 607 PmU.fG.mC.fA.mA.fC.mA.fA.mU.fA.m 857 fC.mU.fG.mG.fA.mU.fA.mU.fU.m 107M U.fC.mC.fA.mG.fU.mU.fC.mU G.fU.mU.fG.mC.fA F11- 608 PmU.fC.mA.fG.mC.fG.mG.fA.mC.fG.m 858 fA.mA.fU.mG.fC.mC.fG.mU.fC.m 108M G.fC.mA.fU.mU.fG.mG.fU.mG C.fG.mC.fU.mG.fA F11- 609 PmU.fG.mA.fA.mA.fG.mC.fU.mU.fU.m 859 fU.mA.fC.mU.fU.mA.fA.mA.fG.mC 109M A.fA.mG.fU.mA.fA.mC.fA.mC .fU.mU.fU.mC.fA F11- 610 PmU.fG.mC.fA.mG.fU.mG.fU.mU.fU.m 860 fU.mA.fC.mA.fG.mA.fA.mA.fC.mA 110M C.fU.mG.fU.mA.fA.mC.fA.mC .fC.mU.fG.mC.fA F11- 611 PmU.fG.mA.fG.mA.fA.mU.fC.mU.fG.m 861 fU.mU.fA.mC.fA.mC.fA.mG.fA.mU 111M U.fG.mU.fA.mA.fU.mU.fC.mA .fU.mC.fU.mC.fA F11- 612 PmU.fU.mC.fC.mA.fG.mU.fC.mC.fA.m 862 fG.mU.fA.mC.fG.mU.fG.mG.fA.m 112M C.fG.mU.fA.mC.fU.mC.fG.mA C.fU.mG.fG.mA.fA F11- 613 PmU.fU.mG.fU.mG.fA.mG.fC.mA.fU.m 863 fA.mA.fG.mC.fA.mA.fU.mG.fC.m 113M U.fG.mC.fU.mU.fG.mA.fA.mA U.fC.mA.fC.mA.fA F11- 614 PmU.fC.mC.fG.mG.fG.mA.fU.mG.fA.m 864 fA.mC.fU.mC.fA.mU.fC.mA.fU.mC 114M U.fG.mA.fG.mU.fG.mC.fA.mG .fC.mC.fG.mG.fA F11- 615 PmU.fC.mC.fA.mC.fU.mU.fU.mA.fU.m 865 fG.mC.fU.mC.fG.mA.fU.mA.fA.m 115M C.fG.mA.fG.mC.fU.mU.fC.mG A.fG.mU.fG.mG.fA F11- 616 PmU.fC.mA.fU.mU.fA.mU.fC.mC.fA.m 866 fU.mA.fA.mA.fA.mU.fG.mG.fA.mil 116M U.fU.mU.fU.mA.fC.mA.fC.mA .fA.mA.fU.mG.fA F11- 617 PmU.fA.mA.fC.mC.fG.mG.fG.mA.fU.m 867 fU.mC.fA.mU.fC.mA.fU.mC.fC.m 117M G.fA.mU.fG.mA.fG.mU.fG.mC C.fG.mG.fU.mU.fA F11- 618 PmU.fU.mU.fC.mU.fU.mU.fG.mG.fG. 868 fA.mA.fU.mG.fG.mC.fC.mC.fA.m 118M mC.fC.mA.fU.mU.fC.mC.fU.mG A.fA.mG.fA.mA.fA F11- 619 PmU.fC.mU.fA.mA.fG.mG.fG.mU.fA.m 869 fC.mA.fA.mG.fA.mU.fA.mC.fC.mC 119M U.fC.mU.fU.mG.fG.mC.fU.mU .fU.mU.fA.mG.fA F11- 620 PmU.fU.mU.fG.mG.fU.mG.fU.mG.fA. 870 fA.mA.fU.mG.fC.mU.fC.mA.fC.mA 120M mG.fC.mA.fU.mU.fG.mC.fU.mU .fC.mC.fA.mA.fA F11- 621 PmU.fC.mA.fU.mA.fU.mG.fG.mG.fU.m 871 fC.mA.fA.mC.fG.mA.fC.mC.fC.mA 121M C.fG.mU.fU.mG.fA.mG.fA.mA .fU.mA.fU.mG.fA F11- 622 PmU.fU.mU.fA.mA.fU.mG.fU.mG.fU.m 872 fU.mG.fG.mA.fU.mA.fC.mA.fC.m 122M A.fU.mC.fC.mA.fG.mA.fG.mA A.fU.mU.fA.mA.fA F11- 623 PmU.fU.mC.fA.mG.fA.mU.fG.mU.fU.m 873 fC.mU.fU.mA.fA.mA.fA.mC.fA.mU 123M U.fU.mA.fA.mG.fG.mA.fG.mA .fC.mU.fG.mA.fA F11- 624 PmU.fU.mU.fC.mC.fA.mA.fU.mG.fA.m 874 fC.mU.fC.mC.fA.mU.fC.mA.fU.m 124M U.fG.mG.fA.mG.fC.mC.fU.mC U.fG.mG.fA.mA.fA F11- 625 PmU.fA.mG.fA.mA.fU.mC.fC.mA.fG.m 875 fG.mU.fG.mG.fA.mC.fU.mG.fG.m 125M U.fC.mC.fA.mC.fG.mU.fA.mC A.fU.mU.fC.mU.fA F11- 626 PmU.fU.mU.fU.mG.fA.mG.fA.mU.fU.m 876 fC.mA.fA.mA.fG.mA.fA.mU.fC.mU 126M C.fU.mU.fU.mG.fG.mG.fC.mC .fC.mA.fA.mA.fA F11- 627 PmU.fA.mA.fU.mC.fA.mU.fC.mC.fU.m 877 fU.mU.fU.mU.fC.mA.fG.mG.fA.m 127M G.fA.mA.fA.mA.fG.mA.fC.mC U.fG.mA.fU.mU.fA F11- 628 PmU.fA.mG.fA.mC.fA.mC.fG.mC.fA.m 878 fG.mA.fU.mU.fU.mU.fG.mC.fG.m 128M A.fA.mA.fU.mC.fU.mU.fA.mG U.fG.mU.fC.mU.fA F11- 629 PmU.fC.mG.fU.mA.fC.mU.fC.mG.fA.m 879 fC.mG.fU.mG.fG.mU.fC.mG.fA.m 129M C.fC.mA.fC.mG.fU.mU.fG.mG G.fU.mA.fC.mG.fA F11- 630 PmU.fC.mA.fU.mC.fC.mA.fG.mU.fC.m 880 fU.mG.fG.mG.fU.mG.fA.mC.fU.m 130M A.fC.mC.fC.mA.fG.mC.fA.mA G.fG.mA.fU.mG.fA F11- 631 PmU.fA.mA.fC.mA.fC.mU.fG.mG.fG.m 881 fA.mG.fC.mA.fU.mC.fC.mC.fA.m 131M A.fU.mG.fC.mU.fG.mU.fG.mC G.fU.mG.fU.mU.fA F11- 632 PmU.fC.mA.fG.mA.fA.mA.fG.mA.fG.m 882 fC.mA.fA.mA.fG.mC.fU.mC.fU.m 132M C.fU.mU.fU.mG.fC.mU.fC.mU U.fU.mC.fU.mG.fA F11- 633 PmU.fU.mU.fC.mU.fU.mU.fG.mA.fG.m 883 fA.mG.fA.mA.fU.mC.fU.mC.fA.mA 133M A.fU.mU.fC.mU.fU.mU.fG.mG .fA.mG.fA.mA.fA F11- 634 PmU.fA.mG.fC.mA.fA.mC.fA.mA.fU.m 884 fU.mG.fG.mA.fU.mA.fU.mU.fG.m 134M A.fU.mC.fC.mA.fG.mU.fU.mC U.fU.mG.fC.mU.fA F11- 635 PmU.fA.mC.fC.mA.fC.mU.fU.mU.fA.m 885 fC.mU.fC.mG.fA.mU.fA.mA.fA.m 135M U.fC.mG.fA.mG.fC.mU.fU.mC G.fU.mG.fG.mU.fA F11- 636 PmU.fC.mC.fC.mU.fU.mC.fC.mC.fU.m 886 fA.mA.fC.mG.fA.mA.fG.mG.fG.m 136M U.fC.mG.fU.mU.fG.mC.fA.mG A.fA.mG.fG.mG.fA F11- 637 PmU.fC.mG.fC.mA.fA.mA.fA.mU.fC.m 887 fC.mC.fU.mA.fA.mG.fA.mU.fU.m 137M U.fU.mA.fG.mG.fU.mG.fA.mC U.fU.mG.fC.mG.fA F11- 638 PmU.fA.mG.fC.mG.fU.mG.fU.mU.fA.m 888 fC.mA.fC.mA.fG.mU.fA.mA.fC.mA 138M C.fU.mG.fU.mG.fG.mA.fG.mG .fC.mG.fC.mU.fA F11- 639 PmU.fC.mU.fC.mC.fU.mU.fC.mC.fC.m 889 fC.mU.fA.mC.fA.mG.fG.mG.fA.m 139M U.fG.mU.fA.mG.fC.mC.fG.mG A.fG.mG.fA.mG.fA F11- 640 PmU.fG.mU.fC.mC.fU.mC.fU.mG.fU.m 890 fG.mA.fG.mA.fU.mA.fC.mA.fG.m 140M A.fU.mC.fU.mC.fU.mU.fC.mU A.fG.mG.fA.mG.fA F11- 641 PmU.fG.mU.fA.mU.fC.mU.fU.mG.fG.m 891 fG.mA.fA.mA.fG.mC.fC.mA.fA.m 141M C .fU. mU .fU .mC .fU. mG .fG .mA G.fA.mU.fA.mC.fA F11- 642 PmU.fC.mU.fC.mU.fU.mG.fG.mC.fA.m 892 fA.mA.fC.mA.fC.mU.fG.mC.fC.mA 142M G.fU.mG.fU.mU.fU.mC.fU.mG .fA.mG.fA.mG.fA F11- 643 PmU.fG.mA.fA.mA.fU.mC.fA.mG.fU.m 893 fA.mU.fG.mA.fC.mA.fC.mU.fG.m 143M G.fU.mC.fA.mU.fG.mG.fU.mA A.fU.mU.fU.mC.fA F11- 644 PmU.fC.mU.fU.mC.fC.mC.fU.mG.fU.m 894 fC.mG.fG.mC.fU.mA.fC.mA.fG.m 144M A.fG.mC.fC.mG.fG.mC.fA.mC G.fG.mA.fA.mG.fA F11- 645 PmU.fC.mU.fG.mG.fC.mC.fG.mC.fU. 895 fA.mA.fG.mG.fG.mA.fG.mC.fG.m 145M mC.fC.mC.fU.mU.fU.mG.fA.mG G.fC.mC.fA.mG.fA F11- 646 PmU.fC.mA.fC.mG.fC.mA.fA.mA.fA.m 896 fU.mA.fA.mG.fA.mU.fU.mU.fU.m 146M U.fC.mU.fU.mA.fG.mG.fU.mG G.fC.mG.fU.mG.fA F11- 647 PmU.fG.mA.fA.mA.fC.mC.fA.mG.fA.m 897 fC.mU.fC.mU.fU.mU.fC.mU.fG.m 147M A.fA.mG.fA.mG.fC.mU.fU.mU G.fU.mU.fU.mC.fA F11- 648 PmU.fA.mA.fA.mG.fC.mU.fU.mU.fA.m 898 fU.mU.fA.mC.fU.mU.fA.mA.fA.mG 148M A.fG.mU.fA.mA.fC.mA.fC.mU .fC.mU.fU.mU.fA F11- 649 PmU.fA.mC.fA.mA.fG.mC.fC.mA.fG.m 899 fC.mU.fA.mA.fU.mC.fU.mG.fG.m 149M A.fU.mU.fA.mG.fA.mA.fA.mG C.fU.mU.fG.mU.fA F11- 650 PmU.fA.mC.fU.mC.fA.mU.fU.mA.fU.m 900 fA.mA.fU.mG.fG. mA.fU. mA.fA.mU 150M C.fC.mA.fU.mU.fU.mU.fA.mC .fG.mA.fG.mU.fA F11- 651 PmU.fC.mC.fU.mG.fA.mA.fA.mA.fG.m 901 fA.mA.fG.mG.fU.mC.fU.mU.fU.m 151M A.fC.mC.fU.mU.fG.mU.fU.mG U.fC.mA.fG.mG.fA F11- 652 PmU.fG.mG.fU.mU.fU.mC.fC.mA.fA.m 902 fC. mA.fU. mC.fA.mU.fU.mG.fG.m 152M u .fG. mA.fU. mG .fG. mA .fG. mC A.fA.mA.fC.mC.fA F11- 653 PmU.fC.mA.fG.mU.fU.mU.fC.mU.fG.m 903 fC.mC.fU.mG.fC.mC.fA.mG.fA.m 153M G.fC.mA.fG.mG.fC.mC.fU.mC A.fA.mC.fU.mG.fA F11- 654 PmU.fA.mU.fG.mG.fC.mA.fG.mA.fA.m 904 fC.mA.fG.mU.fG.mU.fU.mC.fU.m 154M C.fA.mC.fU.mG.fG.mG.fA.mU G.fC.mC.fA.mU.fA F11- 655 PmU.fA.mG.fA.mU.fU.mU.fC.mU.fU.m 905 fU.mC.fU.mC.fA.mA.fA.mG.fA.mA 155M U.fG.mA.fG.mA.fU.mU.fC.mU .fA.mU.fC.mU.fA F11- 656 PmU.fG.mU.fU.mU.fC.mC.fA.mG.fU.m 906 fU.mU.fG.mA.fA.mA.fC.mU.fG.m 156M U.fU.mC.fA.mA.fC.mA.fA.mG G.fA.mA.fA.mC.fA F11- 657 PmU.fU.mC.fC.mU.fC.mU.fG.mU.fA.m 907 fA.mG.fA.mG.fA.mU.fA.mC.fA.m 157M U.fC.mU.fC.mU.fU.mC.fU.mG G.fA.mG.fG.mA.fA F11- 658 PmU.fC. mA.fU. mC.fC.mU.fG.mA.fA.m 908 fG.mU.fC.mU.fU.mU.fU.mC.fA.m 158M A.fA.mG.fA.mC.fC.mU.fU.mG G.fG.mA.fU.mG.fA F11- 659 PmU.fU.mU.fG.mA.fG.mU.fU.mU.fU.m 909 fU.mG.fG.mA.fG.mA.fA.mA.fA.m 159M C.fU.mC.fC.mA.fG.mA.fA.mU C.fU.mC.fA.mA.fA F11- 660 PmU.fA.mA.fU.mU.fC.mA.fC.mU.fG.m 910 fA.mA.fC.mC.fA.mC.fA.mG.fU.m 160M U.fG.mG.fU.mU.fU.mC.fC.mA G.fA.mA.fU.mU.fA F11- 661 PmU.fA.mA.fG.mA.fU.mU.fU.mC.fU.m 911 fC.mU.fC.mA.fA.mA.fG.mA.fA.mA 161M U.fU.mG.fA.mG.fA.mU.fU.mC .fU.mC.fU.mU.fA F11- 662 PmU.fG.mG.fA.mG.fA.mC.fA.mA.fA.m 912 fA.mA.fA.mU.fC.mU.fU.mU.fG.m 162M G.fA.mU.fU.mU.fC.mU.fU.mU U.fC.mU.fC.mC.fA F11- 663 PmU.fG.mA.fA.mA.fA.mU.fC.mA.fU.m 913 fU.mC.fA.mG.fG.mA.fU.mG.fA.m 163M C.fC.mU.fG.mA.fA.mA.fA.mG U.fU.mU.fU.mC.fA F11- 664 PmU.fC.mU.fU.mU.fC.mU.fG.mC.fC.m 914 fA.mA.fA.mA.fU.mG.fG.mC.fA.m 164M A.fU.mU.fU.mU.fA.mU.fA.mC G.fA.mA.fA.mG.fA F11- 665 PmU.fA.mG.fU.mC.fC.mA.fC.mG.fU.m 915 fC.mG.fA.mG.fU.mA.fC.mG.fU.m 165M A.fC.mU.fC.mG.fA.mC.fC.mA G.fG.mA.fC.mU.fA F11- 666 PmU.fU.mU.fA.mA.fU.mG.fC.mG.fU.m 916 fA.mG.fU.mA.fC.mA.fC.mG.fC.m 166M G.fU.mA.fC.mU.fG.mG.fG.mC A.fU.mU.fA.mA.fA F11- 667 PmU.fU.mA.fA.mU.fG.mU.fG.mU.fA.m 917 fC.mU.fG.mG.fA.mU.fA.mC.fA.m 167M U.fC.mC.fA.mG.fA.mG.fA.mU C.fA.mU.fU.mA.fA F11- 668 PmU.fG.mA.fU.mU.fC.mU.fU.mU.fG.m 918 fU.mG.fG.mC.fC.mC.fA.mA.fA.m 168M G.fG.mC.fC.mA.fU.mU.fC.mC G.fA.mA.fU.mC.fA F11- 669 PmU.fU.mG.fA.mA.fA.mC.fC.mA.fG.m 919 fU.mC.fU.mU.fU.mC.fU.mG.fG.m 169M A.fA.mA.fG.mA.fG.mC.fU.mU U.fU.mU.fC.mA.fA F11- 670 PmU.fC.mA.fC.mA.fC.mA.fU.mU.fC.m 920 fC.mU.fG.mG.fU.mG.fA.mA.fU.m 170M A.fC.mC.fA.mG.fA.mA.fA.mC G.fU.mG.fU.mG.fA F11- 671 PmU.fA.mC.fA.mA.fA.mG.fA.mU.fU.m 921 fA.mA.fA.mG.fA.mA.fA.mU.fC.mil 171M U.fC.mU.fU.mU.fG.mA.fG.mA .fU.mU.fG.mU.fA F11- 672 PmU.fC.mA.fU.mU.fU.mC.fU.mA.fU.m 922 fA.mG.fG.mA.fG.mA.fU.mA.fG.m 172M C.fU.mC.fC.mU.fU.mU.fG.mG A.fA.mA.fU.mG.fA F11- 673 PmU.fU.mU.fU.mC.fU.mG.fU.mA.fA.m 923 fC.mA.fG.mU.fG.mU.fU.mA.fC.m 173M C.fA.mC.fU.mG.fU.mC.fU.mU A.fG.mA.fA.mA.fA F11- 674 PmU.fG.mG.fA.mU.fU.mU.fC.mA.fG.m 924 fU.mU.fU.mC.fA.mC.fU.mG.fA.m 174M U.fG.mA.fA.mA.fA.mU.fC.mC A.fA.mU.fC.mC.fA F11- 675 PmU.fC.mG.fC.mU.fC.mC.fC.mU.fU.m 925 fG.mC.fU.mC.fA.mA.fA.mG.fG.m 175M U.fG.mA.fG.mC.fA.mC.fA.mG G.fA.mG.fC.mG.fA F11- 676 PmU.fC.mA.fG.mU.fC.mC.fA.mC.fG.m 926 fG.mA.fG.mU.fA.mC.fG.mU.fG.m 176M U.fA.mC.fU.mC.fG.mA.fC.mC G.fA.mC.fU.mG.fA F11- 677 PmU.fA.mG.fG.mC.fA.mU.fA.mU.fG.m 927 fC.mG.fA.mC.fC.mC.fA.mU.fA.m 177M G.fG.mU.fC.mG.fU.mU.fG.mA U.fG.mC.fC.mU.fA F11- 678 PmU.fA.mU.fG.mU.fC.mC.fU.mC.fU.m 928 fG.mA.fU.mA.fC.mA.fG.mA.fG.m 178M G.fU.mA.fU.mC.fU.mC.fU.mU G.fA.mC.fA.mU.fA F11- 679 PmU.fG.mC.fU.mU.fG.mA.fU.mU.fU.m 929 fC.mA.fC.mC.fA.mA.fA.mA.fU.mC 179M U.fG.mG.fU.mG.fG.mU.fA.mC .fA.mA.fG.mC.fA F11- 680 PmU.fA.mU.fG.mA.fU.mG.fG.mA.fG.m 930 fG.mG.fA.mG.fG.mC.fU.mC.fC.m 180M C.fC.mU.fC.mC.fA.mC.fA.mC A.fU.mC.fA.mU.fA F11- 681 PmU.fU.mC.fG.mU.fU.mG.fA.mG.fA.m 931 fC.mA.fG.mA.fU.mU.fC.mU.fC.m 181M A.fU .mC .fU .mG.fU .mG .fU .mA A.fA.mC.fG.mA.fA F11- 682 PmU.fU.mU.fA.mU.fC.mC.fA.mU.fU.m 932 fU. mG.fU. mA.fA.mA.fA.mU.fG.m 182M U.fU.mA.fC.mA.fC.mA.fA.mC G.fA.mU.fA.mA.fA F11- 683 PmU.fU.mG.fU.mC.fC.mU.fA.mU.fU.m 933 fG.mA.fG.mU.fG.mA.fA.mU.fA.m 183M C.fA.mC.fU.mC.fU.mU.fG.mG G.fG.mA.fC.mA.fA F11- 684 PmU.fC.mA.fA.mU.fA.mU.fC.mC.fA.m 934 fA.mG.fA.mA.fC.mU.fG.mG.fA.m 184M G.fU.mU.fC.mU.fU.mC.fU.mC U.fA.mU.fU.mG.fA F11- 685 PmU.fC.mU.fU.mU.fG.mA.fG.mA.fU.m 935 fA.mA.fA.mG.fA.mA.fU.mC.fU.mC 185M U.fC.mU.fU.mU.fG.mG.fG.mC .fA.mA.fA.mG.fA F11- 686 PmU.fC.mA.fC.mU.fC.mU.fU.mG.fG.m 936 fC.mA.fC.mU.fG.mC.fC.mA.fA.m 186M C.fA.mG.fU. mG.fU. mU.fU.mC G.fA.mG.fU.mG.fA F11- 687 PmU.fC.mU.fU.mG.fA.mA.fA.mG.fA.m 937 fG. mG.fU. mA.fU.mU.fC.mU.fU.m 187M A.fU.mA.fC.mC.fC.mA.fG.mA U.fC.mA.fA.mG.fA F11- 688 PmU.fA.mG.fG.mC.fA.mA.fU.mA.fU.m 938 fG.mU.fA.mU.fG.mA.fU.mA.fU.m 188M C.fA.mU.fA.mC.fC.mC.fG.mC U.fG.mC.fC.mU.fA F11- 689 PmU.fC.mU.fG.mU.fG.mU.fA.mA.fU.m 939 fA.mG.fU.mG.fA.mA.fU.mU.fA.m 189M U.fC.mA.fC.mU.fG.mU.fG.mG C.fA.mC.fA.mG.fA F11- 690 PmU.fA.mA.fU.mA.fU.mC.fC.mA.fC.m 940 fA.mA.fG.mC.fA. mG.fU. mG.fG.m 190M U.fG.mG.fU.mU.fU.mC.fC.mA A.fU.mA.fU.mU.fA F11- 691 PmU.fU.mG.fA.mA.fA.mG.fA.mA.fU.m 941 fU.mG.fG.mG.fU.mA.fU.mU.fC.m 191M A.fC.mC.fC.mA.fG.mA.fA.mA U.fU.mU.fC.mA.fA F11- 692 PmU.fG.mU.fU.mA.fA.mU.fA.mU.fC.m 942 fC.mA.fG.mU.fG.mG.fA.mU.fA.m 192M C.fA.mC.fU.mG.fG.mU.fU.mU U.fU.mA.fA.mC.fA F11- 693 PmU.fU. mG.fU. mC.fA.mU.fG. mG.fU. m 943 fA.mU.fU.mU.fU.mA.fC.mC.fA.mU 193M A.fA.mA.fA.mU.fG.mA.fA.mG .fG.mA.fC.mA.fA F11- 694 PmU.fA.mU.fU.mC.fU.mU.fU.mG.fG.m 944 fA.mU.fG.mG.fC.mC.fC.mA.fA.m 194M G.fC.mC.fA.mU.fU.mC.fC.mU A.fG.mA.fA.mU.fA F11- 695 PmU.fC.mA.fG.mU.fU.mC.fC.mU.fC.m 945 fC.mG.fU.mU.fG.mG.fA. mG.fG.m 195M C.fA.mA.fC.mG.fA.mU.fC.mC A.fA.mC.fU.mG.fA F11- 696 PmU.fG.mG.fG.mU.fG.mU.fG.mC.fU. 946 fA.mC.fU.mG.fA.mA.fG.mC.fA.m 196M mU.fC.mA.fG.mU.fA.mG.fA.mC C.fA.mC.fC.mC.fA F11- 697 PmU.fG.mA.fA.mG.fA.mA.fA.mG.fC.m 947 fU.mU.fA.mA.fA.mG.fC.mU.fU.m 197M U.fU.mU.fA.mA.fG.mU.fA.mA U.fC.mU.fU.mC.fA F11- 698 PmU.fA.mU.fC.mC.fU.mG.fA.mA.fA.m 948 fG.mG.fU.mC.fU.mU.fU.mU.fC.m 198M A.fG.mA.fC.mC.fU.mU.fG.mU A.fG.mG.fA.mU.fA F11- 699 PmU.fA.mG.fA.mA.fA.mG.fC.mU.fU.m 949 fA.mC.fU.mU.fA.mA.fA.mG.fC.mU 199M U.fA.mA.fG.mU.fA.mA.fC.mA .fU.mU.fC.mU.fA F11- 700 PmU.fC.mA.fG.mU.fG.mU.fU.mU.fC.m 950 fU.mU.fA.mC.fA.mG.fA.mA.fA.mC 200M U.fG.mU.fA.mA.fC.mA.fC.mU .fA.mC.fU.mG.fA F11- 701 PmU.fG.mA.fC.mA.fC.mG.fC.mA.fA.m 951 fA.mG.fA.mU.fU.mU.fU.mG.fC.m 201M A.fA.mU.fC.mU.fU.mA.fG.mG G.fU.mG.fU.mC.fA F11- 702 PmU.fG.mU.fG.mU.fG.mA.fG.mC.fA.m 952 fA.mG.fC.mA.fA.mU.fG.mC.fU.m 202M U.fU.mG.fC.mU.fU.mG.fA.mA C.fA.mC.fA.mC.fA F11- 703 PmU.fA.mC.fC.mA.fG.mA.fA.mA.fG.m 953 fA.mA.fG.mC.fU.mC.fU.mU.fU.m 203M A.fG.mC.fU.mU.fU.mG.fC.mU C.fU.mG.fG.mU.fA F11- 704 PmU.fA.mG.fA.mA.fA.mG.fU.mG.fC.m 954 fC.mC.fU.mG.fU.mG.fC.mA.fC.m 204M A.fC.mA.fG.mG.fA.mU.fU.mU U.fU.mU.fC.mU.fA F11- 705 PmU.fU.mU.fU.mA.fU.mU.fU.mC.fA.m 955 fC.mA.fA.mU.fC.mU.fG.mA.fA.mA 205M G.fA.mU.fU.mG.fA.mU.fU.mU .fU.mA.fA.mA.fA F11- 706 PmU.fU.mA.fU.mC.fC.mA.fG.mU.fU.m 956 fA.mG.fA.mA.fG.mA.fA.mC.fU.m 206M C.fU.mU.fC.mU.fC.mC.fC.mA G.fG.mA.fU.mA.fA F11- 707 PmU.fC.mC.fG.mU.fG.mA.fA.mA.fG.m 957 f.mU.fU.mC.fA.mC.fU.mU.fU.m 207M U.fG.mA.fA.mG.fA.mG.fU.mA C.fA.mC.fG.mG.fA F11- 708 PmU.fG.mG.fU.mG.fU.mG.fC.mU.fU. 958 fU.mA.fC.mU.fG.mA.fA.mG.fC.m 208M mC.fA.mG.fU.mA.fG.mA.fC.mA A.fC.mA.fC.mC.fA F11- 709 PmU.fG.mG.fA.mC.fA.mG.fA.mG.fG.m 959 fG.mA.fG.mG.fC.mC.fC.mU.fC.m 209M G .fC .mC .fU .mC .fC .mC .fG .mA U.fG.mU.fC.mC.fA F11- 710 PmU.fA.mA.fG.mA.fA.mA.fA.mU.fC.m 960 fA.mG.fG.mA.fU.mG.fA.mU.fU.m 210M A.fU.mC.fC.mU.fG.mA.fA.mA U .fU.mC.fU.mil .fA F11- 711 PmU.fU.mG.fA.mG.fA.mU.fU.mC.fU.m 961 fC.mC.fC.mA.fA.mA.fG.mA.fA.mU 211M U.fU.mG.fG.mG.fC.mC.fA.mU .fC.mU.fC.mA.fA F11- 712 PmU.fA.mU.fG.mU.fU.mU.fU.mA.fA.m 962 fU.mC.fU.mC.fC.mU.fU.mA.fA.mA 212M G.fG.mA.fG.mA.fC.mA.fA.mA .fA.mC.fA.mU.fA F11- 713 PmU.fC.mA.fC.mA.fG.mU.fU.mU.fC.m 963 fU.mG.fC.mC.fA.mG.fA.mA.fA.m 213M U.fG.mG.fC.mA.fG.mG.fC.mC C.fU.mG.fU.mG.fA F11- 714 PmU.fA.mC.fA.mA.fU.mA.fU.mC.fC.m 964 fG.mA.fA.mC.fU.mG.fG.mA.fU.m 214M A.fG.mU.fU.mC.fU.mU.fC.mU A.fU.mU.fG.mU.fA F11- 715 PmU.fA.mC.fA.mU.fU.mC.fA.mC.fC.m 965 fU.mU.fU.mC.fU.mG.fG.mU.fG.m 215M A.fG.mA.fA.mA.fC.mU.fG.mA A.fA.mU.fG.mU.fA F11- 716 PmU.fC.mA.fA.mG.fG.mC.fA.mA.fU.m 966 fA.mU.fG.mA.fU.mA.fU.mU.fG.m 216M A.fU.mC.fA.mU.fA.mC.fC.mC C.fC.mU.fU.mG.fA F11- 717 PmU.fC.mU.fC.mC.fA.mA.fC.mG.fA.m 967 fC.mA.fG.mG.fA.mU.fC.mG.fU.m 217M U.fC.mC.fU.mG.fG.mG.fC.mU U.fG.mG.fA.mG.fA F11- 718 PmU.fC.mU.fG.mA.fA.mA.fC.mC.fA.m 968 fC.mU.fU.mU.fC.mU.fG.mG.fU.m 218M G.fA.mA.fA.mG.fA.mG.fC.mU U.fU.mC.fA.mG.fA F11- 719 PmU.fA.mA.fU.mC.fU.mC.fC.mC.fU.m 969 fU.mU.fG.mC.fA.mA.fG.mG.fG.m 219M U.fG.mC.fA.mA.fG.mC.fG.mU A.fG.mA.fU.mU.fA F11- 720 PmU.fU.mG.fU.mG.fU.mA.fA.mU.fU.m 970 fC.mA.fG.mU.fG.mA.fA.mU.fU.m 220M C.fA.mC.fU.mG.fU.mG.fG.mU A.fC.mA.fC.mA.fA F11- 721 PmU.fU.mU.fU.mC.fA.mG.fU.mG.fA.m 971 fG.mA.fU.mU.fU.mU.fC.mA.fC.m 221M A.fA.mA.fU.mC.fC.mA.fG.mA U.fG.mA.fA.mA.fA F11- 722 PmU.fA.mA.fA.mU.fC.mA.fU.mC.fC.m 972 fU.mU.fU.mC.fA.mG.fG.mA.fU.m 222M U.fG.mA.fA.mA.fA.mG.fA.mC G.fA.mU.fU.mU.fA F11- 723 PmU.fU.mA.fC.mA.fC.mU.fC.mA.fU.m 973 fG.mG.fA.mU.fA.mA.fU.mG.fA.m 223M U.fA.mU.fC.mC.fA.mU.fU.mU G.fU.mG.fU.mA.fA F11- 724 PmU.fU.mU.fG.mG.fC.mA.fG.mU.fG. 974 fA.mG.fA.mA.fA.mC.fA.mC.fU.mG 224M mU.fU.mU.fC.mU.fG.mU.fA.mA .fC.mC.fA.mA.fA F11- 725 PmU.fG.mG.fU.mA.fC.mA.fC.mU.fC.m 975 fA.mU.fA.mA.fU.mG.fA.mG.fU.m 225M A.fU.mU.fA.mU.fC.mC.fA.mU G.fU.mA.fC.mC.fA F11- 726 PmU.fA.mG.fG.mC.fA.mG.fG.mC.fA.m 976 fC.mC.fA.mU.fA.mU.fG.mC.fC.m 226M U.fA.mU.fG.mG.fG.mU.fC.mG U.fG.mC.fC.mU.fA F11- 727 PmU.fC.mC.fA.mG.fU.mU.fU.mC.fA.m 977 fC.mU.fU.mG.fU.mU.fG.mA.fA.m 227M A.fC.mA.fA.mG.fG.mC.fA.mA A.fC.mU.fG.mG.fA F11- 728 PmU.fU.mG.fG.mC.fC.mG.fC.mU.fC. 978 fA.mA.fA.mG.fG.mG.fA.mG.fC.m 228M mC.fC.mU.fU.mU.fG.mA.fG.mC G.fG.mC.fC.mA.fA F11- 729 PmU.fA.mC.fU.mG.fU.mG.fG.mU.fU.m 979 fC.mU.fG.mG.fA.mA.fA.mC.fC.m 229M U.fC.mC.fA.mG.fU.mU.fU.mC A.fC.mA.fG.mU.fA F11- 730 PmU.fC.mU.fU.mU.fG.mG.fG.mC.fC. 980 fG.mG.fA.mA.fU.mG.fG.mC.fC.m 230M mA.fU.mU.fC.mC.fU.mG.fG.mG C.fA.mA.fA.mG.fA F11- 731 PmU.fU.mA.fA.mG.fA.mA.fA.mA.fU.m 981 fG.mG.fA.mU.fG.mA.fU.mU.fU.m 231M C.fA.mU.fC.mC.fU.mG.fA.mA U.fC.mU.fU.mA.fA F11- 732 PmU.fC.mU.fC.mU.fU.mU.fU.mA.fU.m 982 fC.mU.fG.mA.fA.mA.fU.mA.fA.mA 232M U.fU.mC.fA.mG.fA.mU.fU.mG .fA.mG.fA.mG.fA F11- 733 PmU.fU.mC.fU.mU.fU.mG.fA.mG.fA.m 983 fA.mA.fG.mA.fA.mU.fC.mU.fC.mA 233M U.fU.mC.fU.mU.fU.mG.fG.mG .fA.mA.fG.mA.fA F11- 734 PmU.fA.mA.fU.mG.fA.mU.fG.mG.fA.m 984 fG.mA.fG.mG.fC.mU.fC.mC.fA.m 234M G.fC.mC.fU.mC.fC.mA.fC.mA U.fC.mA.fU.mU.fA F11- 735 PmU.fG.mA.fA.mG.fA.mA.fU.mG.fG.m 985 fU.mU.fC.mU.fG.mC.fC.mA.fU.m 235M C.fA.mG.fA.mA.fC.mA.fC.mU U.fC.mU.fU.mC.fA F11- 736 PmU.fC.mA.fA.mU.fG.mA.fU.mG.fG.m 986 fA.mG.fG.mC.fU.mC.fC.mA.fU.m 236M A.fG.mC.fC.mU.fC.mC.fA.mC C.fA.mU.fU.mG.fA F11- 737 PmU.fA.mU.fG.mG.fA.mG.fC.mC.fU.m 987 fU.mG.fU.mG.fG.mA.fG.mG.fC.m 237M C.fC.mA.fC.mA.fC.mA.fG.mG U.fC.mC.fA.mU.fA F11- 738 PmU.fC.mC.fC.mA.fA.mG.fA.mA.fA.m 988 fA.mC.fU.mG.fA.mU.fU.mU.fC.m 238M U.fC.mA.fG.mU.fG.mU.fC.mA U.fU.mG.fG.mG.fA F11- 739 PmU.fG.mA.fG.mC.fC.mU.fC.mC.fA.m 989 fC.mU.fG.mU.fG.mU.fG.mG.fA.m 239M C.fA.mC.fA.mG.fG.mU.fG.mU G.fG.mC.fU.mC.fA F11- 740 PmU.fC.mU.fC.mC.fC.mA.fA.mG.fA.m 990 fU.mG.fA.mU.fU.mU.fC.mU.fU.m 240M A.fA.mU.fC.mA.fG.mU.fG.mU G.fG.mG.fA.mG.fA F11- 741 PmU.fC.mC.fU.mC.fC.mA.fC.mA.fC.m 991 fC.mA.fC.mC.fU.mG.fU.mG.fU.m 241M A.fG.mG.fU.mG.fU.mC.fU.mC G.fG.mA.fG.mG.fA F11- 742 PmU.fC.mC.fA.mA.fU.mG.fA.mU.fG.m 992 fG.mG.fC.mU.fC.mC.fA.mU.fC.m 242M G fA. mG .fC. mC .fU. mC .fC. m A A.fU.mU.fG.mG.fA F11- 743 PmU.fU.mU.fU.mC.fC.mA.fA.mU.fG.m 993 fU.mC.fC.mA.fU.mC.fA.mU.fU.m 243M A.fU.mG.fG.mA.fG.mC.fC.mU G.fG.mA.fA.mA.fA F11- 744 PmU.fU.mC.fC.mC.fA.mA.fG.mA.fA.m 994 fC.mU.fG.mA.fU.mU.fU.mC.fU.m 244M A.fU.mC.fA.mG.fU.mG.fU.mC U.fG.mG.fG.mA.fA F11- 745 PmU.fA.mG.fC.mC.fU.mC.fC.mA.fC.m 995 fC.mC.fU.mG.fU.mG.fU.mG.fG.m 245M A.fC.mA.fG.mG.fU.mG.fU.mC A.fG.mG.fC.mU.fA F11- 746 PmU.fU.mC.fU.mU.fC.mU.fC.mC.fC.m 996 fU.mU.fC.mU.fU.mG.fG.mG.fA.m 246M A.fA.mG.fA.mA.fA.mU.fC.mA G.fA.mA.fG.mA.fA F11- 747 PmU.fG.mU.fU.mU.fC.mC.fA.mA.fU.m 997 fC.mC.fA.mU.fC.mA.fU.mU.fG.m 247M G.fA.mU.fG.mG.fA.mG.fC.mC G.fA.mA.fA.mC.fA F11- 748 PmU.fU.mC.fC.mA.fA.mU.fG.mA.fU.m 998 fG.mC.fU.mC.fC.mA.fU.mC.fA.m 248M G.fG.mA.fG.mC.fC.mU.fC.mC U.fU.mG.fG.mA.fA F11- 749 PmU.fU.mG.fG.mA.fG.mC.fC.mU.fC.m 999 fG.mU.fG.mU.fG.mG.fA.mG.fG.m 249M C.fA.mC.fA.mC.fA.mG.fG.mU C.fU.mC.fC.mA.fA F11- 750 PmU.fG.mC.fC.mU.fC.mC.fA.mC.fA.m 1000 fA.mC.fC.mU.fG.mU.fG.mU.fG.m 250M C.fA.mG.fG.mU.fG.mU.fC.mU G.fA.mG.fG.mC.fA

In above Table 1 b:

A represents adenine;

U represents uracil;

C represents cytosine;

G represents guanine;

P represents a terminal phosphate group;

m represents a methyl modification at the 2′ position of the sugar of the underlying nucleoside;

f represents a fluoro modification at the 2′ position of the sugar of the underlying nucleoside.

The target sequences in the Factor XI gene, with which the antisense (guide) sequences of Tables 1a/1b interact are set out in Table 1c below.

TABLE 1c Summary sequence table for the nucleobases of the target gene: Seq ID Target sequence Oligo Name No (5′ to 3′) F11-01T 1001 GAGUCACCUAAGAUUUUGC F11-02T 1002 GUGGCAUUUUAAAUCAAUC F11-03T 1003 AGGACAGCAGCGAUUUCUG F11-04T 1004 UCAGGAUGAUUUUCUUAUA F11-05T 1005 UUCCCUAAUACGGUGUUUG F11-06T 1006 UUACCAUGACACUGAUUUC F11-07T 1007 AUGGCAGAAAGCGGGUAUG F11-08T 1008 UGUCUCCUUAAAACAUCUG F11-09T 1009 CCAGAAAGCCAAGAUACCC F11-10T 1010 GCCAGAAGAGAUACAGAGG F11-11T 1011 CAAGAAAUAAUAAUCCAUG F11-12T 1012 GCACUUUCUAAUCUGGCUU F11-13T 1013 GCACCAAUGCCGUCCGCUG F11-14T 1014 UUUAAAUCAAUCUGAAAUA F11-15T 1015 CAGAAAACUAAGAGACAAA F11-16T 1016 ACAGCAUCCCAGUGUUCUG F11-17T 1017 UUUUCUUAUAUCAAGUGGU F11-18T 1018 GGUGUUUGUAAGAAAAUGC F11-19T 1019 UGCCCAGUACACGCAUUAA F11-20T 1020 CGGGAGGCCCUCUGUCCUG F11-21T 1021 CACUCAUCAUCCCGGUUGC F11-22T 1022 CUCAAAGAAAUCUUUGUCU F11-23T 1023 GUGCCAGCAUGCUUCCUCC F11-24T 1024 GUAUUAGGGACAUUUUCCC F11-25T 1025 AGGGCAAGUGUUACUUAAA F11-26T 1026 AAAGCGGGUAUGAUAUUGC F11-27T 1027 AUAUCAAGUGGUACAUUUC F11-28T 1028 UUUUCAGGAUGAUUUUCUU F11-29T 1029 AGGGAAGGGCAAGUGUUAC F11-30T 1030 UGUUUGUAAGAAAAUGCUA F11-31T 1031 UCCCUAAUACGGUGUUUGC F11-32T 1032 UGGAUAUUAACAGCCGCUC F11-33T 1033 GGAUAUUAACAGCCGCUCA F11-34T 1034 CAAAGAAAUCUUUGUCUCC F11-35T 1035 AGGACAUAAAAUAACCCAU F11-36T 1036 UCGACAGUGUCAUGGCUCC F11-37T 1037 UGUGCACUUUCUAAUCUGG F11-38T 1038 GCGAUUUCUGGGUAUUCUU F11-39T 1039 GUCUCCUUAAAACAUCUGA F11-40T 1040 GAGGCAUCUCUGGAUACAC F11-41T 1041 CUGGUGAAUGUGUGACUCA F11-42T 1042 AGGACACAUCUUUCUUUGG F11-43T 1043 UUUCUUAUAUCAAGUGGUA F11-44T 1044 GUUACUUAAAGCUUUCUUC F11-45T 1045 UAAAUCAAUCUGAAAUAAA F11-46T 1046 CAAGCAAUGCUCACACCAA F11-47T 1047 AGGUCUUUUCAGGAUGAUU F11-48T 1048 CUUUCAAGCAAUGCUCACA F11-49T 1048 GUGCCAGAAGAGAUACAGA F11-50T 1050 CUGGAUACACAUUAAGGUU F11-51T 1051 GAAAUAAUAAUCCAUGAUC F11-52T 1052 AUCUCAAAGAAAUCUUUGU F11-53T 1053 CUCCAACUAAAAUACUUCA F11-54T 1054 GGCAUUUUAAAUCAAUCUG F11-55T 1055 CAGAAAGCCAAGAUACCCU F11-56T 1056 AAGAAAUCUUUGUCUCCUU F11-57T 1057 UCUUCAUUUUACCAUGACA F11-58T 1058 GGGAGAAGAACUGGAUAUU F11-59T 1059 GGAGAAGAACUGGAUAUUG F11-60T 1060 UGAAACUGGAAACCACAGU F11-61T 1061 CUGUGCACUUUCUAAUCUG F11-62T 1062 ACCAUGACACUGAUUUCUU F11-63T 1063 UCAAGAAAUAAUAAUCCAU F11-64T 1064 GUGCACUUUCUAAUCUGGC F11-65T 1065 UGUAAAAUGGAUAAUGAGU F11-66T 1066 UUCCCAGGAAUGGCCCAAA F11-67T 1067 CCACCAAAAUCAAGCCCAG F11-68T 1068 GCAUUUUAAAUCAAUCUGA F11-69T 1069 UCAUCAUCCCGGUUGCUUG F11-70T 1070 CUCUGGAUACACAUUAAGG F11-71T 1071 GAAACCACAGUGAAUUACA F11-72T 1072 CAAAGGAGAUAGAAAUGUA F11-73T 1073 CAUCAUUGGAAACCAGUGG F11-74T 1074 AGUGAAUUACACAGAUUCU F11-75T 1075 GCCAAGAGUGAAUAGGACA F11-76T 1076 AUUCUUUCAAGCAAUGCUC F11-77T 1077 CAGCGAUUUCUGGGUAUUC F11-78T 1078 GGUUCAAGAAAUAAUAAUC F11-79T 1079 UCUCCAACUAAAAUACUUC F11-80T 1080 AGUACGUGGACUGGAUUCU F11-81T 1081 UCAAAGAAAUCUUUGUCUC F11-82T 1082 UUUUCACUGAAAUCCUGUG F11-83T 1083 GUAUGAUAUUGCCUUGUUG F11-84T 1084 CGGGUAUGAUAUUGCCUUG F11-85T 1085 GCAGCGAUUUCUGGGUAUU F11-86T 1086 UGGCAUUUUAAAUCAAUCU F11-87T 1087 CUGCCAAGAGUGAAUAGGA F11-88T 1088 AAGAUUUUGCGUGUCUACA F11-89T 1089 GAUUCUGGAGAAAACUCAA F11-90T 1090 AAAGAAUCUCAAAGAAAUC F11-91T 1091 CAGGAUGAUUUUCUUAUAU F11-92T 1092 AGAGUCACCUAAGAUUUUG F11-93T 1093 GGCACAGCAUCCCAGUGUU F11-94T 1094 UCACUGAAAUCCUGUGCAC F11-95T 1095 UUCUAAUCUGGCUUGUAUU F11-96T 1096 UUGAAACUGGAAACCACAG F11-97T 1097 GCAACGAAGGGAAGGGCAA F11-98T 1098 UCUUUUCAGGAUGAUUUUC F11-99T 1099 AUGACACUGAUUUCUUGGG F11-100T 1100 CUCAACGACCCAUAUGCCU F11-101T 1101 GUGAAUUACACAGAUUCUC F11-102T 1102 CGAGUACGUGGACUGGAUU F11-103T 1103 CCAGAAGAGAUACAGAGGA F11-104T 1104 UUCACUGAAAUCCUGUGCA F11-105T 1105 UGCCAUUCUUCAUUUUACC F11-106T 1106 ACACAGAUUCUCAACGACC F11-107T 1107 AGAACUGGAUAUUGUUGCU F11-108T 1108 CACCAAUGCCGUCCGCUGC F11-109T 1109 GUGUUACUUAAAGCUUUCU F11-110T 1110 GUGUUACAGAAACACUGCC F11-111T 1111 UGAAUUACACAGAUUCUCA F11-112T 1112 UCGAGUACGUGGACUGGAU F11-113T 1113 UUUCAAGCAAUGCUCACAC F11-114T 1114 CUGCACUCAUCAUCCCGGU F11-115T 1115 CGAAGCUCGAUAAAGUGGU F11-116T 1116 UGUGUAAAAUGGAUAAUGA F11-117T 1117 GCACUCAUCAUCCCGGUUG F11-118T 1118 CAGGAAUGGCCCAAAGAAU F11-119T 1119 AAGCCAAGAUACCCUUAGU F11-120T 1120 AAGCAAUGCUCACACCAAA F11-121T 1121 UUCUCAACGACCCAUAUGC F11-122T 1122 UCUCUGGAUACACAUUAAG F11-123T 1123 UCUCCUUAAAACAUCUGAG F11-124T 1124 GAGGCUCCAUCAUUGGAAA F11-125T 1125 GUACGUGGACUGGAUUCUG F11-126T 1126 GGCCCAAAGAAUCUCAAAG F11-127T 1127 GGUCUUUUCAGGAUGAUUU F11-128T 1128 CUAAGAUUUUGCGUGUCUA F11-129T 1129 CCAACGUGGUCGAGUACGU F11-130T 1130 UUGCUGGGUGACUGGAUGG F11-131T 1131 GCACAGCAUCCCAGUGUUC F11-132T 1132 AGAGCAAAGCUCUUUCUGG F11-133T 1133 CCAAAGAAUCUCAAAGAAA F11-134T 1134 GAACUGGAUAUUGUUGCUG F11-135T 1135 GAAGCUCGAUAAAGUGGUG F11-136T 1136 CUGCAACGAAGGGAAGGGC F11-137T 1137 GUCACCUAAGAUUUUGCGU F11-138T 1138 CCUCCACAGUAACACGCUG F11-139T 1139 CCGGCUACAGGGAAGGAGG F11-140T 1140 AGAAGAGAUACAGAGGACA F11-141T 1141 UCCAGAAAGCCAAGAUACC F11-142T 1142 CAGAAACACUGCCAAGAGU F11-143T 1143 UACCAUGACACUGAUUUCU F11-144T 1144 GUGCCGGCUACAGGGAAGG F11-145T 1145 CUCAAAGGGAGCGGCCAGG F11-146T 1146 CACCUAAGAUUUUGCGUGU F11-147T 1147 AAAGCUCUUUCUGGUUUCA F11-148T 1148 AGUGUUACUUAAAGCUUUC F11-149T 1149 CUUUCUAAUCUGGCUUGUA F11-150T 1150 GUAAAAUGGAUAAUGAGUG F11-151T 1151 CAACAAGGUCUUUUCAGGA F11-152T 1152 GCUCCAUCAUUGGAAACCA F11-153T 1153 GAGGCCUGCCAGAAACUGU F11-154T 1154 AUCCCAGUGUUCUGCCAUU F11-155T 1155 AGAAUCUCAAAGAAAUCUU F11-156T 1156 CUUGUUGAAACUGGAAACC F11-157T 1157 CAGAAGAGAUACAGAGGAC F11-158T 1158 CAAGGUCUUUUCAGGAUGA F11-159T 1159 AUUCUGGAGAAAACUCAAG F11-160T 1160 UGGAAACCACAGUGAAUUA F11-161T 1161 GAAUCUCAAAGAAAUCUUU F11-162T 1162 AAAGAAAUCUUUGUCUCCU F11-163T 1163 CUUUUCAGGAUGAUUUUCU F11-164T 1164 GUAUAAAAUGGCAGAAAGC F11-165T 1165 UGGUCGAGUACGUGGACUG F11-166T 1166 GCCCAGUACACGCAUUAAA F11-167T 1167 AUCUCUGGAUACACAUUAA F11-168T 1168 GGAAUGGCCCAAAGAAUCU F11-169T 1169 AAGCUCUUUCUGGUUUCAG F11-170T 1170 GUUUCUGGUGAAUGUGUGA F11-171T 1171 UCUCAAAGAAAUCUUUGUC F11-172T 1172 CCAAAGGAGAUAGAAAUGU F11-173T 1173 AAGACAGUGUUACAGAAAC F11-174T 1174 GGAUUUUCACUGAAAUCCU F11-175T 1175 CUGUGCUCAAAGGGAGCGG F11-176T 1176 GGUCGAGUACGUGGACUGG F11-177T 1177 UCAACGACCCAUAUGCCUG F11-178T 1178 AAGAGAUACAGAGGACAUA F11-179T 1179 GUACCACCAAAAUCAAGCC F11-180T 1180 GUGUGGAGGCUCCAUCAUU F11-181T 1181 UACACAGAUUCUCAACGAC F11-182T 1182 GUUGUGUAAAAUGGAUAAU F11-183T 1183 CCAAGAGUGAAUAGGACAG F11-184T 1184 GAGAAGAACUGGAUAUUGU F11-185T 1185 GCCCAAAGAAUCUCAAAGA F11-186T 1186 GAAACACUGCCAAGAGUGA F11-187T 1187 UCUGGGUAUUCUUUCAAGC F11-188T 1188 GCGGGUAUGAUAUUGCCUU F11-189T 1189 CCACAGUGAAUUACACAGA F11-190T 1190 UGGAAACCAGUGGAUAUUA F11-191T 1191 UUUCUGGGUAUUCUUUCAA F11-192T 1192 AAACCAGUGGAUAUUAACA F11-193T 1193 CUUCAUUUUACCAUGACAC F11-194T 1194 AGGAAUGGCCCAAAGAAUC F11-195T 1195 GGAUCGUUGGAGGAACUGC F11-196T 1196 GUCUACUGAAGCACACCCA F11-197T 1197 UUACUUAAAGCUUUCUUCA F11-198T 1198 ACAAGGUCUUUUCAGGAUG F11-199T 1199 UGUUACUUAAAGCUUUCUU F11-200T 1200 AGUGUUACAGAAACACUGC F11-201T 1201 CCUAAGAUUUUGCGUGUCU F11-202T 1202 UUCAAGCAAUGCUCACACC F11-203T 1203 AGCAAAGCUCUUUCUGGUU F11-204T 1204 AAAUCCUGUGCACUUUCUA F11-205T 1205 AAAUCAAUCUGAAAUAAAA F11-206T 1206 UGGGAGAAGAACUGGAUAU F11-207T 1207 UACUCUUCACUUUCACGGC F11-208T 1208 UGUCUACUGAAGCACACCC F11-209T 1209 UCGGGAGGCCCUCUGUCCU F11-210T 1210 UUUCAGGAUGAUUUUCUUA F11-211T 1211 AUGGCCCAAAGAAUCUCAA F11-212T 1212 UUUGUCUCCUUAAAACAUC F11-213T 1213 GGCCUGCCAGAAACUGUGC F11-214T 1214 AGAAGAACUGGAUAUUGUU F11-215T 1215 UCAGUUUCUGGUGAAUGUG F11-216T 1216 GGGUAUGAUAUUGCCUUGU F11-217T 1217 AGCCCAGGAUCGUUGGAGG F11-218T 1218 AGCUCUUUCUGGUUUCAGU F11-219T 1219 ACGCUUGCAAGGGAGAUUC F11-220T 1220 ACCACAGUGAAUUACACAG F11-221T 1221 UCUGGAUUUUCACUGAAAU F11-222T 1222 GUCUUUUCAGGAUGAUUUU F11-223T 1223 AAAUGGAUAAUGAGUGUAC F11-224T 1224 UUACAGAAACACUGCCAAG F11-225T 1225 AUGGAUAAUGAGUGUACCA F11-226T 1226 CGACCCAUAUGCCUGCCUU F11-227T 1227 UUGCCUUGUUGAAACUGGA F11-228T 1228 GCUCAAAGGGAGCGGCCAG F11-229T 1229 GAAACUGGAAACCACAGUG F11-230T 1230 CCCAGGAAUGGCCCAAAGA F11-231T 1231 UUCAGGAUGAUUUUCUUAU F11-232T 1232 CAAUCUGAAAUAAAAGAGG F11-233T 1233 CCCAAAGAAUCUCAAAGAA F11-234T 1234 UGUGGAGGCUCCAUCAUUG F11-235T 1235 AGUGUUCUGCCAUUCUUCA F11-236T 1236 GUGGAGGCUCCAUCAUUGG F11-237T 1237 CCUGUGUGGAGGCUCCAUC F11-238T 1238 UGACACUGAUUUCUUGGGA F11-239T 1239 ACACCUGUGUGGAGGCUCC F11-240T 1240 ACACUGAUUUCUUGGGAGA F11-241T 1241 GAGACACCUGUGUGGAGGC F11-242T 1242 UGGAGGCUCCAUCAUUGGA F11-243T 1243 AGGCUCCAUCAUUGGAAAC F11-244T 1244 GACACUGAUUUCUUGGGAG F11-245T 1245 GACACCUGUGUGGAGGCUC F11-246T 1246 UGAUUUCUUGGGAGAAGAA F11-247T 1247 GGCUCCAUCAUUGGAAACC F11-248T 1248 GGAGGCUCCAUCAUUGGAA F11-249T 1249 ACCUGUGUGGAGGCUCCAU F11-250T 1250 AGACACCUGUGUGGAGGCU

In above Table 1c:

A represents adenine;

U represents uracil;

C represents cytosine;

G represents guanine.

It should also be noted that the scope of the present embodiments extends to sequences that correspond to those in Table 1a or Table 1 b, and wherein the 5′ nucleoside of the antisense (guide) strand (first region as defined herein) can include any nucleobase that can be present in an RNA molecule, in other words can be any of adenine (A), uracil (U), guanine or cytosine (C). Additionally, the scope of the present embodiments extends to sequences that correspond to those in Table 1a or Table 1b, and wherein the 3′ nucleoside of the sense (passenger) strand (second region as defined herein) can include any nucleobase that can be present in an RNA molecule, in other words can be any of adenine (A), uracil (U), guanine or cytosine (C), preferably however a nucleobase that is complementary to the 5′ nucleobase of the antisense (guide) strand (first region as defined herein). These further sequences are shown in Tables 1d (unmodified) and 1e (chemically modified), where N and N′ respectively represent any RNA nucleobase that can be present in the 5′ terminal position of the antisense (guide) strand (first region as defined herein) and in the 3′ terminal position of the sense (passenger) strand (second region as defined herein).

TABLE 1d Summary sequence table for active nucleobase sequences: Oligo Seq Antisense (Guide) Strand Seq ID Sense (Passenger) Strand Name ID No Sequence (5′ to 3′) No Sequence (5′ to 3′) F11- 1251 NCAAAAUCUUAGGUGACUC 1501 CACCUAAGAUUUUGN′ 01N F11- 1252 NAUUGAUUUAAAAUGCCAC 1502 CAUUUUAAAUCAAUN′ 02N F11- 1253 NAGAAAUCGCUGCUGUCCU 1503 CAGCAGCGAUUUCUN′ 03N F11- 1254 NAUAAGAAAAUCAUCCUGA 1504 GAUGAUUUUCUUAUN′ 04N F11- 1255 NAAACACCGUAUUAGGGAA 1505 CUAAUACGGUGUUUN′ 05N F11- 1256 NAAAUCAGUGUCAUGGUAA 1506 CAUGACACUGAUUUN′ 06N F11- 1257 NAUACCCGCUUUCUGCCAU 1507 CAGAAAGCGGGUAUN′ 07N F11- 1258 NAGAUGUUUUAAGGAGACA 1508 UCCUUAAAACAUCUN′ 08N F11- 1259 NGGUAUCUUGGCUUUCUGG 1059 AAAGCCAAGAUACCN′ 09N F11- 1260 NCUCUGUAUCUCUUCUGGC 1510 GAAGAGAUACAGAGN′ 10N F11- 1261 NAUGGAUUAUUAUUUCUUG 1511 AAAUAAUAAUCCAUN′ 11N F11- 1262 NAGCCAGAUUAGAAAGUGC 1512 UUUCUAAUCUGGCUN′ 12N F11- 1263 NAGCGGACGGCAUUGGUGC 1513 CAAUGCCGUCCGCUN′ 13N F11- 1264 NAUUUCAGAUUGAUUUAAA 1514 AAUCAAUCUGAAAUN′ 14N F11- 1265 NUUGUCUCUUAGUUUUCUG 1515 AAACUAAGAGACAAN′ 15N F11- 1266 NAGAACACUGGGAUGCUGU 1516 CAUCCCAGUGUUCUN′ 16N F11- 1267 NCCACUUGAUAUAAGAAAA 1517 CUUAUAUCAAGUGGN′ 17N F11- 1268 NCAUUUUCUUACAAACACC 1518 UUUGUAAGAAAAUGN′ 18N F11- 1269 NUAAUGCGUGUACUGGGCA 1519 CAGUACACGCAUUAN′ 19N F11- 1270 NAGGACAGAGGGCCUCCCG 1520 AGGCCCUCUGUCCUN′ 20N F11- 1271 NCAACCGGGAUGAUGAGUG 1521 CAUCAUCCCGGUUGN′ 21N F11- 1272 NGACAAAGAUUUCUUUGAG 1522 AAGAAAUCUUUGUCN′ 22N F11- 1273 NGAGGAAGCAUGCUGGCAC 1523 CAGCAUGCUUCCUCN′ 23N F11- 1274 NGGAAAAUGUCCCUAAUAC 1524 UAGGGACAUUUUCCN′ 24N F11- 1275 NUUAAGUAACACUUGCCCU 1525 CAAGUGUUACUUAAN′ 25N F11- 1276 NCAAUAUCAUACCCGCUUU 1526 CGGGUAUGAUAUUGN′ 26N F11- 1277 NAAAUGUACCACUUGAUAU 1527 CAAGUGGUACAUUUN′ 27N F11- 1278 NAGAAAAUCAUCCUGAAAA 1528 CAGGAUGAUUUUCUN′ 28N F11- 1279 NUAACACUUGCCCUUCCCU 1529 AAGGGCAAGUGUUAN′ 29N F11- 1280 NAGCAUUUUCUUACAAACA 1530 UGUAAGAAAAUGCUN′ 30N F11- 1281 NCAAACACCGUAUUAGGGA 1531 UAAUACGGUGUUUGN′ 31N F12- 1282 NAGCGGCUGUUAAUAUCCA 1532 UAUUAACAGCCGCUN′ 32N F11- 1283 NGAGCGGCUGUUAAUAUCC 1533 AUUAACAGCCGCUCN′ 33N F11- 1284 NGAGACAAAGAUUUCUUUG 1534 GAAAUCUUUGUCUCN′ 34N F11- 1285 NUGGGUUAUUUUAUGUCCU 1535 CAUAAAAUAACCCAN′ 35N F11- 1286 NGAGCCAUGACACUGUCGA 1536 CAGUGUCAUGGCUCN′ 36N F11- 1287 NCAGAUUAGAAAGUGCACA 1537 CACUUUCUAAUCUGN′ 37N F11- 1288 NAGAAUACCCAGAAAUCGC 1538 UUUCUGGGUAUUCUN′ 38N F11- 1289 NCAGAUGUUUUAAGGAGAC 1539 CCUUAAAACAUCUGN′ 39N F11- 1290 NUGUAUCCAGAGAUGCCUC 1540 CAUCUCUGGAUACAN′ 40N F11- 1291 NGAGUCACACAUUCACCAG 1541 UGAAUGUGUGACUCN′ 41N F11- 1292 NCAAAGAAAGAUGUGUCCU 1542 CACAUCUUUCUUUGN′ 42N F11- 1293 NACCACUUGAUAUAAGAAA 1543 UUAUAUCAAGUGGUN′ 43N F11- 1294 UAAGAAAGCUUUAAGUAAC 1544 CUUAAAGCUUUCUUN′ 44N F11- 1295 NUUAUUUCAGAUUGAUUUA 1545 UCAAUCUGAAAUAAN′ 45N F11- 1296 NUGGUGUGAGCAUUGCUUG 1546 CAAUGCUCACACCAN′ 46N F11- 1297 NAUCAUCCUGAAAAGACCU 1547 CUUUUCAGGAUGAUN′ 47N F11- 1298 NGUGAGCAUUGCUUGAAAG 1548 CAAGCAAUGCUCACN′ 48N F11- 1299 NCUGUAUCUCUUCUGGCAC 1549 CAGAAGAGAUACAGN′ 49N F11- 1300 NACCUUAAUGUGUAUCCAG 1550 AUACACAUUAAGGUN′ 50N F11- 1301 NAUCAUGGAUUAUUAUUUC 1551 UAAUAAUCCAUGAUN′ 51N F11- 1302 NCAAAGAUUUCUUUGAGAU 1552 CAAAGAAAUCUUUGN′ 52N F11- 1303 NGAAGUAUUUUAGUUGGAG 1553 AACUAAAAUACUUCN′ 53N F11- 1304 NAGAUUGAUUUAAAAUGCC 1554 UUUUAAAUCAAUCUN′ 54N F11- 1305 NGGGUAUCUUGGCUUUCUG 1555 AAGCCAAGAUACCCN′ 55N F11- 1306 NAGGAGACAAAGAUUUCUU 1556 AAUCUUUGUCUCCUN′ 56N F11- 1307 NGUCAUGGUAAAAUGAAGA 1557 CAUUUUACCAUGACN′ 57N F11- 1308 NAUAUCCAGUUCUUCUCCC 1558 GAAGAACUGGAUAUN′ 58N F11- 1309 NAAUAUCCAGUUCUUCUCC 1559 AAGAACUGGAUAUUN′ 59N F11- 1310 NCUGUGGUUUCCAGUUUCA 1560 ACUGGAAACCACAGN′ 60N F11- 1311 NAGAUUAGAAAGUGCACAG 1561 GCACUUUCUAAUCUN′ 61N F11- 1312 NAGAAAUCAGUGUCAUGGU 1562 UGACACUGAUUUCUN′ 62N F11- 1313 NUGGAUUAUUAUUUCUUGA 1563 GAAAUAAUAAUCCAN′ 63N F11- 1314 NCCAGAUUAGAAAGUGCAC 1564 ACUUUCUAAUCUGGN′ 64N F11- 1315 NCUCAUUAUCCAUUUUACA 1565 AAAUGGAUAAUGAGN′ 65N F11- 1316 NUUGGGCCAUUCCUGGGAA 1566 CAGGAAUGGCCCAAN′ 66N F11- 1317 NUGGGCUUGAUUUUGGUGG 1567 CAAAAUCAAGCCCAN′ 67N F11- 1318 NCAGAUUGAUUUAAAAUGC 1568 UUUAAAUCAAUCUGN′ 68N F11- 1319 NAAGCAACCGGGAUGAUGA 1569 CAUCCCGGUUGCUUN′ 69N F11- 1320 NCUUAAUGUGUAUCCAGAG 1570 GGAUACACAUUAAGN′ 70N F11- 1321 NGUAAUUCACUGUGGUUUC 1571 CCACAGUGAAUUACN′ 71N F11- 1322 NACAUUUCUAUCUCCUUUG 1572 GGAGAUAGAAAUGUN′ 72N F11- 1323 NCACUGGUUUCCAAUGAUG 1573 AUUGGAAACCAGUGN′ 73N F11- 1324 NGAAUCUGUGUAAUUCACU 1574 AAUUACACAGAUUCN′ 74N F11- 1325 NGUCCUAUUCACUCUUGGC 1575 AGAGUGAAUAGGACN′ 75N F11- 1326 NAGCAUUGCUUGAAAGAAU 1576 UUUCAAGCAAUGCUN′ 76N F11- 1327 NAAUACCCAGAAAUCGCUG 1577 GAUUUCUGGGUAUUN′ 77N F11- 1328 NAUUAUUAUUUCUUGAACC 1578 CAAGAAAUAAUAAUN′ 78N F11- 1329 NAAGUAUUUUAGUUGGAGA 1579 CAACUAAAAUACUUN′ 79N F11- 1330 NGAAUCCAGUCCACGUACU 1580 CGUGGACUGGAUUCN′ 80N F11- 1331 NAGACAAAGAUUUCUUUGA 1581 AGAAAUCUUUGUCUN′ 81N F11- 1332 NACAGGAUUUCAGUGAAAA 1582 CACUGAAAUCCUGUN′ 82N F11- 1333 NAACAAGGCAAUAUCAUAC 1583 GAUAUUGCCUUGUUN′ 83N F11- 1334 NAAGGCAAUAUCAUACCCG 1584 UAUGAUAUUGCCUUN′ 84N F11- 1335 NAUACCCAGAAAUCGCUGC 1585 CGAUUUCUGGGUAUN′ 85N F11- 1336 NGAUUGAUUUAAAAUGCCA 1586 AUUUUAAAUCAAUCN′ 86N F11- 1337 NCCUAUUCACUCUUGGCAG 1587 CAAGAGUGAAUAGGN′ 87N F11- 1338 NGUAGACACGCAAAAUCUU 1588 UUUUGCGUGUCUACN′ 88N F11- 1339 NUGAGUUUUCUCCAGAAUC 1589 CUGGAGAAAACUCAN′ 89N F11- 1340 NAUUUCUUUGAGAUUCUUU 1590 AAUCUCAAAGAAAUN′ 90N F11- 1341 NUAUAAGAAAAUCAUCCUG 1591 AUGAUUUUCUUAUAN′ 91N F11- 1342 NAAAAUCUUAGGUGACUCU 1592 UCACCUAAGAUUUUN′ 92N F11- 1343 NACACUGGGAUGCUGUGCC 1593 CAGCAUCCCAGUGUN′ 93N F11- 1344 NUGCACAGGAUUUCAGUGA 1594 UGAAAUCCUGUGCAN′ 94N F11- 1345 NAUACAAGCCAGAUUAGAA 1595 AAUCUGGCUUGUAUN′ 95N F11- 1346 NUGUGGUUUCCAGUUUCAA 1596 AACUGGAAACCACAN′ 96N F11- 1347 NUGCCCUUCCCUUCGUUGC 1597 CGAAGGGAAGGGCAN′ 97N F11- 1348 NAAAAUCAUCCUGAAAAGA 1598 UUCAGGAUGAUUUUN′ 98N F11- 1349 NCCAAGAAAUCAGUGUCAU 1599 CACUGAUUUCUUGGN′ 99N F11- 1350 NGGCAUAUGGGUCGUUGAG 1600 ACGACCCAUAUGCCN′ 100N F11- 1351 NAGAAUCUGUGUAAUUCAC 1601 AUUACACAGAUUCUN′ 101N F11- 1352 NAUCCAGUCCACGUACUCG 1602 UACGUGGACUGGAUN′ 102N F11- 1353 NCCUCUGUAUCUCUUCUGG 1603 AAGAGAUACAGAGGN′ 103N F11- 1354 NGCACAGGAUUUCAGUGAA 1604 CUGAAAUCCUGUGCN′ 104N F11- 1355 NGUAAAAUGAAGAAUGGCA 1605 AUUCUUCAUUUUACN′ 105N F11- 1356 NGUCGUUGAGAAUCUGUGU 1606 AGAUUCUCAACGACN′ 106N F11- 1357 NGCAACAAUAUCCAGUUCU 1607 CUGGAUAUUGUUGCN′ 107N F11- 1358 NCAGCGGACGGCAUUGGUG 1608 AAUGCCGUCCGCUGN′ 108N F11- 1359 NGAAAGCUUUAAGUAACAC 1609 UACUUAAAGCUUUCN′ 109N F11- 1360 NGCAGUGUUUCUGUAACAC 1610 UACAGAAACACUGCN′ 110N F11- 1361 NGAGAAUCUGUGUAAUUCA 1611 UUACACAGAUUCUCN′ 111N F11- 1362 NUCCAGUCCACGUACUCGA 1612 GUACGUGGACUGGAN′ 112N F11- 1363 NUGUGAGCAUUGCUUGAAA 1613 AAGCAAUGCUCACAN′ 113N F11- 1364 NCCGGGAUGAUGAGUGCAG 1614 ACUCAUCAUCCCGGN′ 114N F11- 1365 NCCACUUUAUCGAGCUUCG 1615 GCUCGAUAAAGUGGN′ 115N F11- 1366 NCAUUAUCCAUUUUACACA 1616 UAAAAUGGAUAAUGN′ 116N F11- 1367 NAACCGGGAUGAUGAGUGC 1617 UCAUCAUCCCGGUUN′ 117N F11- 1368 NUUCUUUGGGCCAUUCCUG 1618 AAUGGCCCAAAGAAN′ 118N F11- 1369 NCUAAGGGUAUCUUGGCUU 1619 CAAGAUACCCUUAGN′ 119N F11- 1370 NUUGGUGUGAGCAUUGCUU 1620 AAUGCUCACACCAAN′ 120N F11- 1371 NCAUAUGGGUCGUUGAGAA 1621 CAACGACCCAUAUGN′ 121N F11- 1372 NUUAAUGUGUAUCCAGAGA 1622 UGGAUACACAUUAAN′ 122N F11- 1373 NUCAGAUGUUUUAAGGAGA 1623 CUUAAAACAUCUGAN′ 123N F11- 1374 NUUCCAAUGAUGGAGCCUC 1624 CUCCAUCAUUGGAAN′ 124N F11- 1375 NAGAAUCCAGUCCACGUAC 1625 GUGGACUGGAUUCUN′ 125N F11- 1376 NUUUGAGAUUCUUUGGGCC 1626 CAAAGAAUCUCAAAN′ 126N F11- 1377 NAAUCAUCCUGAAAAGACC 1627 UUUUCAGGAUGAUUN′ 127N F11- 1378 NAGACACGCAAAAUCUUAG 1628 GAUUUUGCGUGUCUN′ 128N F11- 1379 NCGUACUCGACCACGUUGG 1629 CGUGGUCGAGUACGN′ 129N F11- 1380 NCAUCCAGUCACCCAGCAA 1630 UGGGUGACUGGAUGN′ 130N F11- 1381 NAACACUGGGAUGCUGUGC 1631 AGCAUCCCAGUGUUN′ 131N F11- 1382 NCAGAAAGAGCUUUGCUCU 1632 CAAAGCUCUUUCUGN′ 132N F11- 1383 NUUCUUUGAGAUUCUUUGG 1633 AGAAUCUCAAAGAAN′ 133N F11- 1384 NAGCAACAAUAUCCAGUUC 1634 UGGAUAUUGUUGCUN′ 134N F11- 1385 NACCACUUUAUCGAGCUUC 1635 CUCGAUAAAGUGGUN′ 135N F11- 1386 NCCCUUCCCUUCGUUGCAG 1636 AACGAAGGGAAGGGN′ 136N F11- 1387 NCGCAAAAUCUUAGGUGAC 1637 CCUAAGAUUUUGCGN′ 137N F11- 1388 NAGCGUGUUACUGUGGAGG 1638 CACAGUAACACGCUN′ 138N F11- 1389 NCUCCUUCCCUGUAGCCGG 1639 CUACAGGGAAGGAGN′ 139N F11- 1390 NGUCCUCUGUAUCUCUUCU 1640 GAGAUACAGAGGACN′ 140N F11- 1391 NGUAUCUUGGCUUUCUGGA 1641 GAAAGCCAAGAUACN′ 141N F11- 1392 NCUCUUGGCAGUGUUUCUG 1642 AACACUGCCAAGAGN′ 142N F11- 1393 NGAAAUCAGUGUCAUGGUA 1643 AUGACACUGAUUUCN′ 143N F11- 1394 NCUUCCCUGUAGCCGGCAC 1644 CGGCUACAGGGAAGN′ 144N F11- 1395 NCUGGCCGCUCCCUUUGAG 1645 AAGGGAGCGGCCAGN′ 145N F11- 1396 NCACGCAAAAUCUUAGGUG 1646 UAAGAUUUUGCGUGN′ 146N F11- 1397 NGAAACCAGAAAGAGCUUU 1647 CUCUUUCUGGUUUCN′ 147N F11- 1398 NAAAGCUUUAAGUAACACU 1648 UUACUUAAAGCUUUN′ 148N F11- 1399 NACAAGCCAGAUUAGAAAG 1649 CUAAUCUGGCUUGUN′ 149N F11- 1400 NACUCAUUAUCCAUUUUAC 1650 AAUGGAUAAUGAGUN′ 150N F11- 1401 NCCUGAAAAGACCUUGUUG 1651 AAGGUCUUUUCAGGN′ 151N F11- 1402 NGGUUUCCAAUGAUGGAGC 1652 CAUCAUUGGAAACCN′ 152N F11- 1403 NCAGUUUCUGGCAGGCCUC 1653 CCUGCCAGAAACUGN′ 153N F11- 1404 NAUGGCAGAACACUGGGAU 1654 CAGUGUUCUGCCAUN′ 154N F11- 1405 NAGAUUUCUUUGAGAUUCU 1655 UCUCAAAGAAAUCUN′ 155N F11- 1406 NGUUUCCAGUUUCAACAAG 1656 UUGAAACUGGAAACN′ 156N F11- 1407 NUCCUCUGUAUCUCUUCUG 1657 AGAGAUACAGAGGAN′ 157N F11- 1408 NCAUCCUGAAAAGACCUUG 1658 GUCUUUUCAGGAUGN′ 158N F11- 1409 NUUGAGUUUUCUCCAGAAU 1659 UGGAGAAAACUCAAN′ 159N F11- 1410 NAAUUCACUGUGGUUUCCA 1660 AACCACAGUGAAUUN′ 160N F11- 1411 NAAGAUUUCUUUGAGAUUC 1661 CUCAAAGAAAUCUUN′ 161N F11- 1412 NGGAGACAAAGAUUUCUUU 1662 AAAUCUUUGUCUCCN′ 162N F11- 1413 NGAAAAUCAUCCUGAAAAG 1663 UCAGGAUGAUUUUCN′ 163N F11- 1414 NCUUUCUGCCAUUUUAUAC 1664 AAAAUGGCAGAAAGN′ 164N F11- 1415 NAGUCCACGUACUCGACCA 1665 CGAGUACGUGGACUN′ 165N F11- 1416 NUUAAUGCGUGUACUGGGC 1666 AGUACACGCAUUAAN′ 166N F11- 1417 NUAAUGUGUAUCCAGAGAU 1667 CUGGAUACACAUUAN′ 167N F11- 1418 NGAUUCUUUGGGCCAUUCC 1668 UGGCCCAAAGAAUCN′ 168N F11- 1419 NUGAAACCAGAAAGAGCUU 1669 UCUUUCUGGUUUCAN′ 169N F11- 1420 NCACACAUUCACCAGAAAC 1670 CUGGUGAAUGUGUGN′ 170N F11- 1421 NACAAAGAUUUCUUUGAGA 1671 AAAGAAAUCUUUGUN′ 171N F11- 1422 NCAUUUCUAUCUCCUUUGG 1672 AGGAGAUAGAAAUGN′ 172N F11- 1423 NUUUCUGUAACACUGUCUU 1673 CAGUGUUACAGAAAN′ 173N F11- 1424 NGGAUUUCAGUGAAAAUCC 1674 UUUCACUGAAAUCCN′ 174N F11- 1425 NCGCUCCCUUUGAGCACAG 1675 GCUCAAAGGGAGCGN′ 175N F11- 1426 NCAGUCCACGUACUCGACC 1676 GAGUACGUGGACUGN′ 176N F11- 1427 NAGGCAUAUGGGUCGUUGA 1677 CGACCCAUAUGCCUN′ 177N F11- 1428 NAUGUCCUCUGUAUCUCUU 1678 GAUACAGAGGACAU N′ 178N F11- 1429 NGCUUGAUUUUGGUGGUAC 1679 CACCAAAAUCAAGCN′ 179N F11- 1430 NAUGAUGGAGCCUCCACAC 1680 GGAGGCUCCAUCAUN′ 180N F11- 1431 NUCGUUGAGAAUCUGUGUA 1681 CAGAUUCUCAACGAN′ 181N F11- 1432 NUUAUCCAUUUUACACAAC 1682 UGUAAAAUGGAUAAN′ 182N F11- 1433 NUGUCCUAUUCACUCUUGG 1683 GAGUGAAUAGGACAN′ 183N F11- 1434 NCAAUAUCCAGUUCUUCUC 1684 AGAACUGGAUAUUGN′ 184N F11- 1435 NCUUUGAGAUUCUUUGGGC 1685 AAAGAAUCUCAAAGN′ 185N F11- 1436 NCACUCUUGGCAGUGUUUC 1686 CACUGCCAAGAGUGN′ 186N F11- 1437 NCUUGAAAGAAUACCCAGA 1687 GGUAUUCUUUCAAGN′ 187N F11- 1438 NAGGCAAUAUCAUACCCGC 1688 GUAUGAUAUUGCCUN′ 188N F11- 1439 NCUGUGUAAUUCACUGUGG 1689 AGUGAAUUACACAGN′ 189N F11- 1440 NAAUAUCCACUGGUUUCCA 1690 AACCAGUGGAUAUUN′ 190N F11- 1441 NUGAAAGAAUACCCAGAAA 1691 UGGGUAUUCUUUCAN′ 191N F11- 1442 NGUUAAUAUCCACUGGUUU 1692 CAGUGGAUAUUAACN′ 192N F11- 1443 NUGUCAUGGUAAAAUGAAG 1693 AUUUUACCAUGACAN′ 193N F11- 1444 NAUUCUUUGGGCCAUUCCU 1694 AUGGCCCAAAGAAUN′ 194N F11- 1445 NCAGUUCCUCCAACGAUCC 1695 CGUUGGAGGAACUGN′ 195N F11- 1446 NGGGUGUGCUUCAGUAGAC 1696 ACUGAAGCACACCCN′ 196N F11- 1447 NGAAGAAAGCUUUAAGUAA 1697 UUAAAGCUUUCUUCN′ 197N F11- 1448 NAUCCUGAAAAGACCUUGU 1698 GGUCUUUUCAGGAUN′ 198N F11- 1449 NAGAAAGCUUUAAGUAACA 1699 ACUUAAAGCUUUCUN′ 199N F11- 1450 NCAGUGUUUCUGUAACACU 1700 UUACAGAAACACUGN′ 200N F11- 1451 NGACACGCAAAAUCUUAGG 1701 AGAUUUUGCGUGUCN′ 201N F11- 1452 NGUGUGAGCAUUGCUUGAA 1702 AGCAAUGCUCACACN′ 202N F11- 1453 NACCAGAAAGAGCUUUGCU 1703 AAGCUCUUUCUGGUN′ 203N F11- 1454 NAGAAAGUGCACAGGAUUU 1704 CCUGUGCACUUUCUN′ 204N F11- 1455 NUUUAUUUCAGAUUGAUUU 1705 CAAUCUGAAAUAAAN′ 205N F11- 1456 NUAUCCAGUUCUUCUCCCA 1706 AGAAGAACUGGAUAN′ 206N F11- 1457 NCCGUGAAAGUGAAGAGUA 1707 CUUCACUUUCACGGN′ 207N F11- 1458 NGGUGUGCUUCAGUAGACA 1708 UACUGAAGCACACCN′ 208N F11- 1459 NGGACAGAGGGCCUCCCGA 1709 GAGGCCCUCUGUCCN′ 209N F11- 1460 NAAGAAAAUCAUCCUGAAA 1710 AGGAUGAUUUUCUUN′ 210N F11- 1461 NUGAGAUUCUUUGGGCCAU 1711 CCCAAAGAAUCUCAN′ 211N F11- 1462 NAUGUUUUAAGGAGACAAA 1712 UCUCCUUAAAACAUN′ 212N F11- 1463 NCACAGUUUCUGGCAGGCC 1713 UGCCAGAAACUGUGN′ 213N F11- 1464 NACAAUAUCCAGUUCUUCU 1714 GAACUGGAUAUUGUN′ 214N F11- 1465 NACAUUCACCAGAAACUGA 1715 UUUCUGGUGAAUGUN′ 215N F11- 1466 NCAAGGCAAUAUCAUACCC 1716 AUGAUAUUGCCUUGN′ 216N F11- 1467 NCUCCAACGAUCCUGGGCU 1717 CAGGAUCGUUGGAGN′ 217N F11- 1468 NCUGAAACCAGAAAGAGCU 1718 CUUUCUGGUUUCAGN′ 218N F11- 1469 NAAUCUCCCUUGCAAGCGU 1719 UUGCAAGGGAGAUUN′ 219N F11- 1470 NUGUGUAAUUCACUGUGGU 1720 CAGUGAAUUACACAN′ 220N F11- 1471 NUUUCAGUGAAAAUCCAGA 1721 GAUUUUCACUGAAAN′ 221N F11- 1472 NAAAUCAUCCUGAAAAGAC 1722 UUUCAGGAUGAUUUN′ 222N F11- 1473 NUACACUCAUUAUCCAUUU 1723 GGAUAAUGAGUGUAN′ 223N F11- 1474 NUUGGCAGUGUUUCUGUAA 1724 AGAAACACUGCCAAN′ 224N F11- 1475 NGGUACACUCAUUAUCCAU 1725 AUAAUGAGUGUACCN′ 225N F11- 1476 NAGGCAGGCAUAUGGGUCG 1726 CCAUAUGCCUGCCUN′ 226N F11- 1477 NCCAGUUUCAACAAGGCAA 1727 CUUGUUGAAACUGGN′ 227N F11- 1478 NUGGCCGCUCCCUUUGAGC 1728 AAAGGGAGCGGCCAN′ 228N F11- 1479 NACUGUGGUUUCCAGUUUC 1729 CUGGAAACCACAGUN′ 229N F11- 1480 NCUUUGGGCCAUUCCUGGG 1730 GGAAUGGCCCAAAGN′ 230N F11- 1481 NUAAGAAAAUCAUCCUGAA 1731 GGAUGAUUUUCUUAN′ 231N F11- 1482 NCUCUUUUAUUUCAGAUUG 1732 CUGAAAUAAAAGAGN′ 232N F11- 1483 NUCUUUGAGAUUCUUUGGG 1733 AAGAAUCUCAAAGAN′ 233N F11- 1484 NAAUGAUGGAGCCUCCACA 1734 GAGGCUCCAUCAUUN′ 234N F11- 1485 NGAAGAAUGGCAGAACACU 1735 UUCUGCCAUUCUUCN′ 235N F11- 1486 NCAAUGAUGGAGCCUCCAC 1736 AGGCUCCAUCAUUGN′ 236N F11- 1487 NAUGGAGCCUCCACACAGG 1737 UGUGGAGGCUCCAUN′ 237N F11- 1488 NCCCAAGAAAUCAGUGUCA 1738 ACUGAUUUCUUGGGN′ 238N F11- 1489 NGAGCCUCCACACAGGUGU 1739 CUGUGUGGAGGCUCN′ 239N F11- 1490 NCUCCCAAGAAAUCAGUGU 1740 UGAUUUCUUGGGAGN′ 240N F11- 1491 NCCUCCACACAGGUGUCUC 1741 CACCUGUGUGGAGGN′ 241N F11- 1492 NCCAAUGAUGGAGCCUCCA 1742 GGCUCCAUCAUUGGN′ 242N F11- 1493 NUUUCCAAUGAUGGAGCCU 1743 UCCAUCAUUGGAAAN′ 243N F11- 1494 NUCCCAAGAAAUCAGUGUC 1744 CUGAUUUCUUGGGAN′ 244N F11- 1495 NAGCCUCCACACAGGUGUC 1745 CCUGUGUGGAGGCUN′ 245N F11- 1496 NUCUUCUCCCAAGAAAUCA 1746 UUCUUGGGAGAAGAN′ 246N F11- 1497 NGUUUCCAAUGAUGGAGCC 1747 CCAUCAUUGGAAACN′ 247N F11- 1498 NUCCAAUGAUGGAGCCUCC 1748 GCUCCAUCAUUGGAN′ 248N F11- 1499 NUGGAGCCUCCACACAGGU 1749 GUGUGGAGGCUCCAN′ 249N F11- 1500 NGCCUCCACACAGGUGUCU 1750 ACCUGUGUGGAGGCN′ 250N

In above Table 1d:

A represents adenine;

U represents uracil;

C represents cytosine;

G represents guanine;

N represents any RNA nucleobase;

N′ represents any RNA nucleobase and is preferably complementary to N.

TABLE 1e Summary sequence table for active nucleobase sequences with chemical modifications: Oligo construct Antisense (Guide) Strand construct Sense (Passenger) Strand Name No Sequence (5′ to 3′) No Sequence (5′ to 3′) F11- 1751 PmN.fC.mA.fA.mA.fA.mU.fC.mU.fU. 2001 fC.mA.fC.mC.fU.mA.fA.mG.fA.mU. 01NM mA.fG.mG.fU.mG.fA.mC.fU.mC fU.mU.fU.mG.fN′ F11- 1752 PmN.fA.mU.fU.mG.fA.mU.fU.mU.fA. 2002 fC.mA.fU.mU.fU.mU.fA.mA.fA.mU. 02NM mA.fA.mA.fU.mG.fC.mC.fA.mC fC.mA.fA.mU.fN′ F11- 1753 PmN.fA.mG.fA.mA.fA.mU.fC.mG.fC. 2003 fC.mA.fG.mC.fA.mG.fC.mG.fA.mU. 03NM mU.fG.mC.fU.mG.fU.mC.fC.mU fU.mU.fC.mU.fN′ F11- 1754 PmN.fA.mU.fA.mA.fG.mA.fA.mA.fA. 2004 fG.mA.fU.mG.fA.mU.fU.mU.fU.mC. 04NM mU.fC.mA.fU.mC.fC.mU.fG.mA fU.mU.fA.mU.fN′ F11- 1755 PmN.fA.mA.fA.mC.fA.mC.fC.mG.fU. 2005 fC.mU.fA.mA.fU.mA.fC.mG.fG.mU. 05NM mA.fU.mU.fA.mG.fG.mG.fA.mA fG.mU.fU.mU.fN′ F11- 1756 PmN.fA.mA.fA.mU.fC.mA.fG.mU.fG. 2006 fC.mA.fU.mG.fA.mC.fA.mC.fU.mG. 06NM mU.fC.mA.fU.mG.fG.mU.fA.mA fA.mU.fU.mU.fN′ F11- 1757 PmN.fA.mU.fA.mC.fC.mC.fG.mC.fU. 2007 fC.mA.fG.mA.fA.mA.fG.mC.fG.mG. 07NM mU.fU.mC.fU.mG.fC.mC.fA.mU fG.mU.fA.mU.fN′ F11- 1758 PmN.fA.mG.fA.mU.fG.mU.fU.mU.fU. 2008 fU.mC.fC.mU.fU.mA.fA.mA.fA.mC. 08NM mA.fA.mG.fG.mA.fG.mA.fC.mA fA.mU.fC.mU.fN′ F11- 1759 PmN.fG.mG.fU.mA.fU.mC.fU.mU. 2009 fA.mA.fA.mG.fC.mC.fA.mA.fG.mA. 09NM fG.mG.fC.mU.fU.mU.fC.mU.fG.mG fU.mA.fC.mC.fN′ F11- 1760 PmN.fC.mU.fC.mU.fG.mU.fA.mU.fC. 2010 fG.mA.fA.mG.fA.mG.fA.mU.fA.mC. 10NM mU.fC.mU.fU.mC.fU.mG.fG.mC fA.mG.fA.mG.fN′ F11- 1761 PmN.fA.mU.fG.mG.fA.mU.fU.mA.fU. 2011 fA.mA.fA.mU.fA.mA.fU.mA.fA.mU. 11NM mU.fA.mU.fU.mU.fC.mU.fU.mG fC.mC.fA.mU.fN′ F11- 1762 PmN.fA.mG.fC.mC.fA.mG.fA.mU.fU. 2012 fU.mU.fU.mC.fU.mA.fA.mU.fC.mU. 12NM mA.fG.mA.fA.mA.fG.mU.fG.mC fG.mG.fC.mU.fN′ F11- 1763 PmN.fA.mG.fC.mG.fG.mA.fC.mG.fG. 2013 fC.mA.fA.mU.fG.mC.fC.mG.fU.mC. 13NM mC.fA.mU.fU.mG.fG.mU.fG.mC fG.mG.fC.mU.fN′ F11- 1764 PmN.fA.mU.fU.mU.fC.mA.fG.mA.fU. 2014 fA.mA.fU.mC.fA.mA.fU.mC.fU.mG. 14NM mU.fG.mA.fU.mU.fU.mA.fA.mA fA.mA.fA.mU.fA F11- 1765 PmN.fU.mU.fG.mU.fC.mU.fC.mU.fU. 2015 fA.mA.fA.mC.fU.mA.fA.mG.fA.mG. 15NM mA.fG.mU.fU.mUc.fU.mC.fU.mG fA.mC.fA.mA.fN′ F11- 1766 PmN.fA.mG.fA.mA.fC.mA.fC.mU.fG. 2016 fC.mA.fU.mC.fC.mC.fA.mG.fU.mG. 16NM mG.fG.mA.fU.mG.fC.mU.fG.mU fU.mU.fC.mU.fN′ F11- 1767 PmN.fC.mC.fA.mC.fU.mU.fG.mA.fU. 2017 fC.mU.fU.mA.fU.mA.fU.mC.fA.mA. 17NM mA.fU.mA.fA.mG.fA.mA.fA.mA fG.mU.fG.mG.fN′ F11- 1768 PmN.fC.mA.fU.mU.fU.mU.fC.mU.fU. 2018 fU.mU.fU.mG.fU.mA.fA.mG.fA.mA. 18NM mA.fC.mA.fA.mA.fC.mA.fC.mC fA.mA.fU.mG.fN′ F11- 1769 PmN.fU.mA.fA.mU.fG.mC.fG.mU.fG. 2019 fC.mA.fG.mU.fA.mC.fA.mC.fG.mC. 19NM mU.fA.mC.fU.mG.fG.mG.fC.mA fA.mU.fU.mA.fN′ F11- 1770 PmN.fA.mG.fG.mA.fC.mA.fG.mA.fG. 2020 fA.mG.fG.mC.fC.mC.fU.mC.fU.mG. 20NM mG.fG.mC.fC.mU.fC.mC.fC.mG fU.mC.fC.mU.fN′ F11- 1771 PmN.fC.mA.fA.mC.fC.mG.fG.mG.fA. 2021 fC.mA.fU.mC.fA.mU.fC.mC.fC.mG. 21NM mU.fG.mA.fU.mG.fA.mG.fU.mG fG.mU.fU.mG.fN′ F11- 1772 PmN.fG.mA.fC.mA.fA.mA.fG.mA.fU. 2022 fA.mA.fG.mA.fA.mA.fU.mC.fU.mU. 22NM mU.fU.mC.fU.mU.fU.mG.fA.mG fU.mG.fU.mC.fN′ F11- 1773 PmN.fG.mA.fG.mG.fA.mA.fG.mC.fA. 2023 fC.mA.fG.mC.fA.mU.fG.mC.fU.mU. 23NM mU.fG.mC.fU.mG.fG.mC.fA.mC fC.mC.fU.mC.fN′ F11- 1774 PmN.fG.mG.fA.mA.fA.mA.fU.mG.fU. 2024 fU.mA.fG.mG.fG.mA.fC.mA.fU.mU. 24NM mC.fC.mC.fU.mA.fA.mU.fA.mC fU.mU.fC.mC.fN′ F11- 1775 PmN.fU.mU.fA.mA.fG.mU.fA.mA.fC. 2025 fC.mA.fA.mG.fU.mG.fU.mU.fA.mC. 25NM mA.fC.mU.fU.mG.fC.mC.fC.mU fU.mU.fA.mA.fN′ F11- 1776 PmN.fC.mA.fA.mU.fA.mU.fC.mA.fU. 2026 fC.mG.fG.mG.fU.mA.fU.mG.fA.mU. 26NM mA.fC.mC.fC.mG.fC.mU.fU.mU fA.mU.fU.mG.fN′ F11- 1777 PmN.fA.mA.fA.mU.fG.mU.fA.mC.fC. 2027 fC.mA.fA.mG.fU.mG.fG.mU.fA.mC. 27NM mA.fC.mU.fU.mG.fA.mU.fA.mU fA.mU.fU.mU.fN′ F11- 1778 PmN.fA.mG.fA.mA.fA.mA.fU.mC.fA. 2028 fC.mA.fG.mG.fA.mU.fG.mA.fU.mU. 28NM mU.fC.mC.fU.mG.fA.mA.fA.mA fU.mU.fC.mU.fN′ F11- 1779 PmN.fU.mA.fA.mC.fA.mC.fU.mU.fG. 2029 fA.mA.fG.mG.fG.mC.fA.mA.fG.mU. 29NM mC.fC.mC.fU.mU.fC.mC.fC.mU fG.mU.fU.mA.fN′ F11- 1780 PmN.fA.mG.fC.mA.fU.mU.fU.mU.fC. 2030 fU.mG.fU.mA.fA.mG.fA.mA.fA.mA. 30NM mU.fU.mA.fC.mA.fA.mA.fC.mA fU.mG.fC.mU.fN′ F11- 1781 PmN.fC.mA.fA.mA.fC.mA.fC.mC.fG. 2031 fU.mA.fA.mU.fA.mC.fG.mG.fU.mG. 31NM mU.fA.mU.fU.mA.fG.mG.fG.mA fU.mU.fU.mG.fN′ F11- 1782 PmN.fA.mG.fC.mG.fG.mC.fU.mG.fU. 2032 fU.mA.fU.mU.fA.mA.fC.mA.fG.mC. 32NM mU.fA.mA.fU.mA.fU.mC.fC.mA fC.mG.fC.mU.fN′ F11- 1783 PmN.fG.mA.fG.mC.fG.mG.fC.mU.fG. 2033 fA.mU.fU.mA.fA.mC.fA.mG.fC.mC. 33NM mU.fU.mA.fA.mU.fA.mU.fC.mC fG.mC.fU.mC.fN′ F11- 1784 PmN.fG.mA.fG.mA.fC.mA.fA.mA.fG. 2034 fG.mA.fA.mA.fU.mC.fU.mU.fU.mG. 34NM mA.fU.mU.fU.mC.fU.mU.fU.mG fU.mC.fU.mC.fN′ F11- 1785 PmN.fU.mG.fG.mG.fU.mU.fA.mU.fU. 2035 fC.mA.fU.mA.fA.mA.fA.mU.fA.mA. 35NM mU.fU.mA.fU.mG.fU.mC.fC.mU fC.mC.fC.mA.fN′ F11- 1786 PmN.fG.mA.fG.mC.fC.mA.fU.mG.fA. 2036 fC.mA.fG.mU.fG.mU.fC.mA.fU.mG. 36NM mC.fA.mC.fU.mG.fU.mC.fG.mA fG.mC.fU.mC.fN′ F11- 1787 PmN.fC.mA.fG.mA.fU.mU.fA.mG.fA. 2037 fC.mA.fC.mU.fU.mU.fC.mU.fA.mA. 37NM mA.fA.mG.fU.mG.fC.mA.fC.mA fU.mC.fU.mG.fN′ F11- 1788 PmN.fA.mG.fA.mA.fU.mA.fC.mC.fC. 2038 fU.mU.fU.mC.fU.mG.fG.mG.fU.mA. 38NM mA.fG.mA.fA.mA.fU.mC.fG.mC fU.mU.fC.mU.fN′ F11- 1789 PmN.fC.mA.fG.mA.fU.mG.fU.mU.fU. 2039 fC.mC.fU.mU.fA.mA.fA.mA.fC.mA. 39NM mU.fA.mA.fG.mG.fA.mG.fA.mC fU.mC.fU.mG.fN′ F11- 1790 PmN.fU.mG.fU.mA.fU.mC.fC.mA.fG. 2040 fC.mA.fU.mC.fU.mC.fU.mG.fG.mA. 40NM mA.fG.mA.fU.mG.fC.mC.fU.mC fU.mA.fC.mA.fN′ F11- 1791 PmN.fG.mA.fG.mU.fC.mA.fC.mA.fC. 2041 fU.mG.fA.mA.fU.mG.fU.mG.fU.mG. 41NM mA.fU.mU.fC.mA.fC.mC.fA.mG fA.mC.fU.mC.fN′ F11- 1792 PmN.fC.mA.fA.mA.fG.mA.fA.mA.fG. 2042 fC.mA.fC.mA.fU.mC.fU.mU.fU.mC. 42NM mA.fU.mG.fU.mG.fU.mC.fC.mU fU.mU.fU.mG.fN′ F11- 1793 PmN.fA.mC.fC.mA.fC.mU.fU.mG.fA. 2043 fU.mU.fA.mU.fA.mU.fC.mA.fA.mG. 43NM mU.fA.mU.fA.mA.fG.mA.fA.mA fU.mG.fG.mU.fN′ F11- 1794 PmN.fA.mA.fG.mA.fA.mA.fG.mC.fU. 2044 fC.mU.fU.mA.fA.mA.fG.mC.fU.mU. 44NM mU.fU.mA.fA.mG.fU.mA.fA.mC fU.mC.fU.mU.fN′ F11- 1795 PmN.fU.mU.fA.mU.fU.mU.fC.mA.fG. 2045 fU.mC.fA.mA.fU.mC.fU.mG.fA.mA. 45NM mA.fU.mU.fG.mA.fU.mU.fU.mA fA.mU.fA.mA.fN′ F11- 1796 PmN.fU.mG.fG.mU.fG.mU.fG.mA.fG. 2046 fC.mA.fA.mU.fG.mC.fU.mC.fA.mC. 46NM mC.fA.mU.fU.mG.fC.mU.fU.mG fA.mC.fC.mA.fN′ F11- 1797 PmN.fA.mU.fC.mA.fU.mC.fC.mU.fG. 2047 fC.mU.fU.mU.fU.mC.fA.mG.fG.mA. 47NM mA.fA.mA.fA.mG.fA.mC.fC.mU fU.mG.fA.mU.fN′ F11- 1798 PmN.fG.mU.fG.mA.fG.mC.fA.mU.fU. 2048 fC.mA.fA.mG.fC.mA.fA.mU.fG.mC. 48NM mG.fC.mU.fU.mG.fA.mA.fA.mG fU.mC.fA.mC.fN′ F11- 1799 PmN.fC.mU.fG.mU.fA.mU.fC.mU.fC. 2049 TC.mA.fG.mA.fA.mG.fA.mG.fA.mU. 49NM mU.fU.mC.fU.mG.fG.mC.fA.mC fA.mC.fA.mG.fN′ F11- 1800 PmN.fA.mC.fC.mU.fU.mA.fA.mU.fG. 2050 fA.mU.fA.mC.fA.mC.fA.mU.fU.mA. 50NM mU.fG.mU.fA.mU.fC.mC.fA.mG fA.mG.fG.mU.fN′ F11- 1801 PmN.fA.mU.fC.mA.fU.mG.fG.mA.fU. 2051 fU.mA.fA.mU.fA.mA.fU.mC.fC.mA. 51NM mU.fA.mU.fU.mA.fU.mU.fU.mC fU.mG.fA.mU.fN′ F11- 1802 PmN.fC.mA.fA.mA.fG.mA.fU.mU.fU. 2052 fC.mA.fA.mA.fG.mA.fA.mA.fU.mC. 52NM mC.fU.mU.fU.mG.fA.mG.fA.mU fU.mU.fU.mG.fN′ F11- 1803 PmN.fG.mA.fA.mG.fU.mA.fU.mU.fU. 2053 fA.mA.fC.mU.fA.mA.fA.mA.fU.mA. 53NM mU.fA.mG.fU.mU.fG.mG.fA.mG fC.mU.fU.mC.fN′ F11- 1804 PmN.fA.mG.fA.mU.fU.mG.fA.mU.fU. 2054 fU.mU.fU.mU.fA.mA.fA.mU.fC.mA. 54NM mU.fA.mA.fA.mA.fU.mG.fC.mC fA.mU.fC.mU.fN′ F11- 1805 PmN.fG.mG.fG.mU.fA.mU.fC.mU.fU. 2055 fA.mA.fG.mC.fC.mA.fA.mG.fA.mU. 55NM mG.fG.mC.fU.mU.fU.mC.fU.mG fA.mC.fC.mC.fN′ F11- 1806 PmN.fA.mG.fG.mA.fG.mA.fC.mA.fA. 2056 fA.mA.fU.mC.fU.mU.fU.mG.fU.mC. 56NM mA.fG.mA.fU.mU.fU.mC.fU.mU fU.mC.fC.mU.fN′ F11- 1807 PmN.fG.mU.fC.mA.fU.mG.fG.mU.fA. 2057 fC.mA.fU.mU.fU.mU.fA.mC.fC.mA. 57NM mA.fA.mA.fU.mG.fA.mA.fG.mA fU.mG.fA.mC.fN′ F11- 1808 PmN.fA.mU.fA.mU.fC.mC.fA.mG.fU. 2058 fG.mA.fA.mG.fA.mA.fC.mU.fG.mG. 58NM mU.fC.mU.fU.mC.fU.mC.fC.mC fA.mU.fA.mU.fN′ F11- 1809 PmN.fA.mA.fU.mA.fU.mC.fC.mA.fG. 2059 fA.mA.fG.mA.fA.mC.fU.mG.fG.mA. 59NM mU.fU.mC.fU.mU.fC.mU.fC.mC fU.mA.fU.mU.fN′ F11- 1810 PmN.fC.mU.fG.mU.fG.mG.fU.mU.fU. 2060 fA.mC.fU.mG.fG.mA.fA.mA.fC.mC. 60NM mC.fC.mA.fG.mU.fU.mU.fC.mA fA.mC.fA.mG.fN′ F11- 1811 PmN.fA.mG.fA.mU.fU.mA.fG.mA.fA. 2061 fG.mC.fA.mC.fU.mU.fU.mC.fU.mA. 61NM mA.fG.mU.fG.mC.fA.mC.fA.mG fA.mU.fC.mU.fN′ F11- 1812 PmN.fA.mG.fA.mA.fA.mU.fC.mA.fG. 2062 fU.mG.fA.mC.fA.mC.fU.mG.fA.mU. 62NM mU.fG.mU.fC.mA.fU.mG.fG.mU fU.mU.fC.mU.fN′ F11- 1813 PmN.fU.mG.fG.mA.fU.mU.fA.mU.fU. 2063 fG.mA.fA.mA.fU.mA.fA.mU.fA.mA. 63NM mA.fU.mU.fU.mC.fU.mU.fG.mA fU.mC.fC.mA.fN′ F11- 1814 PmN.fC.mC.fA.mG.fA.mU.fU.mA.fG. 2064 fA.mC.fU.mU.fU.mC.fU.mA.fA.mU. 64NM mA.fA.mA.fG.mU.fG.mC.fA.mC fC.mU.fG.mG.fN′ F11- 1815 PmN.fC.mU.fC.mA.fU.mU.fA.mU.fC. 2065 fA.mA.fA.mU.fG.mG.fA.mU.fA.mA. 65NM mC.fA.mU.fU.mU.fU.mA.fC.mA fU.mG.fA.mG.fN′ F11- 1816 PmN.fU.mU.fG.mG.fG.mC.fC.mA.fU. 2066 fC.mA.fG.mG.fA.mA.fU.mG.fG.mC. 66NM mU.fC.mC.fU.mG.fG.mG.fA.mA fC.mC.fA.mA.fN′ F11- 1817 PmN.fU.mG.fG.mG.f.mU.fU.mG.fA. 2067 fC.mA.fA.mA.fA.mU.fC.mA.fA.mG. 67NM mU.fU.mU.fU.mG.fG.mU.fG.mG fC.mC.fC.mA.fN′ F11- 1818 PmN.fC.mA.fG.mA.fU.mU.fG.mA.fU. 2068 fU.mU.fU.mA.fA.mA.fU.mC.fA.mA. 68NM mU.fU.mA.fA.mA.fA.mU.fG.mC fU.mC.fU.mG.fN′ F11- 1819 PmN.fA.mA.fG.mC.fA.mA.fC.mC.fG. 2069 fC.mA.fU.mC.fC.mC.fG.mG.fU.mU. 69NM mG.fG.mA.fU.mG.fA.mU.fG.mA fG.mC.fU.mU.fN′ F11- 1820 PmN.fC.mU.fU.mA.fA.mU.fG.mU.fG. 2070 fG.mG.fA.mU.fA.mC.fA.mC.fA.mU. 70NM mU.fA.mU.fC.mC.fA.mG.fA.mG fU.mA.fA.mG.fN′ F11- 1821 PmN.fG.mU.fA.mA.fU.mU.fC.mA.fC. 2071 fC.mC.fA.mC.fA.mG.fU.mG.fA.mA. 71NM mU.fG.mU.fG.mG.fU.mU.fU.mC fU.mU.fA.mC.fN′ F11- 1822 PmN.fA.mC.fA.mU.fU.mU.fC.mU.fA. 2072 fG.mG.fA.mG.fA.mU.fA.mG.fA.mA. 72NM mU.fC.mU.fC.mC.fU.mU.fU.mG fA.mU.fG.mU.fN′ F11- 1823 PmN.fC.mA.fC.mU.fG.mG.fU.mU.fU. 2073 fA.mU.fU.mG.fG.mA.fA.mA.fC.mC. 73NM mC.fC.mA.fA.mU.fG.mA.fU.mG fA.mG.fU.mG.fN′ F11- 1824 PmN.fG.mA.fA.mU.fC.mU.fG.mU.fG. 2074 fA.mA.fU.mU.fA.mC.fA.mC.fA.mG. 74NM mU.fA.mA.fU.mU.fC.mA.fC.mU fA.mU.fU.mC.fN′ F11- 1825 PmN.fG.mU.fC.mC.fU.mA.fU.mU.fC. 2075 fA.mG.fA.mG.fU.mG.fA.mA.fU.mA. 75NM mA.fC.mU.fC.mU.fU.mG.fG.mC fG.mG.fA.mC.fN′ F11- 1826 PmN.fA.mG.fC.mA.fU.mU.fG.mC.fU. 2076 fU.mU.fU.mC.fA.mA.fG.mC.fA.mA. 76NM mU.fG.mA.fA.mA.fG.mA.fA.mU fU.mG.fC.mU.fN′ F11- 1827 PmN.fA.mA.fU.mA.fC.mC.fC.mA.fG. 2077 fG.mA.fU.mU.fU.mC.fU.mG.fG.mG. 77NM mA.fA.mA.fU.mC.fG.mC.fU.mG fU.mA.fU.mU.fN′ F11- 1828 PmN.fA.mU.fU.mA.fU.mU.fA.mU.fU. 2078 fC.mA.fA.mG.fA.mA.fA.mU.fA.mA. 78NM mU.fC.mU.fU.mG.fA.mA.fC.mC fU.mA.fA.mU.fN′ F11- 1829 PmN.fA.mA.fG.mU.fA.mU.fU.mU.fU. 2079 fC.mA.fA.mC.fU.mA.fA.mA.fA.mU. 79NM mA.fG.mU.fU.mG.fG.mA.fG.mA fA.mC.fU.mU.fN′ F11- 1830 PmN.fG.mA.fA.mU.fC.mC.fA.mG.fU. 2080 fC.mG.fU.mG.fG.mA.fC.mU.fG.mG. 80NM mC.fC.mA.fC.mG.fU.mA.fC.mU fA.mU.fU.mC.fN′ F11- 1831 PmN.fA.mG.fA.mC.fA.mA.fA.mG.fA. 2081 fA.mG.fA.mA.fA.mU.fC.mU.fU.mU. 81NM mU.fU.mU.fC.mU.fU.mU.fG.mA fG.mU.fC.mU.fN′ F11- 1832 PmN.fA.mC.fA.mG.fG.mA.fU.mU.fU. 2082 fC.mA.fC.mU.fG.mA.fA.mA.fU.mC. 82NM mC.fA.mG.fU.mG.fA.mA.fA.mA fC.mU.fG.mU.fN′ F11- 1833 PmN.fA.mA.fC.mA.fA.mG.fG.mC.fA. 2083 fG.mA.fU.mA.fU.mU.fG.mC.fC.mU. 83NM mA.fU.mA.fU.mC.fA.mU.fA.mC fU.mG.fU.mU.fN′ F11- 1834 PmN.fA.mA.fG.mG.fC.mA.fA.mU.fA. 2084 fU.mA.fU.mG.fA.mU.fA.mU.fU.mG. 84NM mU.fC.mA.fU.mA.fC.mC.fC.mG fC.mC.fU.mU.fN′ F11- 1835 PmN.fA.mU.fA.mC.fC.mC.fA.mG.fA. 2085 fC.mG.fA.mU.fU.mU.fC.mU.fG.mG. 85NM mA.fA.mU.fC.mG.fC.mU.fG.mC fG.mU.fA.mU.fN′ F11- 1836 PmN.fG.mA.fU.mU.fG.mA.fU.mU.fU. 2086 fA.mU.fU.mU.fU.mA.fA.mA.fU.mC. 86NM mA.fA.mA.fA.mU.fG.mC.fC.mA fA.mA.fU.mC.fN′ F11- 1837 PmN.fC.mC.fU.mA.fU.mU.fC.mA.fC. 2087 fC.mA.fA.mG.fA.mG.fU.mG.fA.mA. 87NM mU.fC.mU.fU.mG.fG.mC.fA.mG fU.mA.fG.mG.fN′ F11- 1838 PmN.fG.mU.fA.mG.fA.mC.fA.mC.fG. 2088 fU.mU.fU.mU.fG.mC.fG.mU.fG.mU. 88NM mC.fA.mA.fA.mA.fU.mC.fU.mU fC.mU.fA.mC.fN′ F11- 1839 PmN.fU.mG.fA.mG.fU.mU.fU.mU.fC. 2089 fC.mU.fG.mG.fA.mG.fA.mA.fA.mA. 89NM mU.fC.mC.fA.mG.fA.mA.fU.mC fC.mU.fC.mA.fN′ F11- 1840 PmN.fA.mU.fU.mU.fC.mU.fU.mU.fG. 2090 fA.mA.fU.mC.fU.mC.fA.mA.fA.mG. 90NM mA.fG.mA.fU.mU.fC.mU.fU.mU fA.mA.fA.mU.fN′ F11- 1841 PmN.fU.mA.fU.mA.fA.mG.fA.mA.fA. 2091 fA.mU.fG.mA.fU.mU.fU.mU.fC.mU. 91NM mA.fU.mC.fA.mU.fC.mC.fU.mG fU.mA.fU.mA.fN′ F11- 1842 PmN.fA.mA.fA.mA.fU.mC.fU.mU.fA. 2092 fU.mC.fA.mC.fC.mU.fA.mA.fG.mA. 92NM mG.fG.mU.fG.mA.fC.mU.fC.mU fU.mU.fU.mU.fN′ F11- 1843 PmN.fA.mC.fA.mC.fU.mG.fG.mG.fA. 2093 fC.mA.fG.mC.fA.mU.fC.mC.fC.mA. 93NM mU.fG.mC.fU.mG.fU.mG.fC.mC fG.mU.fG.mU.fN′ F11- 1844 PmN.fU.mG.fC.mA.fC.mA.fG.mG.fA. 2094 fU.mG.fA.mA.fA.mU.fC.mC.fU.mG. 94NM mUfU.mU.fC.mA.fG.mU.fG.mA fU.mG.fC.mA.fN′ F11- 1845 PmN.fA.mU.fA.mC.fA.mA.fG.mC.fC. 2095 fA.mA.fU.mC.fU.mG.fG.mC.fU.mU. 95NM mA.fG.mA.fU.mU.fA.mG.fA.mA fG.mU.fA.mU.fN′ F11- 1846 PmN.fU.mG.fU.mG.fG.mU.fU.mU.fC. 2096 fA.mA.fC.mU.fG.mG.fA.mA.fA.mC. 96NM mC.fA.mG.fU.mU.fU.mC.fA.mA fC.mA.fC.mA.fN′ F11- 1847 PmN.fU.mG.fC.mC.fC.mU.fU.mC.fC. 8207 fC.mG.fA.mA.fG.mG.fG.mA.fA.mG. 97NM mC.fU.mU.fC.mG.fU.mU.fG.mC fG.mG.fC.mA.fN′ F11- 1848 PmN.fA.mA.fA.mA.fU.mC.fA.mU.fC. 2098 fU.mU.fC.mA.fG.mG.fA.mU.fG.mA. 98NM mC.fU.mG.fA.mA.fA.mA.fG.mA fU.mU.fU.mU.fN′ F11- 1849 PmN.fC.mC.fA.mA.fG.mA.fA.mA.fU. 2099 fC.mA.fC.mU.fG.mA.fU.mU.fU.mC. 99NM mC.fA.mG.fU.mG.fU.mC.fA.mU fU.mU.fG.mG.fN′ F11- 1850 PmN.fG.mG.fC.mA.fU.mA.fU.mG.fG. 2100 fA.mC.fG.mA.fC.mC.fC.mA.fU.mA. 100NM mG.fU.mC.fG.mU.fU.mG.fA.mG fU.mG.fC.mC.fN′ F11- 1851 PmN.fA.mG.fA.mA.fU.mC.fU.mG.fU. 2101 fA.mU.fU.mA.fC.mA.fC.mA.fG.mA. 101NM mG.fU.mA.fA.mU.fU.mC.fA.mC fU.mU.fC.mU.fN′ F11- 1852 PmN.fA.mU.fC.mC.fA.mG.fU.mC.fC. 2102 fU.mA.fC.mG.fU.mG.fG.mA.fC.mU. 102NM mA.fC.mG.fU.mA.fC.mU.fC.mG fG.mG.fA.mU.fN′ F11- 1853 PmN.fC.mC.fU.mC.fU.mG.fU.mA.fU. 2103 fA.mA.fG.mA.fG.mA.fU.mA.fC.mA. 103NM mC.fU.mC.fU.mU.fC.mU.fG.mG fG.mA.fG.mG.fN′ F11- 1854 PmN.fG.mC.fA.mC.fA.mG.fG.mA.fU. 2104 fC.mU.fG.mA.fA.mA.fU.mC.fC.mU. 104NM mU.fU.mC.fA.mG.fU.mG.fA.mA fG.mU.fG.mC.fN′ F11- 1855 PmN.fG.mU.fA.mA.fA.mA.fU.mG.fA 2105 fA.mU.fU.mC.fU.mU.fC.mA.fU.mU. 105NM mA.fG.mA.fA.mU.fG.mG.fC.mA fU.mU.fA.mC.fN′ F11- 1856 PmN.fG.mU.fC.mG.fU.mU.fG.mA.fG. 2106 fA.mG.fA.mU.fU.mC.fU.mC.fA.mA. 106NM mA.fA.mU.fC.mU.fG.mU.fG.mU fC.mG.fA.mC.fN′ F11- 1857 PmN.fG.mC.fA.mA.fC.mA.fA.mU.fA. 2107 fC.mU.fG.mG.fA.mU.fA.mU.fU.mG. 107NM mU.fC.mC.fA.mG.fU.mU.fC.mU fU.mU.fG.mC.fN′ F11- 1858 PmN.fC.mA.fG.mC.fG.mG.fA.mC.fG. 2108 fA.mA.fU.mG.fC.mC.fG.mU.fC.mC. 108NM mG.fC.mA.fU.mU.fG.mG.fU.mG fG.mC.fU.mG.fN′ F11- 1859 PmN.fG.mA.fA.mA.fG.mC.fU.mU.fU. 2109 fU.mA.fC.mU.fU.mA.fA.mA.fG.mC. 109NM mA.fA.mG.fU.mA.fA.mC.fA.mC fU.mU.fU.mC.fN′ F11- 1860 PmN.fG.mC.fA.mG.fU.mG.fU.mU.fU. 2110 fU.mA.fC.mA.fG.mA.fA.mA.fC.mA. 110NM mC.fU.mG.fU.mA.fA.mC.fA.mC fC.mU.fG.mC.fN′ F11- 1861 PmN.fG.mA.fG.mA.fA.mU.fC.mU.fG. 2111 fU.mU.fA.mC.fA.mC.fA.mG.fA.mU. 111NM mU.fG.mU.fA.mA.fU.mU.fC.mA fU.mC.fU.mC.fN′ F11- 1862 PmN.fU.mC.fC.mA.fG.mU.fC.mC.fA. 2112 fG.mU.fA.mC.fG.mU.fG.mG.fA.mC. 112NM mC.fG.mU.fA.mC.fU.mC.fG.mA fU.mG.fG.mA.fN′ F11- 1863 PmN.fU.mG.fU.mG.fA.mG.fC.mA.fU. 2113 fA.mA.fG.mC.fA.mA.fU.mG.fC.mU. 113NM mU.fG.mC.fU.mU.fG.mA.fA.mA fC.mA.fC.mA.fN′ F11- 1864 PmN.fC.mC.fG.mG.fG.mA.fU.mG.fA. 2114 fA.mC.fU.mC.fA.mU.fC.mA.fU.mC. 114NM mU.fG.mA.fG.mU.fG.mC.fA.mG fC.mC.fG.mG.fN′ F11- 1865 PmN.fC.mC.fA.mC.fU.mU.fU.mA.fU. 2115 fG.mC.fU.mC.fG.mA.fU.mA.fA.mA. 115NM mC.fG.mA.fG.mC.fU.mU.fC.mG fG.mU.fG.mG.fN′ F11- 1866 PmN.fC.mA.fU.mU.fA.mU.fC.mC.fA. 2116 fU.mA.fA.mA.fA.mU.fG.mG.fA.mU. 116NM mU.fU.mU.fU.mA.fC.mA.fC.mA fA.mA.fU.mG.fN′ F11- 1867 PmN.fA.mA.fC.mC.fG.mG.fG.mA.fU. 2117 fU.mC.fA.mU.fC.mA.fU.mC.fC.mC. 117NM mG.fA.mU.fG.mA.fG.mU.fG.mC fG.mG.fU.mU.fN′ F11- 1868 PmN.fU.mU.fC.mU.fU.mU.fG.mG.fG. 2118 fA.mA.fU.mG.fG.mC.fC.mC.fA.mA. 118NM mC.fC.mA.fU.mU.fC.mC.fU.mG fA.mG.fA.mA.fN′ F11- 1869 PmN.fC.mU.fA.mA.fG.mG.fG.mU.fA. 2119 fC.mA.fA.mG.fA.mU.fA.mC.fC.mC. 119NM mU.fC.mU.fU.mG.fG.mC.fU.mU fU.mU.fA.mG.fN′ F11- 1870 PmN.fU.mU.fG.mG.fU.mG.fU.mG.fA. 2120 fA.mA.fU.mG.fC.mU.fC.mA.fC.mA. 120NM mG.fC.mA.fU.mU.fG.mC.fU.mU fC.mC.fA.mA.fN′ F11- 1871 PmN.fC.mA.fU.mA.fU.mG.fG.mG.fU. 2121 fC.mA.fA.mC.fG.mA.fC.mC.fC.mA. 121NM mC.fG.mU.fU.mG.fA.mG.fA.mA fU.mA.fU.mG.fN′ F11- 1872 PmN.fU.mU.fA.mA.fU.mG.fU.mG.fU. 2122 fU.mG.fG.mA.fU.mA.fC.mA.fC.mA. 122NM mA.fU.mC.fC.mA.fG.mA.fG.mA fU.mU.fA.mA.fN′ F11- 1873 PmN.fU.mC.fA.mG.fA.mU.fG.mU.fU. 2123 fC.mU.fU.mA.fA.mA.fA.mC.fA.mU. 123NM mU.fU.mA.fA.mG.fG.mA.fG.mA fC.mU.fG.mA.fN′ F11- 1874 PmN.fU.mU.fC.mC.fA.mA.fU.mG.fA. 2124 fC.mU.fC.mC.fA.mU.fC.mA.fU.mU. 124NM mU.fG.mG.fA.mG.fC.mC.fU.mC fG.mG.fA.mA.fN′ F11- 1875 PmN.fA.mG.fA.mA.fU.mC.fC.mA.fG. 2125 fG.mU.fG.mG.fA.mC.fU.mG.fG.mA. 125NM mU.fC.mC.fA.mC.fG.mU.fA.mC fU.mU.fC.mU.fN′ F11- 1876 PmN.fU.mU.fU.mG.fA.mG.fA.mU.fU. 2126 fC.mA.fA.mA.fG.mA.fA.mU.fC.mU. 126NM mC.fU.mU.fU.mG.fG.mG.fC.mC fC.mA.fA.mA.fN′ F11- 1877 PmN.fA.mA.fU.mC.fA.mU.fC.mC.fU. 2127 fU.mU.fU.mU.fC.mA.fG.mG.fA.mU. 127NM mG.fA.mA.fA.mA.fG.mA.fC.mC fG.mA.fU.mU.fN′ F11- 1878 PmN.fA.mG.fA.mC.fA.mC.fG.mC.fA. 2128 fG.mA.fU.mU.fU.mU.fG.mC.fG.mU. 128NM mA.fA.mA.fU.mC.fU.mU.fA.mG fG.mU.fC.mU.fN′ F11- 1879 PmN.fC.mG.fU.mA.fC.mU.fC.mG.fA. 2129 fC.mG.fU.mG.fG.mU.fC.mG.fA.mG. 129NM mC.fC.mA.fC.mG.fU.mU.fG.mG fU.mA.fC.mG.fN′ F11- 1880 PmN.fC.mA.fU.mC.fC.mA.fG.mU.fC. 2130 fU.mG.fG.mG.fU.mG.fA.mC.fU.mG. 130NM mA.fC.mC.fC.mA.fG.mC.fA.mA fG.mA.fU.mG.fN′ F11- 1881 PmN.fA.mA.fC.mA.fC.mU.fG.mG.fG. 2131 fA.mG.fC.mA.fU.mC.fC.mC.fA.mG. 131NM mA.fU.mG.fC.mU.fG.mU.fG.mC fU.mG.fU.mU.fN′ F11- 1882 PmN.fC.mA.fG.mA.fA.mA.fG.mA.fG. 2132 fC.mA.fA.mA.fG.mC.fU.mC.fU.mU. 132NM mC.fU.mU.fU.mG.fC.mU.fC.mU fU.mC.fU.mG.fN′ F11- 1883 PmN.fU.mU.fC.mU.fU.mU.fG.mA.fG. 2133 fA.mG.fA.mA.fU.mC.fU.mC.fA.mA. 133NM mA.fU.mU.fC.mU.fU.mU.fG.mG fA.mG.fA.mA.fN′ F11- 1884 PmN.fA.mG.fC.mA.fA.mC.fA.mA.fU. 2134 fU.mG.fG.mA.fU.mA.fU.mU.fG.mU. 134NM mA.fU.mC.fC.mA.fG.mU.fU.mC fU.mG.fC.mU.fN′ F11- 1885 PmN.fA.mC.fC.mA.fC.mU.fU.mU.fA. 2135 fC.mU.fC.mG.fA.mU.fA.mA.fA.mG. 135NM mU.fC.mG.fA.mG.fC.mU.fU.mC fU.mG.fG.mU.fN′ F11- 1886 PmN.fC.mC.fC.mU.fU.mC.fC.mC.fU. 2136 fA.mA.fC.mG.fA.mA.fG.mG.fG.mA. 136NM mU.fC.mG.fU.mU.fG.mC.fA.mG fA.mG.fG.mG.fN′ F11- 1887 PmN.fC.mG.fC.mA.fA.mA.fA.mU.fC. 2137 fC.mC.fU.mA.fA.mG.fA.mU.fU.mU. 137NM mU.fU.mA.fG.mG.fU.mG.fA.mC fU.mG.fC.mG.fN′ F11- 1888 PmN.fA.mG.fC.mG.fU.mG.fU.mU.fA. 2138 fC.mA.fC.mA.fG.mU.fA.mA.fC.mA. 138NM mC.fU.mG.fU.mG.fG.mA.fG.mG fC.mG.fC.mU.fN′ F11- 1889 PmN.fC.mU.fC.mC.fU.mU.fC.mC.fC. 2139 fC.mU.fA.mC.fA.mG.fG.mG.fA.mA. 139NM mU.fG.mU.fA.mG.fC.mC.fG.mG fG.mG.fA.mG.fN′ F11- 1890 PmN.fG.mU.fC.mC.fU.mC.fU.mG.fU. 2140 fG.mA.fG.mA.fU.mA.fC.mA.fG.mA. 140NM mA.fU.mC.fU.mC.fU.mU.fC.mU fG.mG.fA.mC.fN′ F11- 1891 PmN.fG.mU.fA.mU.fC.mU.fU.mG.fG. 2141 fG.mA.fA.mA.fG.mC.fC.mA.fA.mG. 141NM mC.fU.mU.fU.mC.fU.mG.fG.mA fA.mU.fA.mC.fN′ F11- 1892 PmN.fC.mU.fC.mU.fU.mG.fG.mC.fA. 2142 fA.mA.fC.mA.fC.mU.fG.mC.fC.mA. 142NM mG.fU.mG.fU.mU.fU.mC.fU.mG fA.mG.fA.mG.fN′ F11- 1893 PmN.fG.mA.fA.mA.fU.mC.fA.mG.fU. 2143 fA.mU.fG.mA.fC.mA.fC.mU.fG.mA. 143NM mG.fU.mC.fA.mU.fG.mG.fU.mA fU.mU.fU.mC.fN′ F11- 1894 PmN.fC.mU.fU.mC.fC.mC.fU.mG.fU. 2144 fC.mG.fG.mC.fU.mA.fC.mA.fG.mG. 144NM mA.fG.mC.fC.mG.fG.mC.fA.mC fG.mA.fA.mG.fN′ F11- 1895 PmN.fC.mU.fG.mG.fC.mC.fG.mC.fU. 2145 fA.mA.fG.mG.fG.mA.fG.mC.fG.mG. 145NM mC.fC.mC.fU.mU.fU.mG.fA.mG fC.mC.fA.mG.fN′ F11- 1896 PmN.fC.mA.fC.mG.fC.mA.fA.mA.fA. 2146 fU.mA.fA.mG.fA.mU.fU.mU.fU.mG. 146NM mU.fC.mU.fU.mA.fG.mG.fU.mG fC.mG.fU.mG.fN′ F11- 1897 PmN.fG.mA.fA.mA.fC.mC.fA.mG.fA. 2147 fC.mU.fC.mU.fU.mU.fC.mU.fG.mG. 147NM mA.fA.mG.fA.mG.fC.mU.fU.mU fU.mU.fU.mC.fN′ F11- 1898 PmN.fA.mA.fA.mG.fC.mU.fU.mU.fA. 2148 fU.mU.fA.mC.fU.mU.fA.mA.fA.mG. 148NM mA.fG.mU.fA.mA.fC.mA.fC.mU fC.mU.fU.mU.fN′ F11- 1899 PmN.fA.mC.fA.mA.fG.mC.fC.mA.fG. 2149 fC.mU.fA.mA.fU.mC.fU.mG.fG.mC. 149NM mA.fU.mU.fA.mG.fA.mA.fA.mG fU.mU.fG.mU.fN′ F11- 1900 PmN.fA.mC.fU.mC.fA.mU.fU.mA.fU. 2150 fA.mA.fU.mG.fG.mA.fU.mA.fA.mU. 150NM mC.fC.mA.fU.mU.fU.mU.fA.mC fG.mA.fG.mU.fN′ F11- 1901 PmN.fC.mC.fU.mG.fA.mA.fA.mA.fG. 2151 fA.mA.fG.mG.fU.mC.fU.mU.fU.mU. 151NM mA.fC.mC.fU.mU.fG.mU.fU.mG fC.mA.fG.mG.fN′ F11- 1902 PmN.fG.mG.fU.mU.fU.mC.fC.mA.fA. 2152 fC.mA.fU.mC.fA.mU.fU.mG.fG.mA. 152NM mU.fG.mA.fU.mG.fG.mA.fG.mC fA.mA.fC.mC.fN′ F11- 1903 PmN.fC.mA.fG.mU.fU.mU.fC.mU.fG. 2153 fC.mC.fU.mG.fC.mC.fA.mG.fA.mA. 153NM mG.fC.mA.fG.mG.fC.mC.fU.mC fA.mC.fU.mG.fN′ F11- 1904 PmN.fA.mU.fG.mG.fC.mA.fG.mA.fA. 2154 fC.mA.fG.mU.fG.mU.fU.mC.fU.mG. 154NM mC.fA.mC.fU.mG.fG.mG.fA.mU fC.mC.fA.mU.fN′ F11- 1905 PmN.fA.mG.fA.mU.fU.mU.fC.mU.fU. 2155 fU.mC.fU.mC.fA.mA.fA.mG.fA.mA. 155NM mU.fG.mA.fG.mA.fU.mU.fC.mU fA.mU.fC.mU.fN′ F11- 1906 PmN.fG.mU.fU.mU.fC.mC.fA.mG.fU. 2156 fU.mU.fG.mA.fA.mA.fC.mU.fG.mG. 156NM mU.fU.mC.fA.mA.fC.mA.fA.mG fA.mA.fA.mC.fN′ F11- 1907 PmN.fU.mC.fC.mU.fC.mU.fG.mU.fA. 2157 fA.mG.fA.mG.fA.mU.fA.mC.fA.mG. 157NM mU.fC.mU.fC.mU.fU.mC.fU.mG fA.mG.fG.mA.fN′ F11- 1908 PmN.fC.mA.fU.mC.fC.mU.fG.mA.fA. 2158 fG.mU.fC.mU.fU.mU.fU.mC.fA.mG. 158NM mA.fA.mG.fA.mC.fC.mU.fU.mG fG.mA.fU.mG.fN′ F11- 1909 PmN.fU.mU.fG.mA.fG.mU.fU.mU.fU. 2159 fU.mG.fG.mA.fG.mA.fA.mA.fA.mC. 159NM mC.fU.mC.fC.mA.fG.mA.fA.mU fU.mC.fA.mA.fN′ F11- 1910 PmN.fA.mA.fU.mU.fC.mA.fC.mU.fG. 2160 fA.mA.fC.mC.fA.mC.fA.mG.fU.mG. 160NM mU.fG.mG.fU.mU.fU.mC.fC.mA fA.mA.fU.mU.fN′ F11- 1911 PmN.fA.mA.fG.mA.fU.mU.fU.mC.fU. 2161 fC.mU.fC.mA.fA.mA.fG.mA.fA.mA. 161NM mU.fU.mG.fA.mG.fA.mU.fU.mC fU.mC.fU.mU.fN′ F11- 1912 PmN.fG.mG.fA.mG.fA.mC.fA.mA.fA. 2162 fA.mA.fA.mU.fC.mU.fU.mU.fG.mU. 162NM mG.fA.mU.fU.mU.fC.mU.fU.mU fC.mU.fC.mC.fN′ F11- 1913 PmN.fG.mA.fA.mA.fA.mU.fC.mA.fU. 2163 fU.mC.fA.mG.fG.mA.fU.mG.fA.mU. 163NM mC.fC.mU.fG.mA.fA.mA.fA.mG fU.mU.fU.mC.fN′ F11- 1914 PmN.fC.mU.fU.mU.fC.mU.fG.mC.fC. 2164 fA.mA.fA.mA.fU.mG.fG.mC.fA.mG. 164NM mA.fU.mU.fU.mU.fA.mU.fA.mC fA.mA.fA.mG.fN′ F11- 1915 PmN.fA.mG.fU.mC.fC.mA.fC.mG.fU. 2165 fC.mG.fA.mG.fU.mA.fC.mG.fU.mG. 165NM mA.fC.mU.fC.mG.fA.mC.fC.mA fG.mA.fC.mU.fN′ F11- 1916 PmN.fU.mU.fA.mA.fU.mG.fC.mG.fU. 2166 fA.mG.fU.mA.fC.mA.fC.mG.fC.mA. 166NM mG.fU.mA.fC.mU.fG.mG.fG.mC fU.mU.fA.mA.fN′ F11- 1917 PmN.fU.mA.fA.mU.fG.mU.fG.mU.fA. 2167 fC.mU.fG.mG.fA.mU.fA.mC.fA.mC. 167NM mU.fC.mC.fA.mG.fA.mG.fA.mU fA.mU.fU.mA.fN′ F11- 1918 PmN.fG.mA.fU.mU.fC.mU.fU.mU.fG. 2168 fU.mG.fG.mC.fC.mC.fA.mA.fA.mG. 168NM mG.fG.mC.fC.mA.fU.mU.fC.mC fA.mA.fU.mC.fN′ F11- 1919 PmN.fU.mG.fA.mA.fA.mC.fC.mA.fG. 2169 fU.mC.fU.mU.fU.mC.fU.mG.fG.mU. 169NM mA.fA.mA.fG.mA.fG.mC.fU.mU fU.mU.fC.mA.fN′ F11- 1920 PmN.fC.mA.fC.mA.fC.mA.fU.mU.fC. 2170 fC.mU.fG.mG.fU.mG.fA.mA.fU.mG. 170NM mA.fC.mC.fA.mG.fA.mA.fA.mC fU.mG.fU.mG.fN′ F11- 1921 PmN.fA.mC.fA.mA.fA.mG.fA.mU.fU. 2171 fA.mA.fA.mG.fA.mA.fA.mU.fC.mU. 171NM mU.fC.mU.fU.mU.fG.mA.fG.mA fU.mU.fG.mU.fN′ F11- 1922 PmN.fC.mA.fU.mU.fU.mC.fU.mA.fU. 2172 fA.mG.fG.mA.fG.mA.fU.mA.fG.mA. 172NM mC.fU.mC.fC.mU.fU.mU.fG.mG fA.mA.fU.mG.fN′ F11- 1923 PmN.fU.mU.fU.mC.fU.mG.fU.mA.fA. 2173 fC.mA.fG.mU.fG.mU.fU.mA.fC.mA. 173NM mC.fA.mC.fU.mG.fU.mC.fU.mU fG.mA.fA.mA.fN′ F11- 1924 PmN.fG.mG.fA.mU.fU.mU.fC.mA.fG. 2174 fU.mU.fU.mC.fA.mC.fU.mG.fA.mA. 174NM mU.fG.mA.fA.mA.fA.mU.fC.mC fA.mU.fC.mC.fN′ F11- 1925 PmN.fC.mG.fC.mU.fC.mC.fC.mU.fU. 2175 fG.mC.fU.mC.fA.mA.fA.mG.fG.mG. 175NM mU.fG.mA.fG.mC.fA.mC.fA.Mg fA.mG.fC.mG.fN′ F11- 1926 PmN.fC.mA.fG.mU.fC.mC.fA.mC.fG. 2176 fG.mA.fG.mU.fA.mC.fG.mU.fG.mG. 176NM mU.fA.mC.fUn.mC.fG.mA.fC.mC fA.mC.fU.mG.fN′ F11- 1927 PmN.fA.mG.fG.mC.fA.mU.fA.mU.fG. 2177 fC.mG.fA.mC.fC.mC.fA.mU.fA.mU. 177NM mG.fG.mU.fC.mG.fU.mU.fG.mA fG.mC.fC.mU.fN′ F11- 1928 PmN.fA.mU.fG.mU.fC.mC.fU.mC.fU. 2178 fG.mA.fU.mA.fC.mA.fG.mA.fG.mG. 178NM mG.fU.mA.fU.mC.fU.mC.fU.mU fA.mC.fA.mU.fN′ F11- 1929 PmN.fG.mC.fU.mU.fG.mA.fU.mU.fU. 2179 fC.mA.fC.mC.fA.mA.fA.mA.fU.mC. 179NM mU.fG.mG.fU.mG.fG.mU.fA.mC fA.mA.fG.mC.fN′ F11- 1930 PmN.fA.mU.fG.mA.fU.mG.fG.mA.fG. 2180 fG.mG.fA.mG.fG.mC.fU.mC.fC.mA. 180NM mC.fC.mU.fC.mC.fA.mC.fA.mC fU.mC.fA.mU.fN′ F11- 1931 PmN.fU.mC.fG.mU.fU.mG.fA.mG.fA. 2181 fC.mA.fG.mA.fU.mU.fC.mU.fC.mA. 181NM mA.FU.mC.fU.mG.fU.mG.fU.mA fA.mC.fG.mA.fN′ F11- 1932 PmN.fU.mU.fA.mU.fC.mC.fA.mU.fU. 2182 fU.mG.fU.mA.fA.mA.fA.mU.fG.mG. 182NM mU.fU.mA.fC.mA.fC.mA.fA.mC fA.mU.fA.mA.fN′ F11- 1933 PmN.fU.mG.fU.mC.fC.mU.fA.mU.fU. 2183 fG.mA.fG.mU.fG.mA.fA.mU.fA.mG. 183NM mC.fA.mC.fU.mC.fU.mU.fG.mG fG.mA.fC.mA.fN′ F11- 1934 PmN.fC.mA.fA.mU.fA.mU.fC.mC.fA. 2184 fA.mG.fA.mA.fC.mU.fG.mG.fA.mU. 184NM mG.fU.mU.fC.mU.fU.mC.fU.mC fA.mU.fU.mG.fN′ F11- 1935 PmN.fC.mU.fU.mU.fG.mA.fG.mA.fU. 2185 fA.mA.fA.mG.fA.mA.fU.mC.fU.mC. 185NM mU.fC.mU.fU.mU.fG.mG.fG.mC fA.mA.fA.mG.fN′ F11- 1936 PmN.fC.mA.fC.mU.fC.mU.fU.mG.fG. 2186 fC.mA.fC.mU.fG.mC.fC.mA.fA.mG. 186NM mC.fA.mG.fU.mG.fU.mU.fU.mC fA.mG.fU.mG.fN′ F11- 1937 PmN.fC.mU.fU.mG.fA.mA.fA.mG.fA. 2187 fG.mG.fU.mA.fU.mU.fC.mU.fU.mU. 187NM mA.fU.mA.fC.mC.fC.mA.fG.mA fC.mA.fA.mG.fN′ F11- 1938 PmN.fA.mG.fG.mC.fA.mA.fU.mA.fU. 2188 fG.mU.fA.mU.fG.mA.fU.mA.fU.mU. 188NM mC.fA.mU.fA.mC.fC.mC.fG.mC fG.mC.fC.mU.fN′ F11- 1939 PmN.fC.mU.fG.mU.fG.mU.fA.mA.fU. 2189 fA.mG.fU.mG.fA.mA.fU.mU.fA.mC. 189NM mU.fC.mA.fC.mU.fG.mU.fG.mG fA.mC.fA.mG.fN′ F11- 1940 PmN.fA.mA.fU.mA.fU.mC.fC.mA.fC. 92190 fA.mA.fC.mC.fA.mG.fU.mG.fG.mA. 190NM mU.fG.mG.fU.mU.fU.mC.fC.mA fU.mA.fU.mU.fN′ F11- 1941 PmN.fU.mG.fA.mA.fA.mG.fA.mA.fU. 2191 fU.mG.fG.mG.fU.mA.fU.mU.fC.mU. 191NM mA.fC.mC.fC.mA.fG.mA.fA.mA fU.mU.fC.mA.fN′ F11- 1942 PmN.fG.mU.fU.mA.fA.mU.fA.mU.fC. 2192 fC.mA.fG.mU.fG.mG.fA.mU.fA.mU. 192NM mC.fA.mC.fU.mG.fG.mU.fU.mU fU.mA.fA.mC.fN′ F11- 1943 PmN.fU.mG.fU.mC.fA.mU.fG.mG.fU. 2193 fA.mU.fU.mU.fU.mA.fC.mC.fA.mU. 193NM mA.fA.mA.fA.mU.fG.mA.fA.mG fG.mA.fC.mA.fN′ F11- 1944 PmN.fA.mU.fU.mC.fU.mU.fU.mG.fG. 2194 fA.mU.fG.mG.fC.mC.fC.mA.fA.mA. 194NM mG.fC.mC.fA.mU.fU.mC.fC.mU fG.mA.fA.mU.fN′ F11- 1945 PmN.fC.mA.fG.mU.fU.mC.fC.mU.fC. 2195 fC.mG.fU.mU.fG.mG.fA.mG.fG.mA. 195NM mC.fA.mA.fC.mG.fA.mU.fC.mC fA.mG.fU.mG.fN′ F11- 1946 PmN.fG.mG.fG.mU.fG.mU.fG.mC. 2196 fA.mC.fU.mG.fA.mA.fG.mC.fA.mC. 196NM fU.mU.fC.mA.fG.mU.fA.mG.fA.mC fA.mC.fC.mC.fN′ F11- 1947 PmN.fG.mA.fA.mG.fA.mA.fA.mG.fC. 2197 fU.mU.fA.mA.fA.mG.fC.mU.fU.mU. 197NM mU.fU.mU.fA.mA.fG.mU.fA.mA fC.mU.fU.mC.fN′ F11- 1948 PmN.fA.mU.fC.mC.fU.mG.fA.mA.fA. 2198 fG.mG.fU.mC.fU.mU.fU.mU.fC.mA. 198NM mA.fG.mA.fC.mC.fU.mU.fG.mU fG.mG.fA.mU.fN′ F11- 1949 PmN.fA.mG.fA.mA.fA.mG.fC.mU.fU. 2199 fA.mC.fU.mU.fA.mA.fA.mG.fC.mU. 199NM mU.fA.mA.fG.mU.fA.mA.fC.mA fU.mU.fC.mU.fN′ F11- 1950 PmN.fC.mA.fG.mU.fG.mU.fU.mU.fC. 2200 fU.mU.fA.mC.fA.mG.fA.mA.fA.mC. 200NM mU.fG.mU.fA.mA.fC.mA.fC.mU fA.mC.fU.mG.fN′ F11- 1951 PmN.fG.mA.fC.mA.fC.mG.fC.mA.fA. 2201 fA.mG.fA.mU.fU.mU.fU.mG.fC.mG. 201NM mA.fA.mU.fC.mU.fU.mA.fG.mG fU.mG.fU.mC.fN′ F11- 1952 PmN.fG.mU.fG.mU.fG.mA.fG.mC.fA. 2202 fA.mG.fC.mA.fA.mU.fG.mC.fU.mC. 202NM mU.fU.mG.fC.mU.fU.mG.fA.mA fA.mC.fA.mC.fN′ F11- 1953 PmN.fA.mC.fC.mA.fG.mA.fA.mA.fG. 2203 fA.mA.fG.mC.fU.mC.fU.mU.fU.mC. 203NM mA.fG.mC.fU.mU.fU.mG.fC.mU fU.mG.fG.mU.fN′ F11- 1954 PmN.fA.mG.fA.mA.fA.mG.fU.mG.fC. 2204 fC.mC.fU.mG.fU.mG.fC.mA.fC.mU. 204NM mA.fC.mA.fG.mG.fA.mU.fU.mU fU.mU.fC.mU.fN′ F11- 1955 PmN.fU.mU.fU.mA.fU.mU.fU.mC.fA. 2205 fC.mA.fA.mU.fC.mU.fG.mA.fA.mA. 205NM mG.fA.mU.fU.mG.fA.mU.fU.mU fU.mA.fA.mA.fN′ F11- 1956 PmN.fU.mA.fU.mC.fC.mA.fG.mU.fU. 2206 fA.mG.fA.mA.fG.mA.fA.mC.fU.mG. 206NM mC.fU.mU.fC.mU.fC.mC.fC.mA fG.mA.fU.mA.fN′ F11- 1957 PmN.fC.mC.fG.mU.fG.mA.fA.mA.fG. 2207 fC.mU.fU.mC.fA.mC.fU.mU.fU.mC. 207NM mU.fG.mA.fA.mG.fA.mG.fU.mA fA.mC.fG.mG.fN′ F11- 1958 PmN.fG.mG.fU.mG.fU.mG.fC.mU.fU. 2208 fU.mA.fC.mU.fG.mA.fA.mG.fC.mA. 208NM mC.fA.mG.fU.mA.fG.mA.fC.mA fC.mA.fC.mC.fN′ F11- 1959 PmN.fG.mG.fA.mC.fA.mG.fA.mG.fG. 2209 fG.mA.fG.mG.fC.mC.fC.mU.fC.mU. 209NM mG.fC.mC.fU.mC.fC.mC.fG.mA fG.mU.fC.mC.fN′ F11- 1960 PmN.fA.mA.fG.mA.fA.mA.fA.mU.fC. 2210 fA.mG.fG.mA.fU.mG.fA.mU.fU.mU. 210NM mA.fU.mC.fC.mU.fG.mA.fA.mA fU.mC.fU.mU.fN′ F11- 1961 PmN.fU.mG.fA.mG.fA.mU.fU.mC.fU. 2211 fC.mC.fC.mA.fA.mA.fG.mA.fA.mU. 211NM mU.fU.mG.fG.mG.fC.mC.fA.mU fC.mU.fC.mA.fA.fN′ F11- 1962 PmN.fA.mU.fG.mU.fU.mU.fU.mA.fA. 2212 fU.mC.fU.mC.fC.mU.fU.mA.fA.mA. 212NM mG.fG.mA.fG.mA.fC.mA.fA.mA fA.mC.fA.mU.fN′ F11- 1963 PmN.fC.mA.fC.mA.fG.mU.fU.mU.fC. 2213 fU.mG.fC.mC.fA.mG.fA.mA.fA.mC. 213NM mU.fG.mG.fC.mA.fG.mG.fC.mC fU.mG.fU.mG.fN′ F11- 1964 PmN.fA.mC.fA.mA.fU.mA.fU.mC.fC. 2214 fG.mA.fA.mC.fU.mG.fG.mA.fU.mA. 214NM mA.fG.mU.fU.mC.fU.mU.fC.mU fU.mU.fG.mU.fN′ F11- 1965 PmN.fA.mC.fA.mU.fU.mC.fA.mC.fC. 2215 fU.mU.fU.mC.fU.mG.fG.mU.fG.mA. 215NM mA.G.mA.fA.mA.fC.mU.fG.mA fA.mU.fG.mU.fN′ F11- 1966 PmN.fC.mA.fA.mG.fG.mC.fA.mA.fU. 2216 fA.mU.fG.mA.fU.mA.fU.mU.fG.mC. 216NM mA.fU.mC.fA.mU.fA.mC.fC.mC fC.mU.fU.mG.fN′ F11- 1967 PmN.fC.mU.fC.mC.fA.mA.fC.mG.fA. 2217 fC.mA.fG.mG.fA.mU.fC.mG.fU.mU. 217NM mU.fC.mC.fU.mG.fG.mG.fC.mU fG.mG.fA.mG.fN′ F11- 1968 PmN.fC.mU.fG.mA.fA.mA.fC.mC.fA. 2218 fC.mU.fU.mU.fC.mU.fG.mG.fU.mU. 218NM mG.fA.mA.fA.mG.fA.mG.fC.mU fU.mC.fA.mG.fN′ F11- 1969 PmN.fA.mA.fU.mC.fU.mC.fC.mC.fU. 2219 fU.mU.fG.mC.fA.mA.fG.mG.fG.mA. 219NM mU.fG.mC.fA.mA.fG.mC.fG.mU fG.mA.fU.mU.fN′ F11- 1970 PmN.fU.mG.fU.mG.fU.mA.fA.mU.fU. 2220 fC.mA.fG.mU.fG.mA.fA.mU.fU.mA. 220NM mC.fA.mC.fU.mG.fU.mG.fG.mU fC.mA.fC.mA.fN′ F11- 1971 PmN.fU.mU.fU.mC.fA.mG.fU.mG.fA. 2221 fG.mA.fU.mU.fU.mU.fC.mA.fC.mU. 221NM mA.fA.mA.fU.mC.fC.mA.fG.mA fG.mA.fA.mA.fN′ F11- 1972 PmN.fA.mA.fA.mU.fC.mA.fU.mC.fC. 2222 fU.mU.fU.mC.fA.mG.fG.mA.fU.mG. 222NM mU.fG.mA.fA.mA.fA.mG.fA.mC fA.mU.fU.mU.fN′ F11- 1973 PmN.fU.mA.fC.mA.fC.mU.fC.mA.fU. 2223 fG.mG.fA.mU.fA.mA.fU.mG.fA.mG. 223NM mU.fA.mU.fC.mC.fA.mU.fU.mU fU.mG.fU.mA.fN′ F11- 1974 PmN.fU.mU.fG.mG.fC.mA.fG.mU.fG. 2224 fA.mG.fA.mA.fA.mC.fA.mC.fU.mG. 224NM mU.fU.mU.fC.mU.fG.mU.fA.mA fC.mC.fA.mA.fN′ F11- 1975 PmN.fG.mG.fU.mA.fC.mA.fC.mU.fC. 2225 fA.mU.fA.mA.fU.mG.fA.mG.fU.mG. 225NM mA.fU.mU.fA.mU.fC.mC.fA.mU fU.mA.fC.mC.fN′ F11- 1976 PmN.fA.mG.fG.mC.fA.mG.fG.mC.fA. 2226 fC.mC.fA.mU.fA.mU.fG.mC.fC.mU. 226NM mU.fA.mU.fG.mG.fG.mU.fC.mG fG.mC.fC.mU.fN′ F11- 1977 PmN.fC.mC.fA.mG.fU.mU.fU.mC.fA. 2227 fC.mU.fU.mG.fU.mU.fG.mA.fA.mA. 227NM mA.fC.mA.fA.mG.fG.mC.fA.mA fC.mU.fG.mG.fN′ F11- 1978 PmN.fU.mG.fG.mC.fC.mG.fC.mU.fC. 2228 fA.mA.fA.mG.fG.mG.fA.mG.fC.mG. 228NM mC.fC.mU.fU.mU.fG.mA.fG.mC fG.mC.fC.mA.fN′ F11- 1979 PmN.fA.mC.fU.mG.fU.mG.fG.mU.fU. 2229 fC.mU.fG.mG.fA.mA.fA.mC.fC.mA. 229NM mU.fC.mC.fA.mG.fU.mU.fU.mC fC.mA.fG.mU.fN′ F11- 1980 PmN.fC.mU.fU.mU.fG.mG.fG.mC.fC. 2230 fG.mG.fA.mA.fU.mG.fG.mC.fC.mC. 230NM mA.fU.mU.fC.mC.fU.mG.fG.mG fA.mA.fA.mG.fN′ F11- 1981 PmN.fU.mA.fA.mG.fA.mA.fA.mA.fU. 2231 fG.mG.fA.mU.fG.mA.fU.mU.fU.mU. 231NM mC.fA.mU.fC.mC.fU.mG.fA.mA fC.mU.fU.mA.fN′ F11- 1982 PmN.fC.mU.fC.mU.fU.mU.fU.mA.fU. 2232 fC.mU.fG.mA.fA.mA.fU.mA.fA.mA. 232NM mU.fU.mC.fA.mG.fA.mU.fU.mG fA.mG.fA.mG.fN′ F11- 1983 PmN.fU.mC.fU.mU.fU.mG.fA.mG.fA. 2233 fA.mA.fG.mA.fA.mU.fC.mU.fC.mA. 233NM mU.fU.mC.fU.mU.fU.mG.fG.mG fA.mA.fG.mA.fN′ F11- 1984 PmN.fA.mA.fU.mG.fA.mU.fG.mG.fA. 2234 fG.mA.fG.mG.fC.mU.fC.mC.fA.mU. 234NM mG.fC.mC.fU.mC.fC.mA.fC.mA fC.mA.fU.mU.fN′ F11- 1985 PmN.fG.mA.fA.mG.fA.mA.fU.mG.fG. 2235 fU.mU.fC.mU.fG.mC.fC.mA.fU.mU. 235NM mC.fA.mG.fA.mA.fC.mA.fC.mU fC.mU.fU.mC.fN′ F11- 1986 PmN.fC.mA.fA.mU.fG.mA.fU.mG.fG. 2236 fA.mG.fG.mC.fU.mC.fC.mA.fU.mC. 236NM mA.fG.mC.fC.mU.fC.mC.fA.mC fA.mU.fU.mG.fN′ F11- 1987 PmN.fA.mU.fG.mG.fA.mG.fC.mC.fU. 2237 fU.mG.fU.mG.fG.mA.fG.mG.fC.mU. 237NM mC.fC.mA.fC.mA.fC.mA.fG.mG fC.mC.fA.mU.fN′ F11- 1988 PmN.fC.mC.fC.mA.fA.mG.fA.mA.fA. 2238 fA.mC.fU.mG.fA.mU.fU.mU.fC.mU. 238NM mU.fC.mA.fG.mU.fG.mU.fC.mA fU.mG.fG.mG.fN′ F11- 1989 PmN.fG.mA.fG.mC.fC.mU.fC.mC.fA. 2239 fC.mU.fG.mU.fG.mU.fG.mG.fA.mG. 239NM mC.fA.mC.fA.mG.fG.mU.fG.mU fG.mC.fU.mC.fN′ F11- 1990 PmN.fC.mU.fC.mC.fC.mA.fA.mG.fA. 2240 fU.mG.fA.mU.fU.mU.fC.mU.fU.mG. 240NM mA.fA.mU.fC.mA.fG.mU.fG.mU fG.mG.fA.mG.fN′ F11- 1991 PmN.fC.mC.fU.mC.fC.mA.fC.mA.fC. 2241 fC.mA.fC.mC.fU.mG.fU.mG.fU.mG. 241NM mA.fG.mG.fU.mG.fU.mC.fU.mC fG.mA.fG.mG.fN′ F11- 1992 PmN.fC.mC.fA.mA.fU.mG.fA.mU.fG. 2242 fG.mG.fC.mU.fC.mC.fA.mU.fC.mA. 242NM mG.fA.mG.fC.mC.fU.mC.fC.mA fU.mU.fG.mG.fN′ F11- 1993 PmN.fU.mU.fU.mC.fC.mA.fA.mU.fG. 2243 fU.mC.fC.mA.fU.mC.fA.mU.fU.mG. 243NM mA.fU.mG.fG.mA.fG.mC.fC.mU fG.mA.fA.mA.fN′ F11- 1994 PmN.fU.mC.fC.mC.fA.mA.fG.mA.fA. 2244 fC.mU.fG.mA.fU.mU.fU.mC.fU.mU. 244NM mA.fU.mC.fA.mG.fU.mG.fU.mC fG.mG.fG.mA.fN′ F11- 1995 PmN.fA.mG.fC.mC.fU.mC.fC.mA.fC. 2245 fC.mC.fU.mG.fU.mG.fU.mG.fG.mA. 245NM mA.fC.mA.fG.mG.fU.mG.fU.mC fG.mG.fC.mU.fN′ F11- 1996 PmN.fU.mC.fU.mU.fC.mU.fC.mC.fC. 2246 fU.mU.fC.mU.fU.mG.fG.mG.fA.mG. 246NM mA.fA.mG.fA.mA.fA.mU.fC.mA ffA.mA.fG.mA.fN′ F11- 1997 PmN.fG.mU.fU.mU.fC.mC.fA.mA.fU. 2247 fC.mC.fA.mU.fC.mA.fU.mU.fG.mG. 247NM mG.fA.mU.fG.mG.fA.mG.fC.mC A.mA.fA.mC.fN′ F11- 1998 PmN.fU.mC.fC.mA.fA.mU.fG.mA.fU. 2248 fG.mC.fU.mC.fC.mA.fU.mC.fA.mU. 248NM mG.fG.mA.fG.mC.fC.mU.fC.mC fU.mG.fG.mA.fN′ F11- 1999 PmN.fU.mG.fG.mA.fG.mC.fC.mU.fC. 2249 fG.mU.fG.mU.fG.mG.fA.mG.fG.mC. 249NM mC.fA.mC.fA.mC.fA.mG.fG.mU fU.mC.fC.mA.fN′ F11- 2000 PmN.fG.mC.fC.mU.fC.mC.fA.mC.fA. 2250 fA.mC.fC.mU.fG.mU.fG.mU.fG.mG. 250NM mC.fA.mG.fG.mU.fG.mU.fC.mil fA.mG.fG.mC.fN′

In above Table 1e:

A represents adenine;

U represents uracil;

C represents cytosine;

G represents guanine;

P represents a terminal phosphate group;

m represents a methyl modification at the 2′ position of the sugar of the underlying nucleoside;

f represents a fluoro modification at the 2′ position of the sugar of the underlying nucleoside

N represents any RNA nucleobase;

N′ represents any RNA nucleobase and is preferably complementary to N.

Example 2

Oligonucleotides as set out in Tables 1a/1 b above that target FXI mRNA in human hepatoma cells were screened as follows.

Native gel electrophoresis for random FXI oligomeric compounds: Oligomeric compounds including oligonucleotides as set out in Table 1a/1 b above were dissolved in sterile Rnase-, Dnase free water to the final concentration 100 μM. 10 random oligomeric compounds were selected for validation based on following Table 2.

TABLE 2 No. Lot No. ID 1 32407 F11-07  2 32443 F11-43  3 32467 F11-67  4 32482 F11-82  5 32521 F11-121 6 32530 F11-130 7 32555 F11-155 8 32596 F11-196 9 32615 F11-215 10 33642 F11-242

20% TBE gel electrophoresis was carried out for the above oligomeric compounds of Table 2, 10 μm oligonucleotide/lane, staining: SybrGold. FIG. 1 illustrates the stability of the resulting duplexes. Based on this QC data we used all oligomeric compounds in the following screening.

Two independent F11 qPCR assays and were validated for the screening. Both assays produced linear dose response as illustrated in FIG. 2 with high sensitivity and efficiency. Due to known qPCR artifacts caused by siRNAs overlapping with qPCR probe regions, two probes from different target gene regions were used.

Screening F11 oligomeric compounds in hepatoma cell line: Protocol details:

Cell seeding: 10,000 HepG2 cells/well.

Lipofectamine RNAiMax mediated transfection.

Transfection: 20 nM compounds, antibiotic-free EMEM medium 10% FBS, 72 h incubation.

Gene expression was measured by qPCR (Taqman chemistry), adjusted to the standard curve and normalized to the reference gene GAPDH.

Data is expressed as the percentage of gene expression in non-treated cells (NT).

Results of the screening are shown in FIGS. 3 to 12.

26 oligomeric compounds with 80% knockdown cut off were selected for the dose response curves. Basis for this selection is as follows in Table 3.

TABLE 3 Probe 0011 Probe 0011 Probe 0014 Probe 0014 (% of NT) (StDev) (% of NT) (StDev) F11-183 16.38125499 2.013845618 7.390709343 0.566515346 F11-140 9.879406487 3.562127243 14.22784171 3.594956374 F11-27  12.75921626 0.196272116 11.67948753 0.736184873 F11-91  13.02726487 1.209635635 11.9438287 1.262506376 F11-163 11.85412492 0.429451274 14.23620915 0.292814079 F11-207 14.0604508 0.474611347 12.58144382 0.838626235 F11-46  15.99580158 0.887618916 10.81760361 0.429607546 F11-199 12.09311021 0.561879319 16.177289 0.804157804 F11-220 10.19545315 2.801932011 18.89268438 4.374803266 F11-238 13.40181876 0.052184671 17.3012001 1.131315389 F11-98  15.77153606 1.342306305 15.82298746 1.641051662 F11-105 14.09977643 0.481691161 18.58881771 1.10194639 F11-146 13.12223851 1.009310781 19.79764347 0.70176306 F11-152 10.7295455 0.718550243 22.44897671 1.853140055 F11-109 14.71437898 0.483729553 18.58436211 0.097538284 F11-120 15.82404014 0.296398359 17.48975387 2.035559291 F11-218 14.31316962 0.304685608 19.64927627 1.469210086 F11-13  15.75002936 0.544846368 18.21711753 0.233023069 F11-39  19.6320507 2.268987147 14.61318275 1.740915389 F11-210 16.1566738 0.521574928 19.46520418 0.491427909 F11-08  17.52268129 0.100107723 18.84244532 0.566323481 F11-224 16.03733736 0.892648857 20.79529032 0.619058244 F11-182 19.06641913 0.47270836 19.16890424 1.516153913 F11-103 14.8052026 1.32389517 25.00603503 2.748462021 F11-151 17.9105237 0.303879045 21.95923162 0.360854952 F11-223 16.88767639 1.818246469 24.88274643 1.656451297

Example 3

Dose response curves for the 26 FXI lead compounds as identified in Example 2 are shown in FIG. 13.

Dose response curves for the 5 FXI lead compounds are shown in FIG. 14.

Example 4

IC50 values are shown for the 26 FXI lead compounds as identified in Example 2 in following Table 4.

TABLE 4 siRNA (nM) 50 25 12.5 5 2 0.8 0.32 F11-140 10.84824 27.26815 52.49094 74.79465 86.01931 92.5617 108.1231 F11-91 11.21362 17.5123 30.79378 52.89924 71.85335 76.62539 86.24001 F11-46 11.31357 19.1463 34.94334 58.3431 72.36898 79.03502 87.90456 F11-27 12.00189 19.71206 36.34996 58.61257 73.49525 80.52213 95.02346 F11-08 12.88477 23.17136 38.502 60.95352 75.64406 85.64319 94.30091 F11-207 13.33847 28.59863 48.07128 70.58417 80.28337 83.17787 97.52694 F11-146 13.38071 23.04423 40.71772 67.32095 87.86172 94.18917 112.7978 F11-152 14.24965 24.9051 51.57466 70.85458 81.53343 88.18263 105.3212 F11-13 16.1023 30.30924 48.19031 63.18166 75.90383 80.13827 91.06444 F11-220 16.95432 25.76435 52.68453 80.69079 87.87234 98.52989 105.8545 F11-218 17.20341 31.58884 61.17974 77.06415 101.7601 105.0303 109.3946 F11-109 17.57553 29.90478 47.49863 67.90813 83.63117 99.25234 104.6814 F11-105 17.62636 27.2131 48.11403 75.61487 91.99868 99.3779 113.5676 F11-103 19.05623 31.3836 53.66986 70.21575 87.15926 94.18358 109.3758 F11-98 19.08747 25.21664 40.70468 62.53904 90.33434 92.00181 109.9554 F11-39 20.76369 36.33147 56.83281 71.87339 85.66001 88.7146 89.9771 F11-183 22.96668 40.72956 62.72405 82.71394 91.62041 102.8007 117.0328 F11-163 23.72934 27.92605 45.96363 70.65669 90.44246 95.26864 111.0215 F11-223 25.55254 50.53311 79.41138 88.2778 102.639 100.4705 109.0358 F11-151 25.79851 29.31085 43.72433 64.81009 83.78671 85.73753 101.2187 F11-120 26.54193 37.32053 44.77477 68.73705 81.41065 91.22496 92.68608 F11-199 28.11948 37.72515 63.274 74.59009 89.97225 96.10097 97.29022 F11-224 28.19833 42.50665 62.41726 82.4676 85.58443 92.77884 100.0632 F11-210 29.66767 37.73558 58.54817 67.94156 78.98299 88.30405 103.0938 F11-182 32.95932 52.5532 72.82952 81.79542 88.47215 101.748 104.4618 F11-238 73.20162 93.24065 91.91126 90.37185 88.5052 87.39394 99.47702

Example 5

Species cross-reactivity of the 26 FXI lead compounds as identified in Example 2 are shown in following Table 5.

TABLE 5 Selected Macaca Mus Rattus oligos fascicularis musculus norvegicus F11-183 MF 0 0 F11-140 MF 0 0 F11-27  0 0 0 F11-91  MF 0 0 F11-163 MF 0 0 F11-207 MF 0 0 F11-46  MF 0 0 F11-199 MF 0 0 F11-220 MF 0 0 F11-238 MF MUS RN F11-98  MF 0 0 F11-105 MF 0 0 F11-146 MF 0 0 F11-152 MF MUS RN F11-109 MF 0 0 F11-120 MF 0 0 F11-218 MF 0 0 F11-13  MF 0 0 F11-39  MF 0 RN F11-210 MF 0 0 F11-08  MF 0 0 F11-224 MF 0 0 F11-182 MF 0 0 F11-103 MF 0 0 F11-151 MF 0 0 F11-223 MF 0 0

Example 6

Further to the data as provided in Examples 3 to 5, oligonucleotides F11-46/SEQ ID NO: 46, F11-91/SEQ ID NO: 91 and F11-152/SEQ ID NO: 152 have been identified as particularly preferred antisense oligonucleotide sequences to be used in oligomeric compounds as described herein. On this basis, these sequences have been incorporated into overall oligomeric compounds as described herein of the following sequences SEQ ID NOs 2251 to 2253 as set out in following Table 6. Furthermore, selected modifications have been applied to SEQ ID NOs 2251 to 2253 as shown in SEQ ID NOs 2254 to 2286 in following Table 6. All sequences as provided below in Table 6 are set out in the 5′ to 3′ directionality.

TABLE 6 SEQ ID¹ or construct² Oligo Name No Sequence F11-46C 2251 UUGGUGUGAGCAUUGCUUGCAAUGCUCACACCAA (includes (Oligomeric antisense SEQ ID NO 46, and sense SEQ ID NO 296) compound F11-46 complete sequence) F11-91C 2252 UUAUAAGAAAAUCAUCCUGAUGAUUUUCUUAUAA (includes (Oligomeric antisense SEQ ID NO 91, and sense SEQ ID NO 341) compound F11-91 complete sequence) F11-152 C 2253 UGGUUUCCAAUGAUGGAGCCAUCAUUGGAAACCA (includes (Oligomeric antisense SEQ ID NO 152, and sense SEQ ID NO 402) compound F11-152 complete sequence) F11-46CPS 2254 mU(ps)fU(ps)mGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC(ps) (Oligomeric mU(ps)fU(ps)mG(ps)fCmAfAmUfGmCfUmCfAmCfAmCfCmAfA compound (includes antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence/ (ps) modified) F11-91CPS 2255 mU(ps)fU(ps)mAfUmAfAmGfAmAfAmAfUmCfAmU(ps)fC(ps)mC (Oligomeric (ps)fU(ps)mG(ps)fAmUfGmAfUmUfUmUfCmUfUmAfUmAfA compound (includes antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence/ (ps) modified) F11-152CPS 2256 mU(ps)fG(ps)mGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG(ps)mA (Oligomeric (ps)fG(ps)mC(ps)fCmAfUmCfAmUfUmGfGmAfAmAfCmCfA compound (includes antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete / (ps) modified) F11-46VP 2257 (VP)mU(ps)fU(ps)mGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC(ps) (Oligomeric mU(ps)fU(ps)mG(ps)fCmAfAmUfGmCfUmCfAmCfAmCfCmAfA compound (includes antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence / ps and vinyl phosphonate modification) F11-91VP 2258 (VP)mU(ps)fU(ps)mAfUmAfAmGfAmAfAmAfUmCfAmU(ps)fC(ps) (Oligomeric mC(ps)fU(ps)mG(ps)fAmUfGmAfUmUfUmUfCmUfUmAfUmAfA compound (includes antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / ps and vinyl phosphonate modification) F11-152VP 2259 (VP)mU(ps)fG(ps)mGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG(ps) (Oligomeric mA(ps)fG(ps)mC(ps)fCmAfUmCfAmUfUmGfGmAfAmAfCmCfA compound (includes antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete sequence / ps and vinyl phosphonate modification) F11-46IL 2260 mU(ps)fU(ps)mGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC(ps)mU (Oligomeric (ps)fUiGfCmAfAmUfGmCfUmCfAmCfAmCfCmAfA (includes compound antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence / ps and inverted nucleotide loop) F11-91IL 2261 mU(ps)fU(ps)mAfUmAfAmGfAmAfAmAfUmCfAmU(ps)fC(ps)mC (Oligomeric (ps)fUiGfAmUfGmAfUmUfUmUfCmUfUmAfUmAfA (includes compound antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / ps and inverted nucleotide loop) F11-152IL 2262 mU(ps)fG(ps)mGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG(ps)mA (Oligomeric (ps)fGiCfCmAfUmCfAmUfUmGfGmAfAmAfCmCfA (includes compound antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete sequence / ps and inverted nucleotide loop) F11-46IE 2263 mUiUmGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC(ps)mU(ps)fU (Oligomeric (ps)mG(ps)fCmAfAmUfGmCfUmCfAmCfAmCfCiAfA (includes compound antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence / ps and end inverted nucleotide) F11-91IE 2264 mUiUmAfUmAfAmGfAmAfAmAfUmCfAmU(ps)fC(ps)mC(ps)fU(ps) (Oligomeric mG(ps)fAmUfGmAfUmUfUmUfCmUfUmAfUiAfA (includes compound antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / ps and end inverted nucleotide) F11-152IE 2265 mUiGmGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG(ps)mA(ps)fG (Oligomeric (ps)mC(ps)fCmAfUmCfAmUfUmGfGmAfAmAfCiCfA (includes compound antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete sequence / ps and end inverted nucleotide) F11-46II 2266 mU(ps)fU(ps)mGfGmUfGiUfGmAfGmCfAmUfUmG(ps)fC(ps)mU (Oligomeric (ps)fU(ps)mG(ps)fmCfAmAfUmGfCfUmCiAmCfAmCfCmAfA compound (includes antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence / ps and internal inverted nucleotide) F11-91II 2267 mU(ps)fU(ps)mAfUmAfAiGfAmAfAmAfUmCfAmU(ps)fC(ps)mC (Oligomeric (ps)fU(ps)mG(ps)fAmUfGmAfUmUfUmUiCmUfUmAfUmAfA compound (includes antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / ps and internal inverted nucleotide) F11-152II 2268 mU(ps)fG(ps)mGfUmUfUiCfCmAfAmUfGmAfUmG(ps)fG(ps)mA (Oligomeric (ps)fG(ps)mC(ps)fCmAfUmCfAmUfUmGiGmAfAmAfCmCfA compound (includes antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete sequence / ps and internal inverted nucleotide) F11-46MF 2269 mU(ps)fU(ps)mGmGmUmGmUmGmAmGmCmAmUfUmG(ps)mC (Oligomeric (ps)mU(ps)mU(ps)mG(ps)mCmAfAfUfGmCmUmCmAmCmAm compound CmCmAmA (includes antisense SEQ ID NO 46, and sense SEQ F11-46 ID NO 296) complete sequence / ps and minimum 2F) F11-91MF 2270 mU(ps)fU(ps)mAmUmAmAmGmAmAmAmAmUmCfAmU(ps)mC (Oligomeric (ps)mC(ps)mU(ps)mG(ps)mAmUfGfAfUmUmUmUmCmUmUmA compound mUmAmA (includes antisense SEQ ID NO 91, and sense SEQ F11-91 ID NO 341) complete sequence / ps and minimum 2F) F11-152MF 2271 mU(ps)fG(ps)mGmUmUmUmCmCmAmAmUmGmAfUmG(ps)mG (Oligomeric (ps)mA(ps)mG(ps)mC(ps)mCmAfUfCfAmUmUmGmGmAmAm compound AmCmCmA (includes antisense SEQ ID NO 152, and sense F11-152 SEQ ID NO 402) complete sequence / ps and minimum 2F) F11-46ILG 2272 mU(ps)fU(ps)mGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC(ps)mU (Oligomeric (ps)fU(ps)mG(ps)fCmAfAmUfGmCfUCfACfAmCC(ps)mA(ps)fA compound (includes antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence / ps and internal ligand arrangement) F11-91ILG 2273 mU(ps)fU(ps)mAfUmAfAmGfAmAfAmAfUmCfAmU(ps)fC(ps)mC (Oligomeric (ps)fU(ps)mG(ps)fAmUfGmAfUmUfUUfCmUUmAU(ps)mA(ps)fA compound (includes antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / ps and internal ligand arrangement) F11-152ILG 2274 mU(ps)fG(ps)mGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG(ps)mA (Oligomeric (ps)fG(ps)mC(ps)fCmAUmCfAUUmGfGmAfAmAC(ps)mC(ps)fA compound (includes antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete sequence / ps and internal ligand arrangement) F11-46ILGIE 2275 mU(ps)fU(ps)mGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC(ps)mU (Oligomeric (ps)fU(ps)mG(ps)fCmAfAmUfGmCfUCfACfAmCCmAiN″mN′″ compound (includes antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence / ps, internal ligand arrangement and inverted nucleotide end stabilization) F11-91ILGIE 2276 mU(ps)fU(ps)mAfUmAfAmGfAmAfAmAfUmCfAmU(ps)fC(ps)mC (Oligomeric (ps)fU(ps)mG(ps)fAmUfGmAfUmUfUUfCmUUmAUmAiN″mN′″ compound (includes antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / ps, internal ligand arrangement and inverted nucleotide end stabilization) F11-152ILGIE 2277 mU(ps)fG(ps)mGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG(ps)mA (Oligomeric (ps)fG(ps)mC(ps)fCmAUmCfAUUmGfGmAfAmACmCiN″mN′″ compound (includes antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete sequence / ps, internal ligand arrangement and inverted nucleotide end stabilization) F11-46MVP 2278 (mVP)mU(ps)fU(ps)mGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC (Oligomeric (ps)mU(ps)fU(ps)mG(ps)fCmAfAmUfGmCfUmCfAmCfAmCfCmA compound fA (includes antisense SEQ ID NO 46, and sense SEQ ID NO F11-46 296) complete sequence / ps and methyl vinyl phosphonate modification) F11-91MVP 2279 (mVP)mU(ps)fU(ps)mAfU mAfAmGfAmAfAmAfU mCfAmU(ps)fC(ps) (Oligomeric mC(ps)fU(ps)mG(ps)fAmUfGmAfUmUfUmUfCmUfUmAfUmAfA compound (includes antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / ps and methyl vinyl phosphonate modification) F11-152MVP 2280 (mVP)mU(ps)fG(ps)mGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG (Oligomeric (ps)mA(ps)fG(ps)mC(ps)fCmAfUmCfAmUfUmGfGmAfAmAfCmCfA compound (includes antisense SEQ ID NO 152, and sense SEQ ID NO F11-152 402) complete sequence / ps and methyl vinyl phosphonate modification) F11-46IT 2281 iUfUmGfGmUfGmUfGmAfGmCfAmUfUmG(ps)fC(ps)mU(ps)fU(ps) (Oligomeric mG(ps)fCmAfAmUfGmCfUmCfAmCfAmCfCmAiA (includes compound antisense SEQ ID NO 46, and sense SEQ ID NO 296) F11-46 complete sequence / PS and inverted nucleotide terminal stabilization) F11-91IT 2282 iUfUmAfUmAfAmGfAmAfAmAfUmCfAmU(ps)fC(ps)mC(ps)fU(ps) (Oligomeric mG(ps)fAmUfGmAfUmUfUmUfCmUfUmAfUmAiA (includes compound antisense SEQ ID NO 91, and sense SEQ ID NO 341) F11-91 complete sequence / PS and inverted nucleotide terminal stabilization) F11-152IT 2283 iUfGmGfUmUfUmCfCmAfAmUfGmAfUmG(ps)fG(ps)mA(ps)fG (Oligomeric (ps)mC(ps)fCmAfUmCfAmUfUmGfGmAfAmAfCmCiA (includes compound antisense SEQ ID NO 152, and sense SEQ ID NO 402) F11-152 complete sequence / PS and inverted nucleotide terminal stabilization) F11-46CM 2284 NUUGGUGUGAGCAUUGCUUGCAAUGCUCACACCAN′ (Oligomeric (includes antisense SEQ ID NO 46, and sense SEQ ID NO 296) compound F11-46 complete sequence) F11-91CM 2285 NUAUAAGAAAAUCAUCCUGAUGAUUUUCUUAUAN′ (includes (Oligomeric antisense SEQ ID NO 91, and sense SEQ ID NO 341) compound F11-91 complete sequence) F11-152CM 2286 NGGUUUCCAAUGAUGGAGCCAUCAUUGGAAACCN′ (Oligomeric (includes antisense SEQ ID NO 152, and sense SEQ ID NO 402) compound F11-152 complete sequence) ¹In case of nucleobase sequences ²In case of nucleobase and sugar modifications being given

In above Table 6:

A represents adenine;

U represents uracil;

C represents cytosine;

G represents guanine;

m represents a methyl modification at the 2′ position of the sugar of the underlying nucleoside;

f represents a fluoro modification at the 2′ position of the sugar of the underlying nucleoside

N/N″/N′″ represents any RNA nucleobase;

N′ represents any RNA nucleobase and is preferably complementary to N;

(ps) represents a phosphorothioate inter-nucleoside linkage;

i represents an inverted inter-nucleoside linkage, which can be either 3′-3′, or 5′-5′;

vp represents vinyl phosphonate;

mvp represents methyl vinyl phosphonate.

For each of the above constructs of Table 6, a ligand, such as a galnac ligand, is preferably attached at the 3′ end of the sequence. Specifically for SEQ ID NOs 2251, 2252, 2253, this can be respectively illustrated as follows, where Galnac can represent any arrangement of Galnac attachment, preferably however a triantennary galnac attachment:

UUGGUGUGAGCAUUGCUUGCAAUGCUCACACCAA - Galnac UUAUAAGAAAAUCAUCCUGAUGAUUUUCUUAUAA - Galnac UGGUUUCCAAUGAUGGAGCCAUCAUUGGAAACCA - Galnac.

Alternatively for SEQ ID NOs 2272 to 2273 as shown in above Table 6, the ligand, preferably Galnac, attachment can be to an internal non-terminal nucleoside, such as attachment to the nucleosides in the above sequences where the nucleobase is not shown as modified.

Example 7

This Example describes a structure-function relationship study of constructs comprising the nucleobase sequence of SEQ ID NO: 91.

FIG. 18 shows the constructs comprising the nucleobase sequence of SEQ ID NO: 91 which have been tested.

Tests have been performed in primary hepatocytes.

Human plateable 5 donor hepatocytes (Sekisui XenoTech, HPCH05+) are thawed in 45 mL of Human OptiThaw Hepatocyte media (Sekisui Xenotech, K8000), spun down at 200 g for 5 minutes, and resuspended in 2×WEM complete (5% FBS, 2 uM Dexamethasone, Pen/Strep, 8 ug/mL human insulin, 4 mM GlutaMAX, 30 mM HEPES pH 7.4). 2×WEM complete consists of WEM (Gibco, A1217601) and 2× the Hepatocyte Plating Supplement Pack (Gibco, CM3000) with only 1×FBS. The hepatocytes are then plated on 6 well Collagen 1 coated plates (Gibco, A1142803) at 25,000 cell/well at 50 uL per well and allowed to recover and adhere for 4 hours at 37 C.

After 4 hours, GalNac conjugated complexes are diluted to 2 uM in basal WEM and used to make a 2×, 7 step, 5 fold dilution series. 50 uL of each dilution is added to corresponding wells of the plated hepatocytes to make a final dilution series of 1-0.000064 uM in 1×WEM complete.

The cells are allowed to culture for 72 hours at 37 degrees without disruption before harvest and RNA isolation using the PureLink Pro 96 total RNA Purification Kit (Invitrogen, 12173011A) according to the manufacturers protocol.

Results are shown in FIG. 19.

Based on these results, 7 molecules have been designed which are to be subjected to further analysis (see following Examples). These molecules are shown in FIG. 20. Performance data in primary hepatocytes are shown in FIG. 21.

Based on these data, three molecules have been tested in humanized mice; see Example 8 below.

Example 8

This Examples describes testing of the three molecules identified in Example 7 in humanized mice.

Table 7 below shows nucleobase sequences (SEQ ID NOs) and full modification information (construct NOs) of these three molecules.

Designation as used herein Nucleobase sequence Structure of the construct 91-conv-31 UUAUAAGAAAAUCAUCCUGAU /phos/mU*fU*mAfUmAfAmGfAmAfAmAfUmC* UUUCUUAUAA fA*mU*fC*mC*mU*fGmAfUmUfUmUfCmUfUm (SEQ ID NO: 2287) AfU*mA*fA*/3galnac/ (construct NO: 2290) 91-vp UUAUAAGAAAAUCAUCCUGAU /vp/mU/*fU*mAfUmAfAmGfAmAfAmAfUmCfA GAUUUUCUUAUAA mU*fC*mC*fU*mG*fAmUfGmAfUmUfUmUfC (SEQ ID NO: 2288) mUfUmAfU*mA*fA*/3galnac/ (construct NO: 2291) 91-conv-34 (SEQ ID NO: 2288) /phos/mU*fU*mAfUmAfAmGfAmAfAmAfUmCf AmU*fC*mC*fU*mG*fAmUfGmAfUmUfUmUfC mUfUmAfU*mA*fA*/3galnac/ (construct NO: 2292)

In above Table 7

A represents adenine;

U represents uracil;

C represents cytosine;

G represents guanine;

m represents a methyl modification at the 2′ position of the sugar of the underlying nucleoside;

f represents a fluoro modification at the 2′ position of the sugar of the underlying nucleoside;

* represents a phosphorothioate inter-nucleoside linkage;

vp represents vinyl phosphonate;

phos represents phosphonate; and

3galnac represents the toothbrush ligand defined herein above.

FIG. 22 also shows the structures of these molecules. FIG. 23 shows performance of these molecules 5 days after administration.

Based on these results, the construct designated “91-Conv-31” (structure displayed in FIG. 22) has been selected for testing in non-human primates; see Example 9 below. Of note, this molecule is particularly short and comprises only a total of 31 nucleotides.

Example 9

This Example describes a Pharmacodynamics Study of construct designated “91-Conv-31” (structure displayed in FIG. 22) Following Single/Repeat Subcutaneous Injection to Cynomolgus Monkeys.

Material and Methods

For an overview of the study protocol, see FIG. 24. A more detailed account is given below.

Study Protocol

TABLE 8 Study Design Target Dose TOTAL Target Dose Level Target Dose Concentration Dose Group/Phase # of Males Test Article (mg/animal) Volume (mL) (mg/mL) Route G1P1 3 naïve1 saline — 3.5 mL — SC non-naïve G2P1 3 naïve 1 STP122G 3.5 (Target 3.5 mL 1 SC non-naïve as 1 mg/kg) G3P1 3 naïve 1 STP122G 10.5 (Target 3.5 mL 3 SC non-naïve as 3 mg/kg) G4P1 3 naïve 1 STP122G 35 (Target 3.5 mL 10 SC non-naïve as 10 mg/kg) G5P1 3 naïve 1 STP122G 10.5 (Target 3.5 mL 3 SC non-naïve as 3 mg/kg) G6P1 3 naïve 1 STP122G 10.5 (Target 3.5 mL 3 SC non-naïve as 3 mg/kg) Note: 1. Test article storage: Desiccated at room temperature, protected from light. 2. For SC group, animals will be fed on daily diet. 3. For all groups, saline will be used for vehicles 4. ″STP122G″ is an alternative designation for the preferred construct referred to as ″91-Conv-31″ herein

TABLE 9 Dose and Sample Collections Day Day Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk Wk −14 0 1 2 3 4 5 6 7 8 9 10 11 12 13 Dose G1 QD G2 QD G3 QD G4 QD G5 QD QD G6 QD QD QD 1 mL Whole Group1-6 Bl Bl Bl Bl Bl Bl Bl Blood Sampling for Hematology 0.6 mL Serum Group1-6 Se Se Se Se Se Se Se Sampling for Clinical Chemistry 1.7 mL Whole Group1-6 Bl Bl Bl Bl Bl Bl Bl Bl Bl Bl Bl Bl Bl Bl Bl Blood Sampling for Coagulation 2.5 mL Plasma Group1-6 P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se P, Se and 0.3 mL Serum Sampling for PD 1.Wk1 point should be 7 days after Day 0; Wk2 point should be 14 days after Day 0. 2.Single dose with single compound, subcutaneous injection. For Day 0, Wk1 and Wk2, animals will be dosed after all samples collection. 3.(K2) EDTA as the anticoagulant for Hematology blood and sodium citrate as the anticoagulant for Coagulation blood and plasma. 4.Bl is short for blood; P is short for plasma; Se is short for Serum 5.Clinical Pathology Examination Hematology Erythrocyte count (RBC), Red cell distribution width (RDW), Hematocrit (HCT), Platelet count (PLT), Hemoglobin (HGB), Mean platelet volume (MPV), Mean corpuscular volume (MCV), Leukocyte counts (WBC), and Differential (absolute and percent), Mean corpuscular hemoglobin (MCH), Blood smear for possible cytology, Mean corpuscular hemoglobin concentration (MCHC), Absolute reticulocyte count (Retic). Coagulation Prothrombin time (PT), Activated partial thromboplastin time (APTT), Fibrinogen (FIB). Clinical Chemistry Alkaline Phosphatase (ALP), Total Protein (TP), Alanine Aminotransferase (ALT), Albumin (ALB), Aspartate Aminotransferase (AST), g-glutamyltransferase (GGT), Bilirubin, total (TBIL), Globulin (GLB), Phosphorus (P), Albumin/Globulin Ratio Creatinine (CRE), Sodium (Na), Glucose (GLU), Chloride (Cl), Calcium (Ca), Triglycerides (TG), Total Cholesterol (TCHO), Urea (UREA), Potassium (K), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Glutamate dehydrogenase (GLDH).

-   1 Study Information     -   1.1 Study Objective         -   The objective of this study is to determine the             pharmacodynamics (PD) of the compound selected for this             study, following a single/repeat subcutaneous (SC)             administration in male cynomolgus monkeys.     -   1.2 Regulatory Compliance         -   This study is conducted in accordance with the Institutional             Animal Care and Use Committee (IACUC) standard animal             procedures along with the IACUC guidelines that are in             compliance with the Animal Welfare Act and the Guide for the             Care and Use of Laboratory Animals.         -   This study will be conducted in accordance with this             protocol and protocol amendments (if applicable) and the             associated study-specific procedures, and with applicable             Standard Operating Procedures (SOPs) and generally             recognized good laboratory practices. This study will not be             considered within the scope of the Good Laboratory Practice             regulations. -   2 Test Article and Vehicle Information     -   2.1 Test Article         -   Compounds as specified further above.

Storage Conditions: Desiccate at room temperature, protected from light Handling Standard laboratory precautions Instructions: as defined in WuXi SOPs Dose Preparation: Doses will be prepared according to instructions provided by the sponsor. A copy of the instructions, as well as details of preparation, will be maintained in the study records. Dose Solution Analysis Samples: Disposition of Remaining formulations will be Remaining stored at 4°C. Test Article Formulations: Disposition of Remaining test article will be Remaining shipped back to sponsor or discarded Test Article (dry 6 months after the final report powder or solid): is signed or at approval of Sponsor.

-   3 Test System Identification     -   3.1 Animal Specifications

Species Cynomolgus monkeys (Macaca fascicularis) Justification for This is an acceptable species to support PK studies Species for compounds intended to use in humans. Selection History of Dosing 18 naïve animals and 6 non-naïve animals Body Weight 2-7 kg Range Age ≥2.0 years old Sex Male Source Hainan Jingang Laboratory Animal Co. Ltd and other permitted vendor Address of Supplier Nayangxintan Fucheng Town, Qiongshan District, Haikou Hainan Province, P.R. China Method of Unique skin tattoo on chest Identification Justification for The number of animals in each group is the number of Animals minimum number of animals necessary for assessment of interanimal variability. Selection of 24 males will be selected. Animals will have Animals undergone a physical examination for general health by a staff veterinarian. 24 males confirmed as being healthy, will be assigned to study. Acclimation Period Selected animals will be acclimated prior to the study.

-   -   3.2 Animal Care         -   3.2.1 Environmental Conditions             -   The room(s) will be controlled and monitored for                 relative humidity (targeted mean range 40% to 70%, and                 any excursion from this range for more than 3 hours will                 be documented as a deviation) and temperature (targeted                 mean range 18° C. to 26° C., and any excursion from this                 range will be documented as a deviation) with 10 to 20                 air changes/hour. The room will be on a 12-hour                 light/dark cycle except when interruptions are                 necessitated by study activities.         -   3.2.2 Housing             -   Animals will be pair-housed in cages that are in                 accordance with applicable animal welfare laws and                 regulations during acclimation period. The monkeys will                 be housed individually in cages during experiment.             -   Diet and Feeding             -   Animals will be fed twice daily. Stock monkeys will be                 fed approximately 120 grams of Certified Monkey Diet                 daily. These amounts can be adjusted as necessary based                 on food consumption of the group or body weight changes                 of an individual and/or changes in the certified diet.             -   Animals will be fasted overnight prior to blood                 collections for serum chemistry.             -   Drinking Water             -   Reverse osmosis (RO) water will be available to all                 animals, ad libitum.         -   3.2.3 Feed and Water Analyses             -   RO water is analyzed every three months and every batch                 of feed will be analyzed before use. Feed and water                 analyses will be maintained in the facility records.         -   3.2.4 Environmental Enrichment             -   Enrichment toys will be provided.

-   4 Administration of Dose Formulation

Administration Subcutaneous injection via the dorsal area of the Route: animals' thoracic regions. Justification for Dose levels chosen to characterize the the Dose Level: pharmacodynamics of test article in monkeys over the desired dose range and dosing frequencies. Justification This administration route is consistent with the for the proposed initial route of human administration. Administration Route: Dose The dose formulations will be administered per facility Administration: SOPs. SC ADMINISTRATION: SC injection site will be along the dorsal area of the animals' thoracic regions. For multiple or large doses, different sites will be used. When the injection site is altered, the location must be documented in the record.

-   -   4.1 Observations and Examinations         -   4.1.1 Clinical Observations             -   Twice daily (approximately 9:30 a.m. and 4:00 p.m.),                 cage-side observations for general health and appearance                 will be conducted. Animals will be given physical                 examinations prior to study initiation to confirm                 animals' health. On dosing days, the animals will be                 observed at 2, 4 and 6-hours post-dosing. General                 condition, injection site, behavior, activity,                 excretion, respiration or other unusual observations                 noted throughout the study will be recorded in the raw                 data. When necessary, additional clinical observations                 will be performed and recorded. A staff veterinarian or                 veterinary technician will evaluate each animal if                 clinical observations demonstrate declining animal                 condition and the Study Director will be notified. The                 Study Director, or designee, will notify the Sponsor if                 warranted by the evaluation.         -   4.1.2 Body Weight             -   All animals will be weighted weekly. On dosing days,                 animals will be weighed on prior to dosing to determine                 the dose volume to be administered.         -   4.1.3 Blood Collection for Clinical Pathology             -   All blood samples will be collected from a peripheral                 vessel from restrained, non-sedated animals.

TABLE 10 Clinical Pathology Schedule Sample Volume Sampling Tube Type/Size approximately Groups Sample Schedule^(a) Evaluations Information (minimum) 1-6 Blood Once during Hematology K₂EDTA   2 mL 2.0 mL (1.0 mL) pre-study; Serum Plain with 3.5 mL 1.2 mL (1.1 mL) Weeks 2, 3, 4, Chemistry separating 5, 6, and 13. gel Once during Coagulation Sodium   2 mL 1.7 mL (1.3 mL) pre-study; Citrate Weekly. ^(a)Blood sample may be collected from animals subjected to unscheduled euthanasia. Animals may not be fasted under that circumstance.

-   -   -   -   (1) Blood Collection for Hematology: Whole blood (at                 least 1.0 mL) will be collected from the animals into                 commercially available tubes with Potassium (K2) EDTA at                 room temperature (RT). The blood samples will be sent to                 clinical pathology lab in RT and tested for hematology                 parameters listed in the Table 9. A blood smear will be                 prepared from each hematology sample. Blood smears will                 be labeled, stained, and stored. Blood smears may be                 read to investigate results of the hematology analyses.                 If additional examination of blood smears is deemed                 necessary, the smears may be subsequently evaluated and                 this evaluation will be described in a study plan                 amendment.             -   (2) Blood Collection for Coagulation Test: Approximately                 1.7 mL blood will be collected into sodium citrate                 anticoagulation tubes at RT and sent to clinical                 pathology lab. The parameters listed in Table 9 will be                 performed to test coagulation function.             -   (3) Blood Collection for Clinical Chemistry: Whole blood                 samples (approximately 1.2 mL) without anticoagulant                 will be collected and held at RT and up-right for at                 least 30 minutes and sent to clinical pathology lab. The                 samples will be processed to serum, which will be                 examined for the parameters listed in Table 9.

        -   4.1.4 Blood Collection for Pharmacodynamics (PD)

Blood: All blood samples will be collected from a peripheral vessel from restrained, non-sedated animals. Animals: All available, all groups Post-Dose Blood volume: Approximately 5.6 mL Anticoagulant: Sodium citrate Frequency: Refer to Table 9. Actual sample collection times will be recorded in the study records. For samples collected within the first hour of dosing, a ± 1 minute is acceptable. For the remaining time points, samples that are taken within 5% of the scheduled time are acceptable and will not be considered as protocol deviation. Sample For FXI ELISA: 2 mL Blood will be collected into a tube Processing: (Purchased from sponsor’s required company) containing sodium citrate on wet ice. Then all the blood will be mixed upside down 4 times. Samples will be centrifuged (1000 g for 20 minutes at 4° C.) and approximately 1 mL plasma will be transferred into two tubes quickly (approximately 0.50 mL per tube). One tube (labeled frozen plasma) should be frozen instantly in liquid nitrogen, then stored at −80° C. For FXI Activity Assays: 3 mL Blood will be collected into a tube (Purchased from sponsor’s required company) containing sodium citrate on wet ice. Then all the blood will be mixed upside down 4 times. Samples will be centrifuged (1660 g for 10 minutes at 4° C.) and approximately 1.5 mL plasma will be transferred into two labeled polypropylene micro-centrifuge tubes quickly (approximately 0.70 mL per tube). One tube (labeled frozen plasma) should be frozen instantly in liquid nitrogen, then stored at −80° C.. Another tube should be in a cool set to maintain 2-6° C. and shipped within 2-4 hours in 4° C. for analysis of Factor XI protein for Activity Assays. For Serum: Whole blood samples (approximately 0.6 mL) without anticoagulant will be collected and held at RT and up-right for at least 30 minutes and then samples will be centrifuged (3200 g for 10 minutes at 4° C.) and approximately 0.3 mL serum will be transferred into tubes quickly. The tube should be frozen instantly in liquid nitrogen, then stored at −80° C. until analysis.

-   5 Protocol Amendments and Deviations     -   Changes to the approved protocol will be in the form of         amendments approved by the Study Director and the Sponsor.         Amendments will describe the protocol changes clearly and will         include the effective date of the change and the justification         for the change. The Study Director and Study Representative may         authorize protocol changes by telephone or electronic means if         he/she is not physically present at the time urgent or critical         changes are required. Any authorization for such changes made as         above must be documented appropriately and followed by a         properly prepared written protocol amendment. The amendment must         be signed and dated by the Study Director within 45 days of the         effective date(s).     -   All deviations from the protocol and SOPs and the reasons of the         deviations will be documented and acknowledged by the Study         Director. The Sponsors Representative will be informed promptly         of the occurrence of any deviations that might affect the         results of the study, and any corrective actions taken. Protocol         and SOP deviations that could impact data interpretation will be         included in the final report. -   6 Archiving of Materials     -   Test article preparation, test article tracking, in-life data,         protocol, protocol amendments (if applicable), and the original         final report generated as a result of this study will be         archived. -   7 STATISTICAL ANALYSIS     -   The following section does not apply to data recorded on         unscheduled occasions. Such data will be reported on an         individual basis.     -   All numerical data will be subjected to calculation of group         means and standard deviations by using Microsoft Excel software,         unless otherwise stated hereafter. These descriptive statistics         will be presented for each dataset of interest, as determined by         the variable to be analyzed and the dataset classification         variables (for example: sex, measurement occasion, and any other         relevant variable that can be used to specify on which         subdivision the descriptive statistics have to be reported).     -   If a dataset has less than three non-missing values in each         group, then the following inferential data analysis will not be         conducted. No inferential data analysis will be conducted on         toxicokinetic parameters and semi-quantitative data such as:         urine protein, urine pH, urine bilirubin, urine occult blood,         urine glucose, and urine ketones.     -   Whenever there are more than two groups, the homogeneity of the         group variances will be evaluated using Levene's test at the         0.05 significance level. If differences between group variances         are not found to be significant (p>0.05), then a parametric         one-way analysis of variance (ANOVA) will be performed. When         significant differences among the means are indicated by ANOVA         test (p≤0.05), Dunnett's test will be used to perform the group         mean comparisons between the control group and each treated         group.     -   If Levene's test indicates heterogeneous group variances         (p≤0.05) and the data set contains just positive values, log         transformation will be performed. If transformed data still fail         the test for homogeneity of variance (p≤0.05) or where the data         contain zero and/or negative values, then the non-parametric         Kruskal-Wallis test will be used to compare all considered         groups.

When Kruskal-Wallis test is significant (p≤0.05), Dunnett's test on ranks will be used to perform the pairwise group comparisons of interest.

-   -   Whenever there are only two groups to compare, Levene's test         will be performed as described above but a two-sample t-test         will replace the one-way ANOVA, a Wilcoxon rank-sum test will be         performed instead of the Kruskal-Wallis and, no Dunnett's tests         or Dunnett's tests on ranks will be performed.     -   Each pairwise group comparisons of interest will be conducted         via a two-sided test at the 5% significance level. Significant         results will be reported as either p≤0.001, p≤0.01, or p≤0.05,         where p represents the observed probability.

Results

The results of the study are depicted in FIGS. 25, 27 and 28.

FIG. 25 shows performance of construct designated “91-Conv-31” (structure displayed in FIG. 22) in an in vivo study in terms of Factor XI activity knock-down. The effect of different dosages (expressed in mg/kg) and of single or multiple dosing at the beginning are shown and compared to a negative control (saline).

Efficient and unexpectedly long-lasting knock-down is apparent.

FIG. 26 shows the molecular mechanism underlying the tests for targeting specificity as performed in the course of an in vivo study.

APTT stands for activated partial thromboplastin time. It measures the activity of intrinsic pathway of clotting that is impacted by factors like FXI. PT stands for prothrombin time which evaluates the integrity of extrinsic pathway of clotting that looks at the presence of factors like VII, V, X, prothrombin and fibrinogen.

FIG. 27 shows the read-out of the tests illustrated in FIG. 26.

The % FXI plasma activity (FIG. 25), together with APTT and PT data (FIG. 27) demonstrate that the molecule specifically targets FXI and does not have any off-target effect on the extrinsic clotting pathway.

FIG. 28 presents data demonstrating a lack of side effects. A panel liver function and hematology parameters have been assessed. In particular, no elevated levels of liver enzymes and no changes in hematology parameters could be found. 

1. An oligomeric compound that inhibits expression of FXI, comprising a first nucleobase sequence that is at least partially complementary to at least a portion of RNA transcribed from an FXI gene, wherein said first nucleobase sequence is selected from the sequences selected from the group consisting of SEQ ID NOs 1 to 250, and SEQ ID NOs 1251 to
 1500. 2. An oligomeric compound according to claim 1, further comprising a second nucleobase sequence that is at least partially complementary to said first nucleobase sequence and is selected from the group consisting of: SEQ ID NOs 251 to 500, and SEQ ID NOs 1501 to
 1750. 3-12. (canceled)
 13. An oligomeric compound that inhibits expression of FXI, comprising at least a first region of linked nucleosides that is at least partially complementary to at least a portion of an RNA transcribed from an FXI gene, wherein said RNA is selected from the sequences selected from the group consisting of SEQ ID NOs 1001 to
 1250. 14. An oligomeric compound according to claim 13, wherein said RNA is selected from the following sequences, or a portion thereof: SEQ ID NOs 1008, 1013, 1027, 1039, 1046, 1091, 1098, 1103, 1105, 1109, 1120, 1140, 1146, 1151, 1152, 1163, 1182, 1183, 1199, 1207, 1210, 1218, 1220, 1223, 1224,
 1238. 15. An oligomeric compound according to claim 13, wherein said RNA is selected from the following sequences, or a portion thereof: SEQ ID NOs 1008, 1046, 1091, 1146, 1152,
 1207. 16. An oligomeric compound according to claim 13, wherein said RNA is selected from the following sequences, or a portion thereof: SEQ ID NOs 1046, 1091,
 1152. 17. An oligomeric compound according to claim 1, wherein said first region of linked nucleosides consists essentially of 18 to 20 linked nucleosides.
 18. An oligomeric compound according to claim 2, wherein said second region of linked nucleosides consists essentially of 11 to 16, 12 to 15, or 13 to 16 linked nucleosides.
 19. An oligomeric compound according to claim 2, comprising at least one complementary duplex region that comprises at least a portion of said first nucleoside region directly or indirectly linked to at least a portion of said second nucleoside region.
 20. An oligomeric compound according to claim 19, wherein each of said first and second nucleoside regions has a 5′ to 3′ directionality thereby defining 5′ and 3′ regions respectively thereof.
 21. An oligomeric compound according to claim 20, wherein the 5′ region of said first nucleoside region is directly or indirectly linked to the 3′ region of said second nucleoside region, for example by complementary base pairing, and/or wherein the 3′ region of said first nucleoside region is directly or indirectly linked to the 5′ region of said second nucleoside region.
 22. An oligomeric compound according to claim 1, further comprising one or more ligands.
 23. An oligomeric compound according to claim 21, wherein said one or more ligands are conjugated to said second nucleoside region. 24-28. (canceled)
 29. An oligomeric compound according to claim 28, wherein said one or more carbohydrates comprise one or more N-Acetyl-Galactosamine moieties. 30-32. (canceled)
 33. An oligomeric compound according to claim 19, wherein said oligomeric compound comprises a single strand comprising said first and second nucleoside regions, wherein said single strand dimerises whereby at least a portion of said first nucleoside region is directly or indirectly linked to at least a portion of said second nucleoside region so as to form said at least partially complementary duplex region. 34-35. (canceled)
 36. An oligomeric compound according to claim 34, wherein said hairpin loop comprises 4 or 5 linked nucleosides. 37-73. (canceled)
 74. An oligomeric compound according to claim 1, wherein one or more nucleosides of the first nucleoside region and/or the second nucleoside region is an inverted nucleoside and is attached to an adjacent nucleoside via the 3′ carbon of its sugar and the 3′ carbon of the sugar of the adjacent nucleoside, and/or one or more nucleosides of the first nucleoside region and/or the second nucleoside region is an inverted nucleoside and is attached to an adjacent nucleoside via the 5′ carbon of its sugar and the 5′ carbon of the sugar of the adjacent nucleoside. 75-76. (canceled)
 77. An oligomeric compound that inhibits expression of FXI, comprising at least a first region of linked nucleosides having at least a first nucleobase sequence selected from the group consisting of: constructs SEQ NOs 501 to 750, and constructs SEQ NOs 1751 to
 2000. 78. An oligomeric compound according to claim 77, further comprising at least a second region of linked nucleosides having at least a second nucleobase sequence that is at least partially complementary to said first nucleobase sequence, wherein said second nucleobase sequence is a modified sequence and is selected from the group consisting of construct NOs 751 to 1000, and constructs NOs 2001 to
 2250. 79-87. (canceled)
 88. An oligomeric compound according to claim 86 or 87, further comprising one or more ligands. 89-94. (canceled)
 95. An oligomeric compound according to claim 88 wherein said one or more carbohydrates comprise one or more N-Acetyl-Galactosamine moieties. 96-100. (canceled)
 101. A composition comprising an oligomeric compound according to claim 1, and a physiologically acceptable excipient. 102-103. (canceled)
 104. A method of treating a disease or disorder comprising administering an oligomeric compound according to claim 1 to an individual in need of treatment. 105-109. (canceled) 